Tokushima University / Educator and Researcher Directory --- Yagi, Shusuke

Field of Study

○	Medicine
○	Cardiovascular Medicine

Subject of Study

○
○

Book / Paper

Book:

1.	Shusuke Yagi and Masataka Sata : 循環器疾患の治療標的としての心臓周囲脂肪, 医歯薬出版株式会社, Oct. 2023.
2.	Takayuki Ise, 内藤紘一, 佐藤聡見, 小野慎太郎, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : ウェアラブルデバイスとコミュニケーションアプリを用いた遠隔伴走型心リハシステムの開発, Jul. 2023.
3.	Shusuke Yagi, Takayuki Ise, Muneyuki Kadota, Tserensonom Munkhtsetseg, 石井亜由美, 西川幸治 and Masataka Sata : 冠動脈疾患の一次予防に関する身体活動指導, Oct. 2022.
4.	Kumiko Kagawa, 前田悠作, Masahiro Oura, Kimiko Sogabe, 藤野ひかる, 髙橋真美子, 丸橋朋子, 岩佐昌美, 宇高憲吾, Takeshi Harada, Takayuki Ise, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shusuke Yagi, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and 藤野ひかる : Analysis of long-term survivors with cardiac AL amyloidosis, The Japanese Society of Hematology, Oct. 2017. (Summary) <p>Cardiac AL amyloidosis (CA) is generally known as a severe disease with very poor prognosis. Here we retrospectively examined seven patients with CA in our cohort who achieved long-term survival. All six patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT) survived for >3 years, whereas four patients survived for >5 years. Patients who underwent ASCT had prompt hematological responses, and five patients showed organ responses. ASCT helps to achieve a quick and deep hematological response required for long-term survival in patients with CA. New agents have been implemented for the treatment of CA. However, the risks and benefits of each treatment modality should be considered according to patient condition, thus making the best use of ASCT in combination with new agents for the treatment of CA.</p> (Keyword) Cardiac AL amyloidosis / Autologous hematopoietic stem cell transplantation / Long-term survival (Link to Publication Site) ● Publication site (DOI): 10.11406/rinketsu.58.2197 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680011466240 ● Search Scopus @ Elsevier (DOI): 10.11406/rinketsu.58.2197 (DOI: 10.11406/rinketsu.58.2197, CiNii: 1390282680011466240)
5.	Shusuke Yagi : 高血圧症 (Chapter 2 循環器疾患), Ishiyaku Publishers,Inc., Tokyo, May 2014.
6.	Shusuke Yagi and Masataka Sata : 甲状腺疾患と心臓, Nankodo, Tokyo, Jan. 2014.
7.	Michio Shimabukuro, M Dagvasumberel, Masayoshi Ishida, Sachiko Matsumoto, 小塚智沙代, 平良伸一, 屋比久浩市, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Seiichi Oyadomari, 益埼裕章 and Masataka Sata : Ectopic fat deposition, type 2 diabetes mellitus and cardiovascular diseases, Tokushima Medical Association, Tokushima, Apr. 2013. (Summary) There is evidence supporting the notion that excess abdominal fat is predictive of insulin resistance and the presence of related metabolic abnormalities currently referred to as the metabolic syndrome (MetS). Despite the fact that abdominal obesity is a highly prevalent feature of MetS, the mechanisms by which abdominal obesity is causally related to MetS are not fully elucidated. Besides visceral fat accumulation, ectopic lipid deposition, especially in the liver and skeletal muscle, has been implicated in the pathophysiology of diabetes, insulin resistance and obesity-related disorders. In addition, ectopic fat deposition play a critical role in the heart components such as (1) circulatory and locally recruited fat, (2) intra-and extra-myocellular fat, (3) perivascular fat, and (4) pericardial fat. In this review, the contribution of ectopic lipid deposition to global cardiometabolic risk is discussed via possible mechanisms including adipocytokine, insulin resistance and lipotoxicity. (Keyword) Ectopic fat deposition / Diabetes mellitus / Cardiovascular diseases / Obesity / Metabolic syndrome / Lipotoxicity (Tokushima University Institutional Repository) ● Metadata: 109609 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564287418392064 (Tokushima University Institutional Repository: 109609, CiNii: 1050564287418392064)

Academic Paper (Judged Full Paper):

1.	Shusuke Yagi, Ryosuke Miyamoto, Masayoshi Tasaki, Hiroyuki Morino, Ryuji Otani, Muneyuki Kadota, Takayuki Ise, Hiroki Yamazaki, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Daiju Fukuda, Mitsuharu Ueda and Masataka Sata : The APOA1 p.Leu202Arg variant potentially causes autosomal recessive cardiac amyloidosis., Human Genome Variation, Vol.11, No.1, 2024. (Summary) ApoA-I amyloidosis is an extremely rare form of systemic amyloidosis that commonly involves the heart, kidneys, and liver. ApoA-I amyloidosis is caused by amyloidogenic variants of APOA1 that are inherited in an autosomal dominant manner. Here, we report a 69-year-old man with sporadic cardiac amyloidosis who was born to consanguineous parents and carried a homozygous variant of p.Leu202Arg in APOA1. (Tokushima University Institutional Repository) ● Metadata: 119580 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41439-024-00288-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39152105 ● CiNii @ National Institute of Informatics (CRID): 1050864324980555392 ● Summary page in Scopus @ Elsevier: 2-s2.0-85201547622 (Tokushima University Institutional Repository: 119580, DOI: 10.1038/s41439-024-00288-7, PubMed: 39152105, CiNii: 1050864324980555392, Elsevier: Scopus)
2.	Bollos Christine Anne Leah Locsin, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Koji Yamaguchi, Tomomi Matsuura, Tamaki Otani, Takanori Bandoh, Yuya Ueki, Noritake Matsuda, Satoru Takashi, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis Secondary to Atrial Fibrillation Ablation, Asia Oceania Journal of Nuclear Medicine & Biology, 2024. (Summary) We present two patients with a history of paroxysmal atrial fibrillation who developed pulmonary vein stenosis (PVS) following atrial fibrillation (AF) ablation. Case 1 involved a female patient in her 50s who was asymptomatic for pulmonary symptoms but was found to have a high degree of left superior PVS 15 months after AF ablation. This was demonstrated using contrast-enhanced computed tomography (CE-CT) and supported by findings of perfusion defects on ventilation-perfusion (V/Q) scan. Case 2 was a male patient in his 60s who developed progressive left superior PVS nine months after AF ablation, evidenced by serial CE-CT and V/Q scans. PVS is a rare but well-known complication of pulmonary vein ablation for the treatment of AF that can lead to severe complications if left untreated. V/Q scans effectively assess the functional significance of PVS by detecting abnormal blood flow segments. Although a V/Q mismatch characterized by reduced perfusion defects is more commonly used in evaluating pulmonary embolism, PVS should not be disregarded as a differential diagnosis. Few studies emphasize the utility of V/Q scans in managing PVS and highlight V/Q mismatch as a notable finding. This case report aimed to highlight their significance. (Link to Publication Site) ● Publication site (DOI): 10.22038/AOJNMB.2024.79650.1561 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.22038/AOJNMB.2024.79650.1561 (DOI: 10.22038/AOJNMB.2024.79650.1561)
3.	Shusuke Yagi, Muneyuki Kadota, Ryo Bando, Ryosuke Miyamoto, Hiroyuki Morino, Akiyoshi Kakutani, Yoshiaki Kubo, Takayuki Ise, Rie Ueno, Tomoya Hara, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Daiju Fukuda and Masataka Sata : Pulmonary Arterial Hypertension in Neurofibromatosis Type 1: A Case with a Novel NF1 Gene Mutation, Internal Medicine, 2024. (Summary) Neurofibromatosis type 1 (NF1) is an autosomal dominant multi-organ disease. The clinical manifestations include not only skin lesions and malignant tumors but also lung complications, including pulmonary arterial hypertension (PAH). However, the association between gene mutations in NF1 and the occurrence of PAH has not yet been elucidated. We herein report a case of isolated PAH in a 67-year-old woman with NF1, presumably caused by a novel heterozygous mutation, c.4485_4486delinsAT (p.Lys1496Ter), in the NF1 gene. (Tokushima University Institutional Repository) ● Metadata: 119521 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.3856-24 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38987187 ● Search Scopus @ Elsevier (PMID): 38987187 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.3856-24 (Tokushima University Institutional Repository: 119521, DOI: 10.2169/internalmedicine.3856-24, PubMed: 38987187)
4.	A Fujiyoshi, S Kohsaka, J Hata, M Hara, H Kai, D Masuda, N Miyamatsu, Y Nishio, M Ogura, Masataka Sata, K Sekiguchi, Y Takeya, K Tamura, A Wakatsuki, H Yoshida, Y Fujioka, R Fukazawa, O Hamada, A Higashiyama, M Kabayama, K Kanaoka, K Kawaguchi, S Kosaka, A Kunimura, A Miyazaki, M Nii, M Sawano, M Terauchi, Shusuke Yagi, T Akasaka, T Minamino, K Miura and K Node : JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease, Circulation Journal, Vol.88, No.5, 763-842, 2024. (Keyword) Humans / Coronary Artery Disease / Primary Prevention / Japan (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-23-0285 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38479862 ● Search Scopus @ Elsevier (PMID): 38479862 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-23-0285 (DOI: 10.1253/circj.CJ-23-0285, PubMed: 38479862)
5.	N Yamaguchi, Yukina Hirata, Susumu Nishio, TOMONORI Takahashi, Yoshihito Saijo, Muneyuki Kadota, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Kenya Kusunose : Pulmonary Pressure-flow responses to exercise in heart failure treated with angiotensin receptor neprilysin inhibitor., International Journal of Cardiology, Vol.400, 131789, 2024. (Summary) The role of the angiotensin receptor neprilysin inhibitor (ARNI) in cardiac function, particularly its impact on pulmonary circulation, remains underexplored. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (CO) responses as having the potential to assess the disease state. The aim of this study was to assess the effects of ARNI on pulmonary circulation in heart failure. We measured echocardiographic parameters post 6-min walk (6 MW) and compared the changes with baseline and follow-up. Our hypothesis was that pulmonary pressure-flow relationship of the pulmonary circulation obtained by 6 MW stress echocardiography would be improved with treatment. We prospectively enrolled 39 heart failure patients and conducted the 6 MW test indoors. Post-6 MW echocardiography measured echocardiographic variables, and CO was derived from electric cardiometry. Individualized ARNI doses were optimized, with follow-up echocardiographic evaluations after 1 year. Left ventricular (LV) volume were significantly reduced (160.7 ± 49.6 ml vs 136.0 ± 54.3 ml, P < 0.001), and LV ejection fraction was significantly improved (37.6 ± 11.3% vs 44.9 ± 11.5%, P < 0.001). Among the 31 patients who underwent 6 MW stress echocardiographic study at baseline and 1 year later, 6 MW distance increased after treatment (380 m vs 430 m, P = 0.003). The ΔmPAP/ΔCO by 6 MW stress decreased with treatment (6.9 mmHg/L/min vs 2.8 mmHg/L/min, P = 0.002). The left atrial volume index was associated with the response group receiving ARNI treatment for pulmonary circulation. Initiation of ARNI was associated with improvement of left ventricular size and LVEF. Additionally, the 6 MW distance increased and the ΔmPAP/ΔCO was improved to within normal range with treatment. (Tokushima University Institutional Repository) ● Metadata: 118925 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2024.131789 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38246422 ● Search Scopus @ Elsevier (PMID): 38246422 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2024.131789 (Tokushima University Institutional Repository: 118925, DOI: 10.1016/j.ijcard.2024.131789, PubMed: 38246422)
6.	S Yamaguchi, M Maeda, K Oba, G Maimaituxun, O Arasaki, Shusuke Yagi, Kenya Kusunose, Takeshi Soeki, Hirotsugu Yamada, Daiju Fukuda, H Masuzaki, Masataka Sata and Michio Shimabukuro : Sex differences in the association between epicardial adipose tissue volume and left atrial volume index, BMC Cardiovascular Disorders, Vol.24, No.1, 46, 2024. (Summary) Sex disparities in the association between epicardial adipose tissue volume (EATV) and cardiovascular disease have been reported. The sex-dependent effects of EATV on left atrial (LA) size have not been elucidated. Consecutive 247 subjects (median 65 [interquartile range 57, 75] years; 67% of men) who underwent multi-detector computed tomography without significant coronary artery disease or moderate to severe valvular disease were divided into two groups: patients with sinus rhythm (SR) or atrial fibrillation (AF). Sex differences in the association between the EATV index (EATVI) (mL/m) and LA volume index (LAVI) in 63 SR (28 men and 35 women) and 184 AF (137 men and 47 women) patients were evaluated using univariate and multivariate regression analyses. In overall that includes both men and women, the relationship between EATVI and LAVI was not significantly correlated for patients with SR and AF. The relationship between EATVI and LAVI differed between men and women in both SR and AF groups. In SR patients, there was a positive relationship between EATVI and LAVI in men, but not in women. In contrast, in patients with AF, a negative relationship was found between EATVI and LAVI in women, whereas no association was found in men. We evaluated sex differences in the association between EATVI and LAVI in patients with either SR or AF, and found a positive relationship in men with SR and a negative relationship in women with AF. This is the first report to evaluate sex differences in the relationship between EATVI and LAVI, suggesting that EAT may play a role, at least in part, in sex differences in the etiology of AF. (Keyword) Humans / Female / Male / Epicardial Adipose Tissue / Sex Characteristics / Heart Atria / Atrial Fibrillation / Atrial Appendage / Adipose Tissue (Tokushima University Institutional Repository) ● Metadata: 118911 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12872-023-03569-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38218772 ● Search Scopus @ Elsevier (PMID): 38218772 ● Search Scopus @ Elsevier (DOI): 10.1186/s12872-023-03569-1 (Tokushima University Institutional Repository: 118911, DOI: 10.1186/s12872-023-03569-1, PubMed: 38218772)
7.	Munkhtsetseg Tserensonom, Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Muneyuki Kadota, Tomoya Hara, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Lipoprotein (a) is a risk factor of aortic valve calcification in patients with a risk of atherosclerosis, The Journal of Medical Investigation : JMI, Vol.70, No.3.4, 450-456, 2023. (Summary) Aortic valve calcification (AVC), which causes aortic stenosis (AS), is more common in elderly persons. Controlling for conventional risk variables did not, however, reduce the incidence of AS. Thus, residual risk factors of AS should be identified. We enrolled 513 patients who underwent coronary angiography with computed tomography because of suspicion of coronary artery disease (CAD) or ruling out of CAD before aortic valve replacement. Calcium volume was calculated with a commercially available application. Conventional and lipid-related risk factors including serum levels of Lp(a) were evaluated for all patients. Calcium volume and Lp(a) levels were significantly higher in patients who underwent aortic valve replacement than in those who did not. A single regression analysis showed that the calcium volume was positively associated with age and the Lp(a) levels and negatively associated with the estimated glomerular filtration rate. No statistical significance was observed for other risk factors, including oxidized low-density lipoprotein, omega-3 fatty acids levels. The multiple regression analysis revealed that age (P<0.001), female sex (P<0.05), Lp(a) (P<0.01), and hemoglobin A1c (P<0.01) were determinants of the calcium volume. The area under the curve in receiver operating characteristic analysis of Lp(a) for implementation of AVR was 0.65 at an Lp(a) cut-off level of 16 mg/dL. In conclusion, the serum Lp(a) level is a potent risk factor of AVC in patients with high risk of atherosclerosis. J. Med. Invest. 70 : 450-456, August, 2023. (Keyword) Humans / Female / Aged / Aortic Valve / Lipoprotein(a) / Calcium / Aortic Valve Stenosis / Atherosclerosis / Risk Factors / Coronary Artery Disease (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.450 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940531 ● Search Scopus @ Elsevier (PMID): 37940531 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.450 (DOI: 10.2152/jmi.70.450, PubMed: 37940531)
8.	PT Pham, Oyunbileg Bavuu, JR Kim-Kaneyama, XF Lei, T Yamamoto, K Otsuka, Kumiko Suto, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro, GN Barber, Masataka Sata and Daiju Fukuda : Innate Immune System Regulated by Stimulator of Interferon Genes, a Cytosolic DNA Sensor, Regulates Endothelial Function, Journal of the American Heart Association, Vol.12, No.22, e030084, 2023. (Summary) Background Sterile inflammation caused by metabolic disorders impairs endothelial function; however, the underlying mechanism by which hyperglycemia induces inflammation remains obscure. Recent studies have suggested that stimulator of interferon genes (STING), a key cytosolic DNA sensor in the innate immune system, contributes to the pathogenesis of inflammatory diseases. This study examines the role of the STING in endothelial dysfunction in streptozotocin-induced diabetic mice. Methods and Results Injection of streptozotocin promoted the expression of STING and DNA damage markers in the aorta of wild-type mice. Streptozotocin elevated blood glucose and lipid levels in both wild-type and STING-deficient mice, which showed no statistical differences. Genetic deletion of STING ameliorated endothelial dysfunction as determined by the vascular relaxation in response to acetylcholine (<0.001) and increased endothelial nitric oxide synthase phosphorylation in the aorta (<0.05) in STZ-injected mice. Endothelium-independent vascular response to sodium nitroprusside did not differ. Treatment with a direct STING agonist, cyclic GMP-AMP, or mitochondrial DNA increased inflammatory molecule expression (eg, and ) and decreased endothelial nitric oxide synthase phosphorylation in human umbilical vein endothelial cells, partially through the STING pathway. Cyclic GMP-AMP significantly impaired endothelial function of aortic segments obtained from wild-type mice, which was ameliorated in the presence of C-176, a STING inhibitor, or a neutralizing interferon-β antibody. Furthermore, the administration of C-176 ameliorated endothelial dysfunction in STZ-induced diabetic mice (<0.01). Conclusions The DNA damage response regulated by STING impairs endothelial function. STING signaling may be a potential therapeutic target of endothelial dysfunction caused by hyperglycemia. (Tokushima University Institutional Repository) ● Metadata: 119425 (Link to Publication Site) ● Publication site (DOI): 10.1161/JAHA.123.030084 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37947148 ● CiNii @ National Institute of Informatics (CRID): 1360863109951763328 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178405175 (Tokushima University Institutional Repository: 119425, DOI: 10.1161/JAHA.123.030084, PubMed: 37947148, CiNii: 1360863109951763328, Elsevier: Scopus)
9.	Yuichiro Okushi, Yoshihito Saijyo, Hirotsugu Yamada, Hiroaki Toba, Robert Zheng, Hiromitsu Seno, TOMONORI Takahashi, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Kenya Kusunose : Effectiveness of surveillance by echocardiography for Cancer therapeutics-related cardiac dysfunction of patients with breast Cancer, Journal of Cardiology, Vol.82, No.6, 467-472, 2023. (Summary) Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients. We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15 % were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint. The mean age was 59 ± 12 years. During the follow-up period of 15 months (12-17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1 % vs. 5.5 %, adjusted odds ratio: 0.28, 95 % confidential intervals: 0.09-0.94; p = 0.039) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group. The incidence of cardiac complications was significantly lower in the surveillance group than the non-surveillance group, which supports the effectiveness of echocardiographic surveillance in patients with breast cancer. (Tokushima University Institutional Repository) ● Metadata: 118455 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2023.07.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37481235 ● Summary page in Scopus @ Elsevier: 2-s2.0-85166962366 (Tokushima University Institutional Repository: 118455, DOI: 10.1016/j.jjcc.2023.07.002, PubMed: 37481235, Elsevier: Scopus)
10.	Tomoya Hara, Daiju Fukuda, Byambasuren Ganbaatar, Phuong Tran Pham, Kunduziayi Aini, Arief Rahadian, Kumiko Suto, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice, Heart and Vessels, Vol.38, No.11, 1386-1394, 2023. (Summary) The Mediterranean diet, which is characterized by high consumption of olive oil, prevents cardiovascular disease. Meanwhile, olive mill wastewater (OMWW), which is obtained as a byproduct during olive oil production, contains various promising bioactive components such as water-soluble polyphenols. Hydroxytyrosol (HT), the major polyphenol in OMWW, has anti-oxidative and anti-inflammatory properties; however, the atheroprotective effects of OMWW and HT remain to be fully understood. Here, we investigated the effect of OMWW and HT on atherogenesis. Male 8-week-old apolipoprotein E-deficient mice were fed a western-type diet supplemented with OMWW (0.30%w/w) or HT (0.02%w/w) for 20 weeks. The control group was fed a non-supplemented diet. OMWW and HT attenuated the development of atherosclerosis in the aortic arch as determined by Sudan IV staining (P < 0.01, respectively) without alteration of body weight, plasma lipid levels, and blood pressure. OMWW and HT also decreased the production of oxidative stress (P < 0.01, respectively) and the expression of NADPH oxidase subunits (e.g., NOX2 and p22phox) and inflammatory molecules (e.g. IL-1β and MCP-1) in the aorta. The results of in vitro experiments demonstrated that HT inhibited the expression of these molecules that were stimulated with LPS in RAW264.7 cells, murine macrophage-like cells. OMWW and HT similarly attenuated atherogenesis. HT is a major component of water-soluble polyphenols in OMWW, and it inhibited inflammatory activation of macrophages. Therefore, our results suggest that the atheroprotective effects of OMWW are at least partially attributable to the anti-inflammatory effects of HT. (Tokushima University Institutional Repository) ● Metadata: 118456 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00380-023-02290-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37462755 ● Search Scopus @ Elsevier (PMID): 37462755 ● Search Scopus @ Elsevier (DOI): 10.1007/s00380-023-02290-5 (Tokushima University Institutional Repository: 118456, DOI: 10.1007/s00380-023-02290-5, PubMed: 37462755)
11.	A Tanaka, I Taguchi, I Hisauchi, H Yoshida, Michio Shimabukuro, H Hongo, T Ishikawa, T Kadokami, Shusuke Yagi, Masataka Sata and K Node : Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA), European Journal of Medical Research, Vol.28, No.1, 238, 2023. (Summary) Dotinurad is a newer urate-lowering agent that selectively inhibits urate transporter 1 in the renal proximal tubule and increases urinary urate excretion. Currently, little is known about the clinical efficacies of dotinurad in patients with hyperuricemia and hypertension. The aim of this study was to assess the clinical effects of a selective urate reabsorption inhibitor dotinurad on serum uric acid (SUA) levels and relevant vascular markers in patients with hyperuricemia and treated hypertension. This investigator-initiated, multicenter, prospective, single-arm, open-label, exploratory clinical trial in Japan enrolled patients with hyperuricemia and treated hypertension who received a 24-week dotinurad therapy (a starting dose at 0.5 mg once daily and up-titrated to 2 mg once daily). The primary endpoint was a percentage change in the SUA level from baseline to week 24. The secondary endpoints were cardiovascular and metabolic measurements, including changes in the cardio-ankle vascular index (CAVI) and derivatives of reactive oxygen metabolites (d-ROMs) concentration at week 24. Fifty patients (mean age 70.5 ± 11.0 years, with 76.0% being men, and mean SUA level 8.5 ± 1.2 mg/dL) were included in the analysis. The percentage change from baseline in the SUA level at week 24 was - 35.8% (95% confidence interval [CI] - 39.7% to - 32.0%, P < 0.001), with approximately three quarters of patients achieving an SUA level of ≤ 6.0 mg/dL at week 24. The proportional changes from baseline in the geometric mean of CAVI and d-ROMs at week 24 were 0.96 (95% CI 0.92 to 1.00, P = 0.044) and 0.96 (95% CI 0.92 to 1.00, P = 0.044), respectively. In addition to meaningful SUA-lowering effects, 24 weeks of dotinurad therapy may favorably affect arterial stiffness and oxidative stress markers, suggesting off-target vascular protection of dotinurad. Further research is expected to verify our findings and elucidate the entire off-target effects of dotinurad. Trial registration jRCTs021210013, registration date June 24, 2021. (Keyword) Male / Humans / Middle Aged / Aged / Aged, 80 and over / Female / Hyperuricemia / Uric Acid / Prospective Studies / Uricosuric Agents / Hypertension (Tokushima University Institutional Repository) ● Metadata: 118457 (Link to Publication Site) ● Publication site (DOI): 10.1186/s40001-023-01208-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37461063 ● Search Scopus @ Elsevier (PMID): 37461063 ● Search Scopus @ Elsevier (DOI): 10.1186/s40001-023-01208-1 (Tokushima University Institutional Repository: 118457, DOI: 10.1186/s40001-023-01208-1, PubMed: 37461063)
12.	Shusuke Yagi, Tomoya Hara, Hirotsugu Yamada, Kenya Kusunose, Takayuki Ise and Masataka Sata : Intimal Sarcoma of the Pulmonary Artery as an Embolic Cause of Sudden Death, Circulation Journal, Vol.87, No.7, 1036, 2023. (Tokushima University Institutional Repository) ● Metadata: 118374 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-23-0029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37245990 ● Search Scopus @ Elsevier (PMID): 37245990 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-23-0029 (Tokushima University Institutional Repository: 118374, DOI: 10.1253/circj.CJ-23-0029, PubMed: 37245990)
13.	U Munkhjargal, Daiju Fukuda, B Ganbaatar, Kumiko Suto, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice, Journal of Atherosclerosis and Thrombosis, Vol.30, No.4, 326-334, 2023. (Summary) Pharmacological blockade of mineralocorticoid receptors (MRs) is a potential therapeutic approach to reduce cardiovascular complications since MRs play a crucial role in cardiovascular regulation. Recent studies suggest that MR antagonists affect several extrarenal tissues, including vessel function. We investigated the effect of a novel nonsteroidal selective MR blocker, esaxerenone, on diabetes-induced vascular dysfunction. Diabetes was induced by a single dose of streptozotocin in 8-week-old male C57BL/6 mice. Esaxerenone (3 mg/kg/day) or a vehicle was administered by gavage to diabetic mice for 3 weeks. Metabolic parameters, plasma aldosterone levels, and parameters related to renal function were measured. Endothelium-dependent or -independent vascular responses of the aortic segments were analyzed with acetylcholine or sodium nitroprusside, respectively. Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study. Induction of diabetes elevated plasma aldosterone level (P<0.05) and impaired endothelium-dependent vascular relaxation (P<0.05). The administration of esaxerenone ameliorated the endothelial dysfunction (P<0.01) without the alteration of metabolic parameters, blood pressure, and renal function. Esaxerenone improved the eNOS phosphorylation in the aorta obtained from diabetic mice (P<0.05) compared with that in the vehicle-treated group. Furthermore, a major MR agonist, aldosterone, decreased eNOS phosphorylation and increased eNOS phosphorylation in HUVECs, which recovered with esaxerenone. Esaxerenone ameliorated the endothelium-dependent vascular relaxation caused by aldosterone in the aortic segments obtained from C57BL/6 mice (P<0.001). Esaxerenone attenuates the development of diabetes-induced endothelial dysfunction in mice. These results suggest that esaxerenone has potential vascular protective effects in individuals with diabetes. (Tokushima University Institutional Repository) ● Metadata: 118690 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.63382 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35732424 ● Search Scopus @ Elsevier (PMID): 35732424 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63382 (Tokushima University Institutional Repository: 118690, DOI: 10.5551/jat.63382, PubMed: 35732424)
14.	A Kudo, N Machii, T Ono, H Saito, Y Oshiro, R Takahashi, K Oshiro, Y Taneda, M Higa, K Nakachi, Shusuke Yagi, H Masuzaki, Masataka Sata and Michio Shimabukuro : Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study, BMJ Open Diabetes Research & Care, Vol.11, No.2, e003302, 2023. (Summary) This study aimed to evaluate the impacts of dapagliflozin on 24-hour glucose variability and diabetes-related biochemical variables in Japanese patients with type 2 diabetes who had received basal insulin supported oral therapy (BOT). Changes in mean daily blood glucose level before and after 48-72 hours of add-on or no add-on of dapagliflozin (primary end point) and diabetes-related biochemical variables and major safety variables during the 12 weeks (secondary end point) were evaluated in the multicenter, randomized, two-arm, open-label, parallel-group comparison study. Among 36 participants, 18 were included in the no add-on group and 18 were included in the dapagliflozin add-on group. Age, gender, and body mass index were comparable between the groups. There were no changes in continuous glucose monitoring metrics in the no add-on group. In the dapagliflozin add-on group, mean glucose (183-156 mg/dL, p=0.001), maximum glucose (300-253, p<0.01), and SD glucose (57-45, p<0.05) decreased. Time in range increased (p<0.05), while time above the range decreased in the dapagliflozin add-on group but not in the no add-on group. After 12-week treatment with dapagliflozin add-on, 8-hydroxy-2'-deoxyguanosine (8OHdG), as well as hemoglobin A1c (HbA1c), decreased. This study showed that the mean daily blood glucose and other daily glucose profiles were amended after 48-72 hours of dapagliflozin add-on in Japanese patients with type 2 diabetes who received BOT. The diabetes-related biochemical variables such as HbA1c and urinary 8OHdG were also obtained during the 12 weeks of dapagliflozin add-on without major adverse events. A preferable 24-hour glucose profile in 'time in ranges' and an improvement in reactive oxygen species by dapagliflozin warrant us to evaluate these benefits in larger clinical studies. UMIN000019457. (Keyword) Humans / Diabetes Mellitus, Type 2 / Blood Glucose / Hypoglycemic Agents / Glycated Hemoglobin / Blood Glucose Self-Monitoring / 8-Hydroxy-2'-Deoxyguanosine / East Asian People / Treatment Outcome / Insulins (Tokushima University Institutional Repository) ● Metadata: 118567 (Link to Publication Site) ● Publication site (DOI): 10.1136/bmjdrc-2022-003302 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37028805 ● Search Scopus @ Elsevier (PMID): 37028805 ● Search Scopus @ Elsevier (DOI): 10.1136/bmjdrc-2022-003302 (Tokushima University Institutional Repository: 118567, DOI: 10.1136/bmjdrc-2022-003302, PubMed: 37028805)
15.	Noritake Matsuda, Hideki Otsuka, Tamaki Otani, Shota Azane, Yamato Kunikane, Yoichi Otomi, Yuya Ueki, Masahiro Kubota, Masafumi Amano, Shusuke Yagi, Masataka Sata and Masafumi Harada : New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy, Japanese Journal of Radiology, Vol.41, No.4, 428-436, 2023. (Summary) Amyloid light chain (AL) and transthyretin (ATTR) are the major subtypes of cardiac amyloidosis (CA). Tc-pyrophosphate (PYP) scintigraphy is used to differentiate ATTR from other CA subtypes. We adapted the standardized uptake value (SUV) for Tc-PYP and proposed two quantitative indices, amyloid deposition volume (AmyDV) and total amyloid uptake (TAU). This study aimed to evaluate the utility of these quantitative indices in differentiating ATTR from non-ATTRs. Before the SUV measurement, the Becquerel calibration factor (BCF) of Tc was obtained by a phantom experiment. Thirty-two patients who had undergone hybrid SPECT/CT imaging 3 h after injection of Tc-PYP (370 MBq) were studied. CT attenuation correction for image reconstruction was applied in all. We calculated SUV, AmyDV, and TAU using a quantitative analysis software program for bone SPECT (GI-BONE) and analyzed AmyDV using two methods: threshold method (set 40%); and constant value method (average SUV of ribs). We assessed the diagnostic ability of heart-to-contralateral lung (H/CL) ratio, SUV, AmyDV, and TAU to differentiate ATTR from non-ATTR using receiver operating characteristic (ROC) analysis. Statistically significant differences in all quantitative indices were observed between ATTR and non-ATTR. The area under the curve of each quantitative index for discriminating between ATTR and non-ATTR were as follows: H/CL, 0.997; SUV, 0.953; SUV (M1), 0.964; SUV (M2), 0.969; AmyDV (M1), 0.875; AmyDV (M2), 0.974; and TAU, 0.974. The AmyDV (M2) had higher diagnostic ability than AmyDV (M1). Thus, TAU was calculated as AmyDV (M2) × SUV (M2). In the ROC curve, SUV, AmyDV, and TAU had almost the same diagnostic ability as H/CL in distinguishing ATTR from non-ATTRs. We propose two novel 3D-based quantitative parameters (AmyDV and TAU) that have almost equal ability to discriminate ATTR from non-ATTR. (Tokushima University Institutional Repository) ● Metadata: 117912 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-022-01364-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36449252 ● Summary page in Scopus @ Elsevier: 2-s2.0-85143121783 (Tokushima University Institutional Repository: 117912, DOI: 10.1007/s11604-022-01364-0, PubMed: 36449252, Elsevier: Scopus)
16.	TOMONORI Takahashi, Kenya Kusunose, S Hayashi, Robert Zheng, Natsumi Yamaguchi, Sae Morita, Yukina Hirata, Susumu Nishio, Yoshihito Saijyo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Isoproterenol loading transesophageal echocardiography in atrial fibrillation, The International Journal of Cardiovascular Imaging, Vol.39, No.3, 511-518, 2023. (Summary) In patients with sludge or severe spontaneous echo contrast (SEC) in the left atrial appendage (LAA), cases with isoproterenol loading transesophageal echocardiography (ISP-TEE) have been reported to identify the presence of thrombus in the LAA. This study aimed to assess the validity and hemodynamic changes of ISP-TEE in the LAA. We prospectively enrolled patients with atrial fibrillation (AF) who underwent ISP-TEE. The degree of sludge/SEC was categorized as being either absent (grade 0), mild SEC (grade 1), moderate SEC (grade 2), severe SEC or sludge (grade 3). The hemodynamic evaluation was performed by measuring LAA flow velocity, LAA tissue Doppler imaging (LAA-TDI) velocity, and pulmonary vein systolic forward flow velocity (PVS). In total, 35 patients (mean age 71 ± 7 years; 71% male) underwent ISP-TEE. Among 35 patients, 30 patients had grade 3 or 2 SEC, 5 patients had grade 1 SEC. After ISP loading, 23 patients (66% of all patients) showed improved sludge/SEC and one patient was diagnosed with thrombus in the LAA. There were 25 patients with grade 1 SEC, or no SEC (classified as Group1), 10 patients had residual sludge or grade 2 to 3 SEC (classified as Group2) after ISP administration. LAA flow, LAA-TDI, and PVS velocities were significantly higher in group 1 than in group 2 after ISP administration. There was no complication during the examination and after 24 h and 3 months. ISP infusion may be a potential tool to recognize LAA thrombus under the sludge/SEC during TEE in AF. (Keyword) Humans / Male / Middle Aged / Aged / Female / Atrial Fibrillation / Echocardiography, Transesophageal / Isoproterenol / Sewage / Atrial Appendage / Predictive Value of Tests / Thrombosis (Tokushima University Institutional Repository) ● Metadata: 118275 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10554-022-02749-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36357528 ● Search Scopus @ Elsevier (PMID): 36357528 ● Search Scopus @ Elsevier (DOI): 10.1007/s10554-022-02749-y (Tokushima University Institutional Repository: 118275, DOI: 10.1007/s10554-022-02749-y, PubMed: 36357528)
17.	Kenya Kusunose, Yuichiro Okushi, Y Okayama, Robert Zheng, M Nakai, Y Sumita, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Benefits of guideline-directed medical therapy to loop diuretics in management of heart failure, The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 41-53, 2023. (Keyword) heart failure / angiotensin-converting enzyme inhibitor / angiotensin receptor blocker / β-blockers / mineralocorticoid receptor antagonists (Tokushima University Institutional Repository) ● Metadata: 118306 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.41 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164742 ● CiNii @ National Institute of Informatics (CRID): 1390296055446303872 ● Search Scopus @ Elsevier (PMID): 37164742 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.41 (Tokushima University Institutional Repository: 118306, DOI: 10.2152/jmi.70.41, PubMed: 37164742, CiNii: 1390296055446303872)
18.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Hiroyuki Ito, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Y Tsuruo and Masataka Sata : Association of Microluminal Structures Assessed by Optical Coherence Tomography With Local Inflammation in Adjacent Epicardial Adipose Tissue and Coronary Plaque Characteristics in Fresh Cadavers, Circulation Journal, Vol.87, No.2, 329-335, 2023. (Summary) Coronary intraplaque microluminal structures (MS) are associated with plaque vulnerability, and the inward progression of vascular inflammation from the adventitia towards the media and intima has also been demonstrated. Therefore, in the present study we investigated the relationships among MS, local inflammation in adjacent epicardial adipose tissue (EAT), and coronary plaque characteristics.Methods and Results: Optical coherence tomography (OCT) revealed MS in the left anterior descending coronary artery in 10 fresh cadaveric hearts. We sampled 30 lesions and subdivided them based on the presence of MS: MS (+) group (n=19) and MS (-) group (n=11). We measured inflammatory molecule levels in the adjacent EAT and percentage lipid volume assessed by integrated backscatter intravascular ultrasound in each lesion. The expression levels of vascular endothelial growth factor B and C-C motif chemokine ligand 2 were significantly higher in the MS (+) group than in the MS (-) group (0.9±0.7 vs. 0.2±0.2 arbitrary units (AU), P=0.04 and 1.5±0.5 vs. 0.6±0.7 AU, P=0.02, respectively). Percentage lipid volume was significantly higher in the MS (+) group than in the MS (-) group (38.7±16.5 vs. 23.7±10.9%, P=0.03). Intraplaque MS observed on OCT were associated with lipid-rich plaques and local inflammation in the adjacent EAT. Collectively, these results suggest that local inflammation in the EAT is associated with coronary plaque vulnerability via MS. (Tokushima University Institutional Repository) ● Metadata: 117602 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-22-0299 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244741 ● Search Scopus @ Elsevier (PMID): 36244741 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-22-0299 (Tokushima University Institutional Repository: 117602, DOI: 10.1253/circj.CJ-22-0299, PubMed: 36244741)
19.	石井亜由美, Takayuki Ise, 西川孝治, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi, Tetsuya Matsuura and Masataka Sata : TAVI後の認知機能低下に関わる因子の検討, 心臓リハビリテーション(JJCR), Vol.29, No.3,4, 242-208, 2023.
20.	Tomonori Takahashi, Kenya Kusunose, Robert Zheng, Natsumi Yamaguchi, Yukina Hirata, Susumu Nishio, Yoshihito Saijyo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Association between cardiovascular risk factors and left ventricular strain distribution in patients without previous cardiovascular disease, Journal of Echocardiography, Vol.20, No.4, 208-215, 2022. (Summary) Some cardiovascular (CV) risk factors, such as hypertension and diabetes mellitus, have been reported to reduce left ventricular (LV) longitudinal strain (LS) even in patients with preserved LV ejection fraction. We hypothesized that multiple CV risk factors might cause changes in myocardial strain. Our study aimed to assess the association between multiple CV risk factors and strain in patients without previous CV disease (CVD). We retrospectively evaluated 137 patients without CVD, who underwent echocardiography at our institution between May 2017 and February 2020. They were divided into four groups based on the number of risk factors (group 0: no risk factor, group 1: one risk factor, group 2: two risk factors, and groups 3: three or four risk factors). Risk factors were hypertension, dyslipidemia, diabetes mellitus, and chronic kidney disease. Absolute values of global LS (GLS) and relative apical LS ratio (RALSR) defined using the equation: average apical LS/(average basal LS + average mid LS) and was used as a marker of strain distribution. Out of 137 patients, group 0 had 35 patients, group 1 had 35 patients, group 2 had 32 patients, and group 3 had 35 patients. GLS was 22.4 ± 2.0%, 21.7 ± 2.1%, 21.3 ± 1.8%, 20.7 ± 2.2%, and RALSR was 0.64 ± 0.06, 0.66 ± 0.06, 0.68 ± 0.08, 0.69 ± 0.07 in groups 0-3, respectively. The one-way ANOVA detected significant differences between groups in GLS (p = 0.005) and RALSR (p = 0.037), respectively. Group 3 had a significantly lower GLS and higher RALSR than group 0 (p < 0.05). In patients without previous CVD, LS decreased especially from the basal segment as the number of cardiovascular risks increased. The segmental LS may be markers of occult LV dysfunction in patients with CV risk factors. (Keyword) Humans / Cardiovascular Diseases / Retrospective Studies / Risk Factors / Stroke Volume / Ventricular Function, Left / Ventricular Dysfunction, Left / Heart Disease Risk Factors / Hypertension (Link to Publication Site) ● Publication site (DOI): 10.1007/s12574-022-00576-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35562627 ● Search Scopus @ Elsevier (PMID): 35562627 ● Search Scopus @ Elsevier (DOI): 10.1007/s12574-022-00576-7 (DOI: 10.1007/s12574-022-00576-7, PubMed: 35562627)
21.	O Bavuu, Daiju Fukuda, B Ganbaatar, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet., European Journal of Pharmacology, 175190, 2022. (Summary) Esaxerenone is a novel, non-steroidal selective mineralocorticoid receptor (Csige et al.) blocker. MR activation plays a crucial role in the development of cardiovascular and metabolic diseases. In this study, we investigated the effects of esaxerenone on various metabolic parameters in mice. Esaxerenone (3 mg/kg/day) was orally administered to high-fat diet (HFD)-fed male C57BL/6 mice. Mice fed a normal diet (ND) served as controls. Glucose and insulin tolerance, plasma lipid levels, and transaminase levels were assessed as metabolic parameters. Macrophage accumulation in the adipose tissue was evaluated using histological analysis. 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes were used for in vitro experiments. Gene expression and insulin signaling were examined using quantitative RT-PCR and western blotting, respectively. HFD successfully induced insulin resistance compared with that in ND. Esaxerenone ameliorated insulin resistance (P < 0.05) without altering other metabolic parameters, such as the lipid profile. Esaxerenone administration tended to decrease plasma transaminase levels compared with those in the non-treated group. In the adipose tissue, esaxerenone decreased macrophage accumulation (P < 0.05) and increased the expression levels of adiponectin and PPARγ. Aldosterone significantly decreased the expression levels of PPARγ and adiponectin in 3T3-L1 adipocytes. Furthermore, aldosterone attenuated insulin-induced Akt phosphorylation in 3T3-L1 adipocytes, HepG2 cells, and C2C12 myotubes in a dose-dependent manner (P < 0.01). These effects were ameliorated by pretreatment with esaxerenone. Esaxerenone ameliorated insulin resistance in HFD-fed mice. Reduction of inflammation and improvement in insulin signaling may underlie the beneficial effects of esaxerenone. (Tokushima University Institutional Repository) ● Metadata: 117375 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2022.175190 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35961594 ● Search Scopus @ Elsevier (PMID): 35961594 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2022.175190 (Tokushima University Institutional Repository: 117375, DOI: 10.1016/j.ejphar.2022.175190, PubMed: 35961594)
22.	Kenya Kusunose, Hirotsugu Yamada, Y Saijo, Susumu Nishio, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Clinical course and decision-making in heart failure by preload stress echocardiography: a preliminary study, ESC Heart Failure, Vol.9, No.6, 4020-4029, 2022. (Summary) Abnormal left ventricular diastolic response to preload stress can be an early marker of heart failure (HF). The aim of this study was to assess clinical course in patients with HF with preserved ejection fraction (HFpEF) who underwent preload stress echocardiography. In the subgroup analysis, we assessed the prognosis of patients with unstable signs during preload stress classified by treatment strategies. We prospectively conducted preload stress echocardiographic studies between January 2006 and December 2013 in 211 patients with HFpEF. Fifty-eight patients had abnormal diastolic reserve during preload stress (unstable impaired relaxation: unstable IR). Of 58 patients with unstable IR, 19 patients were assigned to additional therapy by increased or additional therapy and 39 patients were assigned to standard therapy. Composite outcomes were prespecified as the primary endpoint of death and hospitalization for deteriorating HF. During a median period of 6.9 years, 19 patients (33%) reached the composite outcome. Unstable group with standard therapy had significantly shorter event-free survival than stable group. Patients with uptitration of therapy had longer event-free survival than those with standard therapy group after adjustment of laboratory data (hazard ratio, 0.20, 95% confidence interval, 0.05-0.90; P = 0.036); the 10 year event-free survival in patients with and without uptitration of therapy was 93% and 51%, respectively (P = 0.023). Patients with unstable sign had significantly shorter event-free survival than patients with stable sign. After additional therapy, the prognosis of patients with unstable signs improved. This technique may impact decision-making for improving their prognosis. (Tokushima University Institutional Repository) ● Metadata: 118008 (Link to Publication Site) ● Publication site (DOI): 10.1002/ehf2.14127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36017722 ● Search Scopus @ Elsevier (PMID): 36017722 ● Search Scopus @ Elsevier (DOI): 10.1002/ehf2.14127 (Tokushima University Institutional Repository: 118008, DOI: 10.1002/ehf2.14127, PubMed: 36017722)
23.	Koji Yamaguchi, Tetsuzo Wakatsuki, Tomomi Matsuura, Kazuhisa Matsumoto, Yutaka Kawabata, Muneyuki Kadota, Kenya Kusunose, Takayuki Ise, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Drug-coated balloon angioplasty for severe pulmonary vein stenosis resulting from cryoballoon ablation for atrial fibrillation, Journal of Cardiology Cases, Vol.26, 35-38, 2022. (Tokushima University Institutional Repository) ● Metadata: 117234 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jccase.2022.02.009 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85127324683 (Tokushima University Institutional Repository: 117234, DOI: 10.1016/j.jccase.2022.02.009, Elsevier: Scopus)
24.	Y Okushi, Kenya Kusunose, M Nakai, Y Sumita, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism, American Journal of Cardiovascular Drugs, Vol.22, No.4, 407-416, 2022. (Summary) The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician's discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. We aimed to compare the mortality associated with the use of rivaroxaban, edoxaban, and apixaban in clinical practice. We identified 38,245 patients with first hospitalization for VTE from the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). We classified patients into three groups by DOAC (rivaroxaban and edoxaban group, rivaroxaban and apixaban group, and edoxaban and apixaban group) and compared the in-hospital mortality and bleeding risk by propensity score (PS) matching in each group. After PS matching, patients with rivaroxaban use had significantly lower total in-hospital mortality (1.2% vs. 2.1%; odds ratio [OR] 0.55, p = 0.012) and in-hospital mortality within 21 days (0.4% vs. 1.0%; OR 0.41, p = 0.020) and 28 days (0.7% vs. 1.3%; OR 0.53, p = 0.042) than patients with apixaban use. In the subanalysis, significant differences were only observed in patients younger than 80 years of age, patients with pulmonary embolism, and patients without heart failure. There was no significant difference in in-hospital mortality in the other groups and in the rate of bleeding events among the three groups. On PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE. (Link to Publication Site) ● Publication site (DOI): 10.1007/s40256-021-00514-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34927214 ● Search Scopus @ Elsevier (PMID): 34927214 ● Search Scopus @ Elsevier (DOI): 10.1007/s40256-021-00514-5 (DOI: 10.1007/s40256-021-00514-5, PubMed: 34927214)
25.	Kazuhisa Matsumoto, Takeshi Tobiume, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Tetsuzo Wakatsuki, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Evaluation of the input site and characteristics of the antegrade fast pathway based on three-dimensional bi-atrial stimulus-ventricle mapping, Journal of Interventional Cardiac Electrophysiology, Vol.63, No.2, 417-424, 2022. (Summary) Previous studies examined the right atrial (RA) input site of the antegrade fast pathway (AFp) (AFpI). However, the left atrial (LA) input to the atrioventricular (AV) node has not been extensively evaluated. In this study, we created three-dimensional (3-D) bi-atrial stimulus-ventricle (St-V) maps and analyzed the input site and characteristics of the AFp in both the RA and LA. Forty-four patients diagnosed with atrial fibrillation or WPW syndrome were included in this study. Three-dimensional bi-atrial St-V mapping was performed using an electroanatomical mapping system. Sites exhibiting the minimal St-V interval (MinSt-V) were defined as AFpIs and were classified into seven segments, four in the RA (F, S, M, and I) and three in the LA (M1, M2, and M3). By combining the MinSt-V in the RA and LA, the AFpIs were classified into three types: RA, LA, and bi-atrial (BA) types. The clinical and electrophysiological characteristics were compared. AFpIs were most frequently observed at site S in the RA (34%) and M2 in the LA (50%), and the BA type was the most common (57%). AFpIs in the LA were recognized in 75% of the patients. There were no clinical or electrophysiological indicators for predicting AFpI sites. Three-dimensional bi-atrial St-V maps could classify AFpIs in both the RA and LA. AFpIs in the LA were frequently recognized. There were no significant clinical or electrophysiological indicators for predicting AFpI sites, and 3-D bi-atrial St-V mapping was the only method to reveal the precise AFp input site. (Tokushima University Institutional Repository) ● Metadata: 116382 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10840-021-01026-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34231099 ● Search Scopus @ Elsevier (PMID): 34231099 ● Search Scopus @ Elsevier (DOI): 10.1007/s10840-021-01026-7 (Tokushima University Institutional Repository: 116382, DOI: 10.1007/s10840-021-01026-7, PubMed: 34231099)
26.	Shusuke Yagi, Daiju Fukuda, Takayuki Ise, Koji Yamaguchi, Kenya Kusunose, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Tomohiro Soga, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinji Kawahito and Masataka Sata : Clinical clerkship students' preferences and satisfaction regarding online lectures during the COVID-19 pandemic, BMC Medical Education, Vol.22, No.1, 43, 2022. (Summary) The COVID-19 pandemic has caused an unprecedented disruption in medical education. Students and lecturers had to adapt to online education. The current study aimed to investigate the level of satisfaction and future preference for online lectures among clinical clerkship students and elucidated the factors that affect these outcomes. We selected a sample of 114 medical students undergoing clinical clerkship during the COVID-19 pandemic. We conducted onsite lectures before the pandemic and online lectures after the outbreak. A survey was conducted, and the sample included students and 17 lecturers. The average scores of total satisfaction and future preference related to online lectures were computed. Students' scores on total satisfaction with online lectures and their future preference were higher than those for onsite lectures. Scores on the ease of debating dimension were low and those on accessibility of lectures in online lectures were higher than those in onsite lectures. There was no difference between the two groups in the scores on the comprehensibility and ease of asking questions dimensions. Results of the multiple regression analysis revealed that accessibility determined total satisfaction, and future preference was determined by comprehensibility as well as accessibility. Contrary to students' future preferences, lecturers favored onsite lectures to online ones. Online lectures are an acceptable mode of teaching during the COVID-19 pandemic for students undergoing clinical clerkship. Online lectures are expected to become more pervasive to avoid the spread of COVID-19. (Keyword) COVID-19 / Clinical Clerkship / Humans / Pandemics / Personal Satisfaction / SARS-CoV-2 / Students, Medical (Tokushima University Institutional Repository) ● Metadata: 116989 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12909-021-03096-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35042505 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123015852 (Tokushima University Institutional Repository: 116989, DOI: 10.1186/s12909-021-03096-7, PubMed: 35042505, Elsevier: Scopus)
27.	Nao Ishii, Kenya Kusunose, A Shono, K Matsumoto, Susumu Nishio, Natsumi Yamaguchi, Yukina Hirata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Effects of Radiofrequency Catheter Ablation on Cardiac Reserve Using Preload Stress Echocardiography in Paroxysmal and Persistent Atrial Fibrillation, The American Journal of Cardiology, Vol.168, 71-77, 2022. (Summary) The effects of catheter ablation on exercise tolerance and quality of life in patients with atrial fibrillation (AF) have been reported. We assessed cardiac function in more detail using the leg positive pressure (LPP) technique and found that contractile reserve is particularly important in relation to exercise tolerance and prognosis. In this study, we used the LPP technique to examine changes in contractile reserve immediately after ablation and 6 months later. We prospectively enrolled patients who underwent catheter ablation for AF at 2 institutes. We performed LPP stress echocardiography 2 to 3 days after (FU-1) and 6 months after (FU-2) ablation to examine changes in cardiac function indexes. The primary end point was improvement in contractile reserve. Ultimately, 109 patients (mean age 67.4 ± 9.6 years; 70% men) underwent 2 sessions of LPP stress echocardiography. The median CHADS-VAS score was 2 (interquartile range 13). From FU-1 to FU-2, the change in the stroke volume index after the LPP maneuver increased in patients with paroxysmal and persistent AF with low CHADS-VAS scores (both p <0.05). Regardless of AF subtype, contractile reserve at FU-2 improved in patients with low CHADS-VAS scores compared with that at FU-1. In contrast, patients with high CHADS-VAS scores had no change. In conclusion, patients with AF with a low CHADS-VAS score had improved contractile reserve after ablation, whereas patients with high scores did not show any improvement. Aggressive interventions in patients with high scores may lead to better management after catheter ablation. (Keyword) Aged / Atrial Fibrillation / Catheter Ablation / Echocardiography, Stress / Female / Humans / Male / Middle Aged / Predictive Value of Tests / Quality of Life / Risk Assessment / Risk Factors / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 116987 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjcard.2021.12.026 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35063270 ● Search Scopus @ Elsevier (PMID): 35063270 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjcard.2021.12.026 (Tokushima University Institutional Repository: 116987, DOI: 10.1016/j.amjcard.2021.12.026, PubMed: 35063270)
28.	Kumiko Suto, Daiju Fukuda, Masakazu Shinohara, Byambasuren Ganbaatar, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-Ichi Hirata and Masataka Sata : Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice., Journal of Atherosclerosis and Thrombosis, Vol.28, No.12, 1349-1360, 2021. (Summary) Various pathological processes related to diabetes cause endothelial dysfunction. Eicosanoids derived from arachidonic acid (AA) have roles in vascular regulation. Fibrates have recently been shown to attenuate vascular complications in diabetics. Here we examined the effects of pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, on plasma eicosanoid levels and endothelial function in diabetic mice. Diabetes was induced in 7-week-old male wild-type mice by a single injection of streptozotocin (150 mg/kg). Pemafibrate (0.3 mg/kg/day) was administered orally for 3 weeks. Untreated mice received vehicle. Circulating levels of eicosanoids and free fatty acids were measured using both gas and liquid chromatography-mass spectrometry. Endothelium-dependent and endothelium-independent vascular responses to acetylcholine and sodium nitroprusside, respectively, were analyzed. Pemafibrate reduced both triglyceride and non-high-density lipoprotein -cholesterol levels (P<0.01), without affecting body weight. It also decreased circulating levels of AA (P<0.001), thromboxane B (P<0.001), prostaglandin E, leukotriene B (P<0.05), and 5-hydroxyeicosatetraenoic acid (P<0.001), all of which were elevated by the induction of diabetes. In contrast, the plasma levels of 15-deoxy-Δ-prostaglandin J, which declined following diabetes induction, remained unaffected by pemafibrate treatment. In diabetic mice, pemafibrate decreased palmitic acid (PA) and stearic acid concentrations (P<0.05). Diabetes induction impaired endothelial function, whereas pemafibrate ameliorated it (P<0.001). The results of ex vivo experiments indicated that eicosanoids or PA impaired endothelial function. Pemafibrate diminished the levels of vasoconstrictive eicosanoids and free fatty acids accompanied by a reduction of triglyceride. These effects may be associated with the improvement of endothelial function by pemafibrate in diabetic mice. (Tokushima University Institutional Repository) ● Metadata: 116054 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.61101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33775978 ● Search Scopus @ Elsevier (PMID): 33775978 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.61101 (Tokushima University Institutional Repository: 116054, DOI: 10.5551/jat.61101, PubMed: 33775978)
29.	Kenya Kusunose, Miharu Arase, Robert Zheng, Yukina Hirata, Susumu Nishio, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Clinical Utility of Overlap Time for Incomplete Relaxation to Predict Cardiac Events in Heart Failure: Incomplete relaxation in heart failure, Journal of Cardiac Failure, Vol.27, No.11, 1222-1230, 2021. (Summary) The overlap time of transmitral flow can be a novel marker of subclinical left ventricular (LV) dysfunction for predicting adverse events in heart failure (HF). We aimed to 1) investigate the role of overlap time of E-A wave in association with clinical parameters, and 2) evaluate whether the overlap time could add prognostic information with respect to other conventional clinical prognosticators in HF. We prospectively evaluated 153 patients hospitalized with HF (mean age 68±15 years; 63% male). The primary endpoint was readmission following HF and cardiac death. During a median period of 25 months, 43 patients were either readmitted or died. Overlap time appeared to be associated with worse outcomes. After adjustment for readmission score and ratio of diastolic filling period and cardiac cycle length in a Cox proportional-hazards model, overlap time was associated with event free survival, independent of elevated left atrial pressure (LAP) based on guidelines. When overlap time was added to the model based on clinical variables and elevated LAP, the C-statistic significantly improves from 0.70 (95% CI: 0.63-0.77) to 0.77 (95% CI: 0.69-0.83, compared P=0.035). This preliminary study suggested that prolonged overlap time may have potential for predicting readmission and cardiac mortality risk assessment in HF. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cardfail.2021.05.018 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34129950 ● Search Scopus @ Elsevier (PMID): 34129950 ● Search Scopus @ Elsevier (DOI): 10.1016/j.cardfail.2021.05.018 (DOI: 10.1016/j.cardfail.2021.05.018, PubMed: 34129950)
30.	Robert Zheng, Kenya Kusunose, Y Okushi, Y Okayama, M Nakai, Y Sumita, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Impact of cancer on short-term in-hospital mortality after primary acute myocardial infarction, Open Heart, Vol.8, No.2, e00186, 2021. (Tokushima University Institutional Repository) ● Metadata: 116972 (Link to Publication Site) ● Publication site (DOI): 10.1136/openhrt-2021-001860 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34810277 ● Summary page in Scopus @ Elsevier: 2-s2.0-85120377378 (Tokushima University Institutional Repository: 116972, DOI: 10.1136/openhrt-2021-001860, PubMed: 34810277, Elsevier: Scopus)
31.	Kenya Kusunose, Hironori Takahashi, Susumu Nishio, Yukina Hirata, Robert Zheng, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Kenji Shimada, Yasuhisa Kanematsu, Yasushi Takagi and Masataka Sata : Predictive value of left atrial function for latent paroxysmal atrial fibrillation as the cause of embolic stroke of undetermined source, Journal of Cardiology, Vol.78, No.5, 355-361, 2021. (Summary) In patients with embolic stroke of undetermined source (ESUS), paroxysmal atrial fibrillation (AF) is often diagnosed, however, the risk of paroxysmal AF in ESUS has not been well described. Several studies have suggested a linkage between left atrial (LA) functional parameters and risk of AF in stroke patients. The aim of this study was to assess the role of LA functional parameters as predictors of latent paroxysmal AF in ESUS on admission. Between January 2015 and December 2019, consecutive stroke patients with suspected ESUS at admission were prospectively included in this study. They were under hospital electrocardiographic monitoring for detection of new-onset AF. Various echocardiographic parameters including left atrial strain were assessed for association with new-onset AF. We gathered 1082 consecutive patients with ischemic stroke. After exclusions, 121 patients with suspected ESUS at admission formed the study cohort. New-onset AF was detected in 46 (38%) patients during hospital electrocardiographic monitoring (median follow-up: 18 days). LA pump and reservoir strains were significantly and independently associated with new-onset AF. Receiver operating characteristic analysis for the association with new-onset AF showed that the areas under the curve (AUCs) of clinical parameters plus one of each strain (LA pump strain: AUC: 0.86±0.04 and LA reservoir strain: AUC: 0.76±0.05) models were significantly better than plus LA volume index (AUC: 0.68±0.04, compared p-values <0.05). LA strain was significantly associated with new development of AF. Patients with impaired LA function at admission should be carefully monitored to find AF. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2021.05.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34119401 ● Search Scopus @ Elsevier (PMID): 34119401 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jjcc.2021.05.005 (DOI: 10.1016/j.jjcc.2021.05.005, PubMed: 34119401)
32.	Tomohiro Soga, Shinji Kawahito, Naoji Mita, Shusuke Yagi, K Nitta, K Takata, Fumihiko Tada, Hiroyuki Kinoshita, Kazumi Takaishi and Hiroshi Kitahata : Viability of intensive insulin therapy during pediatric surgery, Clinical Pediatric Anesthesia, Vol.27, No.1, 3-8, 2021. (Keyword) intensive insulin therapy / pediatrics / surgery / continuous blood glucose monitoring / artificial endocrine pancreas (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520294113670277632 (CiNii: 1520294113670277632)
33.	Kenya Kusunose, Yuichiro Okushi, Yoshihiro Okayama, Robert Zheng, Michikazu Nakai, Yoko Sumita, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Use of Echocardiography and Heart Failure In-Hospital Mortality from Registry Data in Japan., Journal of Cardiovascular Development and Disease, Vol.8, No.10, 124, 2021. (Summary) Echocardiography requires a high degree of skill on the part of the examiner, and the skill may be more improved in larger volume centers. This study investigated trends and outcomes associated with the use and volume of echocardiographic exams from a real-world registry database of heart failure (HF) hospitalizations. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). A first analysis was performed to assess the trend of echocardiographic examinations between 2012 and 2016. A secondary analysis was performed to assess whether echocardiographic use was associated with in-hospital mortality in 2015. During this period, the use of echocardiography grew at an average annual rate of 6%. Patients with echocardiography had declining rates of hospital mortality, and these trends were associated with high hospitalization costs. In the 2015 sample, a total of 52,832 echocardiograms were examined, corresponding to 65.6% of all HF hospital admissions for that year. We found that the use and volume of echocardiography exams were associated with significantly lower odds of all-cause hospital mortality in heart failure (adjusted odds ratio (OR): 0.48 for use of echocardiography and 0.78 for the third tertile; both < 0.001). The use of echocardiography was associated with decreased odds of hospital mortality in HF. The volumes of echocardiographic examinations were also associated with hospital mortality. (Tokushima University Institutional Repository) ● Metadata: 117323 (Link to Publication Site) ● Publication site (DOI): 10.3390/jcdd8100124 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34677193 ● Summary page in Scopus @ Elsevier: 2-s2.0-85116636823 (Tokushima University Institutional Repository: 117323, DOI: 10.3390/jcdd8100124, PubMed: 34677193, Elsevier: Scopus)
34.	Shusuke Yagi, T Takahashi, K Murakami, M Azuma, M Sugano, R Miyamoto, M Niki, Hirotsugu Yamada, Yutaka Kawabata, Tani Akihiro, Daiju Fukuda, Muneyuki Kadota, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Tomomi Matsuura, Koji Yamaguchi, Takeshi Soeki, Tetsuzo Wakatsuki, H Hata and Masataka Sata : Infective Endocarditis from Furuncle with Meningitis Complication Caused by Methicillin-resistant Staphylococcus aureus, Internal Medicine, Vol.60, No.20, 3251-3255, 2021. (Tokushima University Institutional Repository) ● Metadata: 118014 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.6902-20 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33867390 ● Search Scopus @ Elsevier (PMID): 33867390 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.6902-20 (Tokushima University Institutional Repository: 118014, DOI: 10.2169/internalmedicine.6902-20, PubMed: 33867390)
35.	Yuta Torii, Kenya Kusunose, Yukina Hirata, Susumu Nishio, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure, Journal of the American Society of Echocardiography, Vol.34, No.9, 966-975, 2021. (Summary) Heart failure with recovered ejection fraction (HFrecEF) has been reported in several previous studies to have a better prognosis than heart failure with reduced ejection fraction (HFrEF). However, the factors associated with HFrecEF have not been identified. The aim of this study was to test the hypothesis that left atrial (LA) strain could help identify patients with recovered ejection fraction (EF) among those with heart failure (HF) with low EF on admission. One hundred consecutive patients hospitalized for the first time for new-onset HF were enrolled. Patients were clinically diagnosed with HFrEF on admission (left ventricular EF < 40%) and received optimal treatment for HF. Twenty-eight patients improved to HFrecEF during 6 months of follow-up. Regarding clinical background, there were significantly more women and a lower rate of atrial fibrillation in the HFrecEF group than in the HFrEF group. In a multivariate logistic regression analysis, LA strain was an independent predictor of HFrecEF, even after adjustment for gender and left ventricular EF (odds ratio: 4.06; 95% CI: 2.04-8.07; P < .001). A cutoff value of 10.8% for LA strain showed high sensitivity (96%) and specificity (82%) in identifying HFrecEF in patients with HF presenting with low EF on admission. During a follow-up period of 24 ± 13 months, 31 patients (31%) had cardiovascular death or readmission for HF. Patients with reduced LA strain (<10.8%) had significantly shorter event-free survival than those with preserved LA strain (P = .02). LA strain is a useful indicator for predicting HFrecEF and should be considered as a routine measurement in patients with HFrEF on admission. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.echo.2021.03.016 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33852960 ● Search Scopus @ Elsevier (PMID): 33852960 ● Search Scopus @ Elsevier (DOI): 10.1016/j.echo.2021.03.016 (DOI: 10.1016/j.echo.2021.03.016, PubMed: 33852960)
36.	Tomomi Matsuura, Takeshi Soeki, Daiju Fukuda, Etsuko Uematsu, Takeshi Tobiume, Tomoya Hara, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation, Circulation Journal, Vol.85, No.8, 1383-1391, 2021. (Summary) Activated factor X (FXa), which contributes to chronic inflammation via protease-activated receptor 2 (PAR2), might play an important role in atrial fibrillation (AF) arrhythmogenesis. This study aimed to assess whether PAR2 signaling contributes to AF arrhythmogenesis and whether rivaroxaban ameliorates atrial inflammation and prevents AF.Methods and Results:In Study 1, PAR2 deficient (PAR2-/-) and wild-type mice were infused with angiotensin II (Ang II) or a vehicle via an osmotic minipump for 2 weeks. In Study 2, spontaneously hypertensive rats (SHRs) were treated with rivaroxaban, warfarin, or vehicle for 2 weeks after 8 h of right atrial rapid pacing. The AF inducibility and atrial remodeling in both studies were examined. Ang II-treated PAR2-/- mice had a lower incidence of AF and less mRNA expression of collagen1 and collagen3 in the atrium compared to wild-type mice treated with Ang II. Rivaroxaban significantly reduced AF inducibility compared with warfarin or vehicle. In SHRs treated with a vehicle, rapid atrial pacing promoted gene expression of inflammatory and fibrosis-related biomarkers in the atrium. Rivaroxaban, but not warfarin, significantly reduced expression levels of these genes. The FXa-PAR2 signaling pathway might contribute to AF arrhythmogenesis associated with atrial inflammation. A direct FXa inhibitor, rivaroxaban, could prevent atrial inflammation and reduce AF inducibility, probably by inhibiting the pro-inflammatory activation. (Tokushima University Institutional Repository) ● Metadata: 116065 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-20-1006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33746155 ● Summary page in Scopus @ Elsevier: 2-s2.0-85111576585 (Tokushima University Institutional Repository: 116065, DOI: 10.1253/circj.CJ-20-1006, PubMed: 33746155, Elsevier: Scopus)
37.	Pham Tran Phuong, Daiju Fukuda, Sachiko Nishimoto, JR Kim-Kaneyama, XF Lei, Yutaka Takahashi, Tomohito Sato, Kimie Tanaka, Kumiko Suto, Yutaka Kawabata, Koji Yamaguchi, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Kenji Shimada, Yasuhisa Kanematsu, Yasushi Takagi, Michio Shimabukuro, Mitsutoshi Setou, Glen N Barber and Masataka Sata : STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases, European Heart Journal, Vol.42, No.42, 4336-4348, 2021. (Summary) Lifestyle-related diseases promote atherosclerosis, a chronic inflammatory disease; however, the molecular mechanism remains largely unknown. Endogenous DNA fragments released under over-nutrient condition provoke sterile inflammation through the recognition by DNA sensors. Here, we investigated the role of stimulator of interferon genes (STING), a cytosolic DNA sensor, in atherogenesis. Apolipoprotein E-deficient (Apoe-/-) mice fed a western-type diet (WTD), a hypercholesterolaemic mouse model, showed higher STING expression and markers for DNA damage such as γH2AX, p53, and single-stranded DNA (ssDNA) accumulation in macrophages in the aorta compared with wild-type (WT) mice. The level of cGAMP, a STING agonist, in the aorta was higher in Apoe-/- mice. Genetic deletion of Sting in Apoe-/- mice reduced atherosclerotic lesions in the aortic arch, lipid, and macrophage accumulation in plaques, and inflammatory molecule expression in the aorta compared with the control. Pharmacological blockade of STING using a specific inhibitor, C-176, ameliorated atherogenesis in Apoe-/- mice. In contrast, bone marrow-specific STING expression in Apoe-/- mice stimulated atherogenesis. Expression or deletion of STING did not affect metabolic parameters and blood pressure. In vitro studies revealed that STING activation by cGAMP or mitochondrial DNA accelerated inflammatory molecule expression (e.g. TNF-α or IFN-β) in mouse and human macrophages. Activation of nuclear factor-κB and TANK binding kinase 1 was involved in STING-associated vascular inflammation and macrophage activation. Furthermore, human atherosclerotic lesions in the carotid arteries expressed STING and cGAMP. Stimulator of interferon genes stimulates pro-inflammatory activation of macrophages, leading to the development of atherosclerosis. Stimulator of interferon genes signalling may serve as a potential therapeutic target for atherosclerosis. (Link to Publication Site) ● Publication site (DOI): 10.1093/eurheartj/ehab249 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34226923 ● Summary page in Scopus @ Elsevier: 2-s2.0-85120384111 (DOI: 10.1093/eurheartj/ehab249, PubMed: 34226923, Elsevier: Scopus)
38.	B Ganbaatar, Daiju Fukuda, M Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, KI Hirata and Masataka Sata : Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice, Journal of Atherosclerosis and Thrombosis, Vol.28, No.6, 630-642, 2021. (Summary) The bioactive lipid, sphingosine-1-phosphate (S1P), has various roles in the physiology and pathophysiology of many diseases. There are five S1P receptors; however, the role of each S1P receptor in atherogenesis is still obscure. Here we investigated the contribution of S1P receptor 2 (S1P2) to atherogenesis by using a specific S1P2 antagonist, ONO-5430514, in apolipoprotein E-deficient (Apoe) mice. Apoe mice fed with a western-type diet (WTD) received ONO-5430514 (30 mg/kg/day) or vehicle. To examine the effect on atherogenesis, Sudan IV staining, histological analysis, qPCR, and vascular reactivity assay was performed. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. WTD-fed Apoe mice had significantly higher S1P2 expression in the aorta compared with wild-type mice. S1P2 antagonist treatment for 20 weeks reduced atherosclerotic lesion development (p<0.05). S1P2 antagonist treatment for 8 weeks ameliorated endothelial dysfunction (p<0.05) accompanied with significant reduction of lipid deposition, macrophage accumulation, and inflammatory molecule expression in the aorta compared with vehicle. S1P2 antagonist attenuated the phosphorylation of JNK in the abdominal aorta compared with vehicle (p<0.05). In HUVEC, S1P promoted inflammatory molecule expression such as MCP-1 and VCAM-1 p<0.001), which was attenuated by S1P2 antagonist or a JNK inhibitor (p<0.01). S1P2 antagonist also inhibited S1P-induced JNK phosphorylation in HUVEC (p<0.05). Our results suggested that an S1P2 antagonist attenuates endothelial dysfunction and prevents atherogenesis. S1P2, which promotes inflammatory activation of endothelial cells, might be a therapeutic target for atherosclerosis. (Tokushima University Institutional Repository) ● Metadata: 116449 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.54916 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32879149 ● Search Scopus @ Elsevier (PMID): 32879149 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.54916 (Tokushima University Institutional Repository: 116449, DOI: 10.5551/jat.54916, PubMed: 32879149)
39.	Y Okushi, Kenya Kusunose, Y Okayama, Robert Zheng, M Nakai, Y Sumita, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute Hospital Mortality of Venous Thromboembolism in Patients With Cancer From Registry Data, Journal of the American Heart Association, Vol.10, No.11, e019373, 2021. (Summary) Background The prognosis of patients with cancer-venous thromboembolism (VTE) is not well known because of a lack of registry data. Moreover, there is also no knowledge on how specific types are related to prognosis. We sought to evaluate the clinical characteristics and outcomes of patients with cancer-associated VTE, compared with a matched cohort without cancer using real-world registry data of VTE. Methods and Results This study was based on the Diagnosis Procedure Combination database in the JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination). Of 5 106 151 total patients included in JROAD-DPC, we identified 49 580 patients who were first hospitalized with VTE from April 2012 to March 2017. Propensity score was estimated with a logistic regression model, with cancer as the dependent variable and 18 clinically relevant covariates. After propensity matching, there were 25 148 patients with VTE with or without cancer. On propensity score-matched analysis with 25 148 patients with VTE, patients with cancer had higher total in-hospital mortality within 7 days (1.3% versus 1.1%, odds ratio [OR], 1.66; 95% CI, 1.31-2.11; <0.0001), 14 days (2.5% versus 1.5%, OR, 2.07; 95% CI, 1.72-2.49; <0.0001), and 30 days (4.8% versus 2.0%, OR, 2.85; 95% CI, 2.45-3.31; <0.0001). On analysis for each type of cancer, in-hospital mortality in 11 types of cancer was significantly high, especially pancreas (OR, 12.96; 95% CI, 6.41-26.20), biliary tract (OR, 8.67; 95% CI, 3.00-25.03), and liver (OR, 7.31; 95% CI, 3.05-17.50). Conclusions Patients with cancer had a higher in-hospital acute mortality for VTE than those without cancer, especially in pancreatic, biliary tract, and liver cancers. (Tokushima University Institutional Repository) ● Metadata: 116140 (Link to Publication Site) ● Publication site (DOI): 10.1161/JAHA.120.019373 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34027673 ● Search Scopus @ Elsevier (PMID): 34027673 ● Search Scopus @ Elsevier (DOI): 10.1161/JAHA.120.019373 (Tokushima University Institutional Repository: 116140, DOI: 10.1161/JAHA.120.019373, PubMed: 34027673)
40.	Shinji Kawahito, 木下浩之, Kazumi Takaishi, Tomohiro Soga, Shusuke Yagi and Hiroshi Kitahata : 細胞骨格ターンオーバー調節物質による細胞内経路制御機構の解明と麻酔薬作用, Precision Medicine, Vol.4, No.4, 32-35, 2021. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523951030917611264 (CiNii: 1523951030917611264)
41.	Miharu Arase, Kenya Kusunose, N Yamaguchi, Yukina Hirata, Susumu Nishio, Y Okushi, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis., Open Heart, Vol.8, No.1, e001559, 2021. (Tokushima University Institutional Repository) ● Metadata: 116465 (Link to Publication Site) ● Publication site (DOI): 10.1136/openhrt-2020-001559 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1136/openhrt-2020-001559 (Tokushima University Institutional Repository: 116465, DOI: 10.1136/openhrt-2020-001559)
42.	Kenya Kusunose, Y Okushi, Y Okayama, Robert Zheng, M Abe, M Nakai, Y Sumita, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Association between Vitamin D and Heart Failure Mortality in 10,974 Hospitalized Individuals., Nutrients, Vol.13, No.2, 335, 2021. (Summary) A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials. (Tokushima University Institutional Repository) ● Metadata: 116464 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu13020335 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33498709 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099832739 (Tokushima University Institutional Repository: 116464, DOI: 10.3390/nu13020335, PubMed: 33498709, Elsevier: Scopus)
43.	Gulinu Maimaituxun, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Shusuke Yagi, Yuta Torii, Nao Yamada, Takeshi Soeki, H Masuzaki, Masataka Sata and Michio Shimabukuro : Deleterious Effects of Epicardial Adipose Tissue Volume on Global Longitudinal Strain in Patients With Preserved Left Ventricular Ejection Fraction, Frontiers in Cardiovascular Medicine, Vol.7, 607825, 2021. (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2020.607825 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33521062 ● Search Scopus @ Elsevier (PMID): 33521062 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2020.607825 (DOI: 10.3389/fcvm.2020.607825, PubMed: 33521062)
44.	Hironori Tanaka, Yoshihito Saijyo, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi, Shusuke Yagi, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, Masataka Sata and Tetsuji Takayama : An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration, Internal Medicine, Vol.60, No.12, 1839-1845, 2021. (Summary) A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved. (Tokushima University Institutional Repository) ● Metadata: 116336 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.5914-20 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456037 ● Search Scopus @ Elsevier (PMID): 33456037 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.5914-20 (Tokushima University Institutional Repository: 116336, DOI: 10.2169/internalmedicine.5914-20, PubMed: 33456037)
45.	Akira Takashima, Shusuke Yagi, Koji Yamaguchi, Kiyoe Kurahashi, Yuko Kojima, Robert Zheng, Takayuki Ise, Kenya Kusunose, Sumiko Yoshida, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 189-191, 2021. (Summary) The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of androgen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or atherosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypogonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 : 189-191, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 116019 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994469 ● Search Scopus @ Elsevier (PMID): 33994469 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.189 (Tokushima University Institutional Repository: 116019, DOI: 10.2152/jmi.68.189, PubMed: 33994469)
46.	Yutaka Kawabata, Takeshi Soeki, Hiroyuki Ito, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, M Kitani, K Kawano, Y Taketani and Masataka Sata : Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients, International Journal of Hypertension, 6653851, 2020. (Tokushima University Institutional Repository) ● Metadata: 115937 (Link to Publication Site) ● Publication site (DOI): 10.1155/2020/6653851 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33489354 ● Summary page in Scopus @ Elsevier: 2-s2.0-85098701678 (Tokushima University Institutional Repository: 115937, DOI: 10.1155/2020/6653851, PubMed: 33489354, Elsevier: Scopus)
47.	Takeshi Tobiume, R Kato, Tomomi Matsuura, Kazuhisa Matsumoto, M Hara, N Takamori, Y Taketani, K Okwa, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Takeshi Soeki, Masataka Sata and K Matsumoto : Antegrade slow pathway mapping of typical atrioventricular nodal reentrant tachycardia based on direct slow pathway capture, Journal of Arrhythmia, Vol.37, No.1, 128-139, 2020. (Tokushima University Institutional Repository) ● Metadata: 116343 (Link to Publication Site) ● Publication site (DOI): 10.1002/joa3.12484 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33664895 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099515348 (Tokushima University Institutional Repository: 116343, DOI: 10.1002/joa3.12484, PubMed: 33664895, Elsevier: Scopus)
48.	Kenya Kusunose, nao Yamada, Hirotsugu Yamada, Susumu Nishio, Yoshihito Saijoh, Yukina Hirata, Yuta Torii, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Association between Right Ventricular Contractile Function and Cardiac Events in Isolated Post-capillary and Combined Pre- and Post-capillary Pulmonary Hypertension, Journal of Cardiac Failure, Vol.26, No.1, 43-51, 2020. (Summary) Recent studies have shown that patients with combined pre- and postcapillary pulmonary hypertension (CpcPH) had worse outcomes than those with isolated postcapillary pulmonary hypertension (IpcPH). However, the prognostic factors including right ventricular (RV) function have not been well documented. The aim of this study was to assess the differentiation of PH phenotypes, using echocardiography, and the association between RV longitudinal strain and cardiac events. We prospectively recruited consecutive patients who had undergone right heart catheterization. The primary endpoint was cardiovascular death or readmission due to heart failure. We included 137 patients with Group 2 PH. A RV longitudinal strain of 17% was sensitive (85%) and specific (70%) to determine the CpcPH. During a median period of 31 months, 43 patients experienced the primary endpoint during follow-up. In a multivariate analysis, RV longitudinal strain was associated with the primary endpoint in both CpcPH and IpcPH (HR: 0.84, P = 0.003; HR: 0.86, P = 0.001). Lower RV longitudinal strain was independently associated with worse outcomes in CpcPH and IpcPH. RV longitudinal strain may play a prognostic role in PH phenotypes. (Tokushima University Institutional Repository) ● Metadata: 114190 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cardfail.2019.08.021 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31487533 ● Summary page in Scopus @ Elsevier: 2-s2.0-85072539026 (Tokushima University Institutional Repository: 114190, DOI: 10.1016/j.cardfail.2019.08.021, PubMed: 31487533, Elsevier: Scopus)
49.	Shinji Kawahito, Tomohiro Soga, Shusuke Yagi, Naoji Mita, Kazumi Takaishi, Hiroyuki Kinoshita, Tetsuya Kitagawa and Hiroshi Kitahata : Pathophysiology and complications during extracorporeal circulation, The Journal of Medical Investigation : JMI, Vol.67, No.3,4, 229-235, 2020. (Tokushima University Institutional Repository) ● Metadata: 115409 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.229 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148893 ● Search Scopus @ Elsevier (PMID): 33148893 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.229 (Tokushima University Institutional Repository: 115409, DOI: 10.2152/jmi.67.229, PubMed: 33148893)
50.	Yuta Torii, Kenya Kusunose, Robert Zheng, Hirotsugu Yamada, Rie Amano, Rikizo Matsumoto, Yukina Hirata, Susumu Nishio, Nao Yamada, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Yoshihiro Okayama and Masataka Sata : Association between Sarcopenia/Lower Muscle Mass and Short-Term Regression of Deep Vein Thrombosis Using Direct Oral Anticoagulants, International Heart Journal, Vol.61, No.4, 787-794, 2020. (Summary) Advanced age, obesity, and muscle weakness are independent factors in the onset of deep vein thrombosis (DVT). Recently, an association between sarcopenia and DVT has been reported. We hypothesized that sarcopenia related factors, observed by ultrasonography, are associated with the regression effect on the thrombus following anticoagulation therapy. The present study focused on gastrocnemius muscle (GCM) thickness and the GCM's internal echogenic brightness. We examined the association with DVT regression following direct oral anticoagulants (DOACs) treatment.The prospective cohort study period was between October 2017 and August 2018. We enrolled 46 patients diagnosed with DVT by ultrasonography, who were aged >60 years old and treated with DOACs. Sarcopenia was evaluated using the Asian Working Group for Sarcopenia flowchart. The average DOACs treatment period was 94 days, and 29 patients exhibited thrombus regression. On univariate logistic regression analysis, sarcopenia, average GCM diameter index, and gastrocnemius integrated backscatter index were significantly associated with thrombus regression. In a multivariate model, only the average GCM diameter index correlated with thrombus regression.The average GCM diameter index is associated with DVT regression treated with DOACs. Considering the GCM diameter during DVT treatment can be a marker to make a decision for the treatment of DVT. (Keyword) Aged / Aged, 80 and over / Factor Xa Inhibitors / female / Humans / male / Middle Aged / Muscle, Skeletal / Prospective Studies / Sarcopenia / Ultrasonography / Venous Thrombosis (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.20-032 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32684602 ● Summary page in Scopus @ Elsevier: 2-s2.0-85088879684 (DOI: 10.1536/ihj.20-032, PubMed: 32684602, Elsevier: Scopus)
51.	Kenya Kusunose, M Fujiwara, Hirotsugu Yamada, Susumu Nishio, Y Saijo, N Yamada, Yukina Hirata, Yuta Torii, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Deterioration of Biventricular Strain Is an Early Marker of Cardiac Involvement in Confirmed Sarcoidosis, European Heart Journal Cardiovascular Imaging, Vol.21, No.7, 796-804, 2020. (Summary) Risk assessment of developing cardiac involvement in systemic sarcoidosis can be challenging because of limited data. Recently, attention has been given to left ventricular and right ventricular (LV and RV) involvement in cardiac sarcoidosis (CS) and its prevalence, relevance, and prognostic value. The aim of this study was to assess the role of biventricular strain to predict prognosis in confirmed sarcoidosis patients. LV and RV longitudinal strains (LSs) were evaluated by 2D speckle tracking in 139 consecutive confirmed sarcoidosis patients without other pre-existing structural heart diseases, and 52 age- and gender-matched control subjects. The primary endpoint was CS-related events (cardiac death or development of cardiac involvement). Sarcoidosis without cardiac involvement had significantly lower LV and RV free wall LS compared with control subjects. Basal LS had a higher area under the curve for differentiation of sarcoidosis in patients without cardiac involvement compared to control (cut-off value: -18% with 89% sensitivity and 69% specificity). During a median period of 50 months, the occurrence of CS-related events was observed in 20 patients. In a multivariate analysis, basal LV LS and RV free wall LS were associated with the events [hazard ratio (HR) 0.72, P < 0.001 and HR: 0.83, P = 0.006, respectively]. Patients with impaired biventricular function had significantly shorter event-free survival than those with preserved biventricular function (P < 0.001). Deterioration of biventricular strain was associated with CS-related events. This information might be useful for clinical evaluation and follow-up in sarcoidosis. (Link to Publication Site) ● Publication site (DOI): 10.1093/ehjci/jez235 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31566217 ● Summary page in Scopus @ Elsevier: 2-s2.0-85086792785 (DOI: 10.1093/ehjci/jez235, PubMed: 31566217, Elsevier: Scopus)
52.	Hiroyuki Ito, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Yoshihiro Tsuruo and Masataka Sata : Atherosclerotic Coronary Plaque Is Associated With Adventitial Vasa Vasorum and Local Inflammation in Adjacent Epicardial Adipose Tissue in Fresh Cadavers, Circulation Journal, Vol.84, No.5, 769-775, 2020. (Tokushima University Institutional Repository) ● Metadata: 116640 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-19-0914 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32281556 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083919450 (Tokushima University Institutional Repository: 116640, DOI: 10.1253/circj.CJ-19-0914, PubMed: 32281556, Elsevier: Scopus)
53.	B Ganbaatar, Daiju Fukuda, M Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, KI Hirata and Masataka Sata : Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-deficient Mice, European Journal of Pharmacology, Vol.15, No.875, 173040, 2020. (Summary) Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE) mice. Male streptozotocin (STZ) - induced diabetic ApoE mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E and thromboxane B (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-α in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2020.173040 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32114052 ● Summary page in Scopus @ Elsevier: 2-s2.0-85080985939 (DOI: 10.1016/j.ejphar.2020.173040, PubMed: 32114052, Elsevier: Scopus)
54.	Arief Rahadian, Daiju Fukuda, HM Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice, Journal of Atherosclerosis and Thrombosis, Vol.27, No.11, 1141-1151, 2020. (Summary) Recent studies have demonstrated that selective sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, although their mechanism remains obscure. We examined the effect of canagliflozin, an SGLT2i, on atherogenesis and investigated its underlying mechanism. Canagliflozin (30 mg/kg/day) was administered by gavage to streptozotocin-induced diabetic apolipoprotein E-deficient (ApoE) mice. Sudan IV staining was performed at the aortic arch. Immunostaining, quantitative RT-PCR, and vascular reactivity assay were performed using the aorta. In vitro experiments using human umbilical vein endothelial cells (HUVECs) were also performed. Canagliflozin decreased blood glucose (P<0.001) and total cholesterol (P<0.05) levels. Sudan IV staining showed that 12-week canagliflozin treatment decreased atherosclerotic lesions (P<0.05). Further, 8-week canagliflozin treatment ameliorated endothelial dysfunction, as determined by acetylcholine-induced vasodilation (P<0.05), and significantly reduced the expressions of inflammatory molecules such as ICAM-1 and VCAM-1 in the aorta at the RNA and protein levels. Canagliflozin also reduced the expressions of NADPH oxidase subunits such as NOX2 and p22phox in the aorta and reduced urinary excretion of 8-OHdG, suggesting a reduction in oxidative stress. Methylglyoxal, a precursor of advanced glycation end products, increased the expressions of ICAM-1 and p22phox in HUVECs (P<0.05, both). Methylglyoxal also decreased the phosphorylation of eNOS and Akt but increased the phosphorylation of eNOS and p38 MAPK in HUVECs. Canagliflozin prevents endothelial dysfunction and atherogenesis in diabetic ApoE mice. Anti-inflammatory and antioxidative potential due to reduced glucose toxicity to endothelial cells might be its underlying mechanisms. (Tokushima University Institutional Repository) ● Metadata: 115926 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.52100 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32101837 ● CiNii @ National Institute of Informatics (CRID): 1390286426514028416 ● Search Scopus @ Elsevier (PMID): 32101837 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.52100 (Tokushima University Institutional Repository: 115926, DOI: 10.5551/jat.52100, PubMed: 32101837, CiNii: 1390286426514028416)
55.	Maimaituxun Gulinu, Hirotsugu Yamada, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirata Yukina, Nishio Susumu, Takeshi Soeki, Masuzaki Hiroaki, Masataka Sata and Michio Shimabukuro : Association of Local Epicardial Adipose Tissue Depots and Left Ventricular Diastolic Performance in Patients With Preserved Left Ventricular Ejection Fraction, Circulation Journal, Vol.84, No.2, 203-216, 2020. (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-19-0793 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31956209 ● Summary page in Scopus @ Elsevier: 2-s2.0-85079208017 (DOI: 10.1253/circj.CJ-19-0793, PubMed: 31956209, Elsevier: Scopus)
56.	Arief Rahadian, Daiju Fukuda, HM Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice, Vascular Pharmacology, Vol.124, 106632, 2020. (Summary) Diabetic patients have coagulation abnormalities, in which thrombin plays a key role. Whereas accumulating evidence suggests that it also contributes to the development of vascular dysfunction through the activation of protease-activated receptors (PARs). Here we investigated whether the blockade of thrombin attenuates endothelial dysfunction in diabetic mice. Induction of diabetes by streptozotocin (STZ) increased the expression of PAR1, PAR3, and PAR4 in the aorta. STZ-induced diabetic mice showed impairment of endothelial function, while the administration of dabigatran etexilate, a direct thrombin inhibitor, significantly attenuated endothelial dysfunction in diabetic mice with no alteration of metabolic parameters including blood glucose level. Dabigatran did not affect endothelium-independent vasodilation. Dabigatran decreased the expression of inflammatory molecules (e.g., MCP-1 and ICAM-1) in the aorta of diabetic mice. Thrombin increased the expression of these inflammatory molecules and the phosphorylation of IκBα, and decreased the phosphorylation of eNOS in human umbilical endothelial cells (HUVEC). Thrombin significantly impaired the endothelium-dependent vascular response of aortic rings obtained from wild-type mice. Inhibition of NF-κB attenuated thrombin-induced inflammatory molecule expression in HUVEC and ameliorated thrombin-induced endothelial dysfunction in aortic rings. Dabigatran attenuated the development of diabetes-induced endothelial dysfunction. Thrombin signaling may serve as a potential therapeutic target in diabetic condition. (Tokushima University Institutional Repository) ● Metadata: 114211 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.vph.2019.106632 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31759113 ● Search Scopus @ Elsevier (PMID): 31759113 ● Search Scopus @ Elsevier (DOI): 10.1016/j.vph.2019.106632 (Tokushima University Institutional Repository: 114211, DOI: 10.1016/j.vph.2019.106632, PubMed: 31759113)
57.	K Aini, Daiju Fukuda, K Tanaka, Y Higashikuni, Yukina Hirata, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice, International Heart Journal, Vol.60, No.6, 1421-1429, 2019. (Summary) Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with possible vascular protection effects. Endothelial dysfunction is an initiation step in atherogenesis. The purpose of this study was to investigate whether vildagliptin (Vilda) attenuates the development of endothelial dysfunction and atherosclerotic lesions in nondiabetic apolipoprotein E-deficient (ApoE) mice. Eight-week-old nondiabetic ApoE mice fed a Western-type diet received Vilda (50 mg/kg/day) for 20 weeks or 8 weeks. After 20 weeks of treatment, Vilda administration reduced atherogenesis in the aortic arch as determined by en face Sudan IV staining compared with the vehicle group (P < 0.05). Vilda also reduced lipid accumulation (P < 0.05) and vascular cell adhesion molecule-1 (VCAM-1) expression (P < 0.05) and tended to decrease macrophage infiltration (P = 0.05) into atherosclerotic plaques compared with vehicle. After 8 weeks of treatment, endothelium-dependent vascular reactivity was examined. Vilda administration significantly attenuated the impairment of endothelial function in nondiabetic ApoE mice compared with the vehicle group (P < 0.05). Vilda treatment did not alter metabolic parameters, including blood glucose level, in both study protocols. To investigate the mechanism, aortic segments obtained from wild-type mice were incubated with exendin-4 (Ex-4), a glucagon-like peptide-1 (GLP-1) analog, in the presence or absence of lipopolysaccharide (LPS). Ex-4 attenuated the impairment of endothelium-dependent vasodilation induced by LPS (P < 0.01). Furthermore, Ex-4 promoted phosphorylation of eNOS at Ser1177 which was decreased by LPS in human umbilical endothelial cells (P < 0.05). Vilda inhibited the development of endothelial dysfunction and prevented atherogenesis in nondiabetic ApoE mice. Our results suggested that GLP-1-dependent amelioration of endothelial dysfunction is associated with the atheroprotective effects of Vilda. (Keyword) Animals / Apolipoproteins E / Atherosclerosis / Cell Culture Techniques / Dipeptidyl-Peptidase IV Inhibitors / Disease Models, Animal / Endothelial Cells / Endothelium, Vascular / Mice / Mice, Inbred C57BL / Vascular Cell Adhesion Molecule-1 / Vildagliptin (Tokushima University Institutional Repository) ● Metadata: 114212 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.19-117 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31735774 ● Summary page in Scopus @ Elsevier: 2-s2.0-85075961168 (Tokushima University Institutional Repository: 114212, DOI: 10.1536/ihj.19-117, PubMed: 31735774, Elsevier: Scopus)
58.	Kenya Kusunose, Yuta Torii, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Yoshihito Saijoh, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Association of Echocardiography Before Major Elective Non-Cardiac Surgery With Improved Postoperative Outcomes - Possible Implications for Patient Care., Circulation Journal, Vol.83, No.12, 2512-2519, 2019. (Summary) Whether preoperative echocardiography improves postoperative outcomes is not well established, so we examined the value of echocardiographic assessment on the onset of postoperative heart failure (HF), and determining which patients benefitted most from undergoing echocardiography prior to major elective non-cardiac surgery.Methods and Results:We identified all patients aged 50 years and older who had major elective non-cardiac surgery, and excluded patients with previously identified severe cardiovascular disease. The primary endpoint was the onset of HF during hospitalization. A total of 806 patients were included in the analysis. During hospitalization, 49 patients (6%) reached the primary endpoint. Within the matched cohort, preoperative echocardiography was associated with a statistically significant decrease in postoperative HF (hazard ratio: 0.46, P=0.01). In subgroup analyses, age, sex, body surface area, hypertension, diabetes mellitus, prior HF, surgical type, chronic kidney disease, pulmonary disease, and malignancy influenced the association of echocardiography with postoperative HF. The use of echocardiography in elderly patients with certain risk factors was associated with improved postoperative outcomes. The basis for this finding remains to be determined; particularly whether echocardiography is simply a marker of a population with better outcomes or whether it leads to better management that improves outcomes. (Keyword) Aged / Echocardiography / Female / Heart Failure / Humans / Incidence / Japan / Male / Middle Aged / Predictive Value of Tests / Preoperative Care / Retrospective Studies / Risk Assessment / Risk Factors / Surgical Procedures, Operative / Time Factors / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 114189 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-19-0663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31611537 ● Search Scopus @ Elsevier (PMID): 31611537 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-19-0663 (Tokushima University Institutional Repository: 114189, DOI: 10.1253/circj.CJ-19-0663, PubMed: 31611537)
59.	Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Yoshihito Saijoh, Yuta Torii, nao Yamada, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Pulmonary Artery Hypertension-Specific Therapy Improves Exercise Tolerance and Outcomes in Exercise-Induced Pulmonary Hypertension, JACC. Cardiovascular Imaging, Vol.12, No.12, 2576-2579, 2019. (Tokushima University Institutional Repository) ● Metadata: 114191 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2019.07.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31422131 ● Search Scopus @ Elsevier (PMID): 31422131 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcmg.2019.07.002 (Tokushima University Institutional Repository: 114191, DOI: 10.1016/j.jcmg.2019.07.002, PubMed: 31422131)
60.	PT Pham, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice, Scientific Reports, Vol.9, No.1, 11206, 2019. (Summary) Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular function through activation of protease-activated receptors (PARs). Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose level. Rivaroxaban promoted eNOS phosphorylation in the aorta (P < 0.001). Induction of diabetes to PAR2-deficient (PAR2) mice did not affect endothelial function and eNOS phosphorylation in the aorta compared with non-diabetic PAR2 mice. FXa or a PAR2 agonist significantly impaired endothelial function in aortic rings obtained from WT mice, but not in those from PAR2 mice. FXa promoted JNK phosphorylation (P < 0.01) and reduced eNOS phosphorylation (P < 0.05) in human coronary artery endothelial cells (HCAEC). FXa-induced endothelial dysfunction in aortic rings (P < 0.001) and eNOS phosphorylation (P < 0.05) in HCAEC were partially ameliorated by a JNK inhibitor. Rivaroxaban ameliorated diabetes-induced endothelial dysfunction. Our results suggest that FXa or PAR2 is a potential therapeutic target. (Tokushima University Institutional Repository) ● Metadata: 114192 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-47474-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31371788 ● Search Scopus @ Elsevier (PMID): 31371788 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-47474-0 (Tokushima University Institutional Repository: 114192, DOI: 10.1038/s41598-019-47474-0, PubMed: 31371788)
61.	Yuta Torii, Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Amano Rie, Yamao Masami, Zheng Robert, Yoshihito Saijoh, nao Yamada, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Updated Left Ventricular Diastolic Function Recommendations and Cardiovascular Events in Patients with Heart Failure Hospitalization, Journal of the American Society of Echocardiography, Vol.32, No.10, 1286-1297, 2019. (Summary) Evaluation of diastolic dysfunction is crucial in determining elevated left atrial pressure. However, a validation of the long-term prognostic value of the newly proposed algorithm updated in 2016 has not been performed. The aim of the present study was to investigate the relative value of the updated 2016 diastolic dysfunction grading system for the incidence of readmission in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Two hundred thirty-two patients hospitalized with HF were retrospectively evaluated. Subjects were divided into two subgroups: those with HFrEF (n = 127) and those with HFpEF (n = 105). Readmission risk scores were calculated using the Yale Center for Outcomes Research and Evaluation HF, LACE index, and HOSPITAL scores. The primary end point was readmission following HF and cardiac death. Over a period of 24 months, 86 patients were either readmitted or died. Multivariate Cox analysis was performed on both the HFrEF and HFpEF groups. In the HFrEF group, both the 2009 and 2016 algorithms had superior incremental value for the association of the primary end point to several readmission risk scores. In the HFpEF group, only the 2016 algorithm led to significant improvement in association with the primary end point. The 2016 algorithm had incremental value over several readmission risk scores alone. The recommendations of the 2016 algorithm can be useful for readmission and cardiac mortality risk assessment in patients with HFrEF and HFpEF. The use of echocardiography to estimate elevated left atrial pressure appears to identify a higher risk group and may allow a more tailored approach to therapy. (Tokushima University Institutional Repository) ● Metadata: 114193 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.echo.2019.06.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31378421 ● Summary page in Scopus @ Elsevier: 2-s2.0-85069976367 (Tokushima University Institutional Repository: 114193, DOI: 10.1016/j.echo.2019.06.006, PubMed: 31378421, Elsevier: Scopus)
62.	Nami Kakuta, Shinji Kawahito, Naoji Mita, Tomohiro Soga, Shusuke Yagi, Shiho Satomi, Fumihiko Tada, Kinoshita Hiroyuki, Kazumi Takaishi and Hiroshi Kitahata : Continuous blood glucose monitoring during pediatric cardiopulmonary bypass., Clinical Pediatric Anesthesia, Vol.25, No.1, 3-7, 2019. (Tokushima University Institutional Repository) ● Metadata: 113628 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564288848711808 (Tokushima University Institutional Repository: 113628, CiNii: 1050564288848711808)
63.	M Kajikawa, T Maruhashi, T Hidaka, S Matsui, H Hashimoto, Y Takaeko, Y Nakano, S Kurisu, Y Kihara, FM Yusoff, S Kishimoto, K Chayama, C Goto, K Noma, A Nakashima, T Hiro, A Hirayama, K Shiina, H Tomiyama, Shusuke Yagi, Amano Rie, Hirotsugu Yamada, Masataka Sata and Y Higashi : Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study, Scientific Reports, Vol.9, No.1, 10206, 2019. (Summary) The dipeptidyl peptidase-4 inhibitor saxagliptin is a widely used antihyperglycemic agent in patients with type 2 diabetes. The purpose of this study was to evaluate the effects of saxagliptin on endothelial function in patients with type 2 diabetes. This was a prospective, multicenter, interventional study. A total of 34 patients with type 2 diabetes were enrolled at four university hospitals in Japan. Treatment of patients was initially started with saxagliptin at a dose of 5 mg daily. Assessment of endothelial function assessed by flow-mediated vasodilation (FMD) and measurement of stromal cell-derived factor-1α (SDF-1α) were conducted at baseline and at 3 months after treatment with saxagliptin. A total of 31 patients with type 2 diabetes were included in the analysis. Saxagliptin significantly increased FMD from 3.1 ± 3.1% to 4.2 ± 2.4% (P = 0.032) and significantly decreased total cholesterol from 190 ± 24 mg/dL to 181 ± 25 mg/dL (P = 0.002), glucose from 160 ± 53 mg/dL to 133 ± 25 mg/dL (P < 0.001), HbA1c from 7.5 ± 0.6% to 7.0 ± 0.6% (P < 0.001), urine albumin-to-creatinine ratio from 63.8 ± 134.2 mg/g to 40.9 ± 83.0 mg/g (P = 0.043), and total SDF-1α from 2108 ± 243 pg/mL to 1284 ± 345 pg/mL (P < 0.001). These findings suggest that saxagliptin is effective for improving endothelial function. (Tokushima University Institutional Repository) ● Metadata: 114195 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-46726-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31308448 ● Summary page in Scopus @ Elsevier: 2-s2.0-85069056464 (Tokushima University Institutional Repository: 114195, DOI: 10.1038/s41598-019-46726-3, PubMed: 31308448, Elsevier: Scopus)
64.	Shinji Kawahito, Naoji Mita, Tomohiro Soga, Shusuke Yagi, Nami Kakuta, Shiho Satomi, Hiroyuki Kinoshita, Kazumi Takaishi, Tetsuya Kitagawa and Hiroshi Kitahata : Accuracy and reliability of continuous blood glucose monitoring during pediatric cardiopulmonary bypass., Journal of Artificial Organs, Vol.22, No.4, 353-356, 2019. (Summary) The purpose of this study was to assess the accuracy and reliability of a continuous blood glucose monitoring system (artificial endocrine pancreas; STG-55, Nikkiso, Tokyo, Japan) during pediatric cardiopulmonary bypass surgery. Twenty-five pediatric patients scheduled to undergo cardiovascular surgery with cardiopulmonary bypass (age 4 months to 11 years; body weight 5.6-59.7 kg) were enrolled. The glucose sensor line of the artificial endocrine pancreas was connected to the venous side of the cardiopulmonary bypass circuit and used for continuous blood glucose monitoring. We obtained 192 samples for blood gas assessment from the cardiopulmonary bypass circuit, and i-STAT (Abbott, East Windsor, NJ, USA) was used for conventional blood glucose assessment. The accuracies of continuous glucose measurements (STG-55) and conventional intermittent glucose measurements (i-STAT) during cardiopulmonary bypass were compared by means of Clarke error grid analysis. The results were divided into five zones, A, B, C, D, and E, and 78.6% of paired measurements were in zone A, while 21.4% were in zone B. We confirmed that the results of this continuous blood glucose monitoring system for cardiopulmonary bypass during pediatric cardiovascular surgery were highly reliable. An artificial endocrine pancreas may facilitate the safe use of intensive insulin therapy during pediatric cardiovascular surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10047-019-01111-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31236730 ● Search Scopus @ Elsevier (PMID): 31236730 ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-019-01111-9 (DOI: 10.1007/s10047-019-01111-9, PubMed: 31236730)
65.	Rie Ueno, Shusuke Yagi, Mika Bando and Masataka Sata : Long-surviving Anomalous Origin of the Right Pulmonary Artery from the Ascending Aorta Complicated with Pulmonary Arteriovenous Fistula, Internal Medicine, Vol.58, No.18, 2749-2750, 2019. (Tokushima University Institutional Repository) ● Metadata: 113417 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.2455-18 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31178488 ● Summary page in Scopus @ Elsevier: 2-s2.0-85072509638 (Tokushima University Institutional Repository: 113417, DOI: 10.2169/internalmedicine.2455-18, PubMed: 31178488, Elsevier: Scopus)
66.	Shusuke Yagi, Hiromu Yamazaki, Susumu Nishio, Kenya Kusunose, Hirotsugu Yamada and Masataka Sata : Simultaneous Pulmonary Arterial and Venous Round Structures in Pulmonary Aspergillosis., Circulation Journal, Vol.83, No.6, 1416, 2019. (Tokushima University Institutional Repository) ● Metadata: 113219 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-18-0898 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30393271 ● Summary page in Scopus @ Elsevier: 2-s2.0-85066748188 (Tokushima University Institutional Repository: 113219, DOI: 10.1253/circj.CJ-18-0898, PubMed: 30393271, Elsevier: Scopus)
67.	Daiju Fukuda, Sachiko Nishimoto, Kunduziayi Aini, Atsushi Tanaka, Tsuyoshi Nishiguchi, Joo-Ri Kim-Kaneyama, Xiao-Feng Lei, Kiyoshi Masuda, Takuya Naruto, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Issei Imoto, Takashi Akasaka, Michio Shimabukuro and Masataka Sata : Toll-Like Receptor 9 Plays a Pivotal Role in Angiotensin II-Induced Atherosclerosis, Journal of the American Heart Association, Vol.8, No.7, e010860, 2019. (Summary) Background Toll-like receptor ( TLR ) 9 recognizes bacterial DNA , activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR 9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E-deficient ( Apoe ) mice. Methods and Results Tlr9-deficient Apoe ( Tlr9 Apoe ) mice and Apoe mice on a Western-type diet received subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double-stranded DNA, an endogenous ligand of TLR 9, in these mice. Genetic deletion or pharmacologic blockade of TLR 9 in angiotensin II-infused Apoe mice attenuated atherogenesis in the aortic arch ( P<0.05), reduced the accumulation of lipid and macrophages in atherosclerotic plaques, and decreased RNA expression of inflammatory molecules in the aorta with no alteration of metabolic parameters. On the other hand, restoration of TLR 9 in bone marrow in Tlr9 Apoe mice promoted atherogenesis in the aortic arch ( P<0.05). A TLR 9 agonist markedly promoted proinflammatory activation of Apoe macrophages, partially through p38 mitogen-activated protein kinase signaling. In addition, genomic DNA extracted from macrophages promoted inflammatory molecule expression more effectively in Apoe macrophages than in Tlr9 Apoe macrophages. Furthermore, in humans, circulating double-stranded DNA in the coronary artery positively correlated with inflammatory features of coronary plaques determined by optical coherence tomography in patients with acute myocardial infarction ( P<0.05). Conclusions TLR 9 plays a pivotal role in the development of vascular inflammation and atherogenesis through proinflammatory activation of macrophages. TLR 9 may serve as a potential therapeutic target for atherosclerosis. (Keyword) Aged / Angiotensin II / Animals / Aorta, Thoracic / atherosclerosis / Bone Marrow Transplantation / Cell-Free Nucleic Acids / Chemokine CCL2 / female / Humans / In Vitro Techniques / inflammation / Lipids / Macrophages / Macrophages, Peritoneal / male / Mice / knockout mice / Mice, Knockout, ApoE / Microscopy, Electron / Myocardial Infarction / Percutaneous Coronary Intervention / Plaque, Atherosclerotic / RNA, Messenger / Reverse Transcriptase Polymerase Chain Reaction / Toll-Like Receptor 9 / Tomography, Optical Coherence / Tumor Necrosis Factor-alpha / Vasoconstrictor Agents (Tokushima University Institutional Repository) ● Metadata: 113231 (Link to Publication Site) ● Publication site (DOI): 10.1161/JAHA.118.010860 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30905257 ● Summary page in Scopus @ Elsevier: 2-s2.0-85063712345 (Tokushima University Institutional Repository: 113231, DOI: 10.1161/JAHA.118.010860, PubMed: 30905257, Elsevier: Scopus)
68.	Yukina Hirata, Kenya Kusunose, Hirotsugu Yamada, Sae Morita, Yuta Torii, Susumu Nishio, Robert Zheng, Yoshihito Saijo, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Left atrial functional response after a marathon in healthy amateur volunteers, The International Journal of Cardiovascular Imaging, Vol.35, No.4, 633-643, 2019. (Summary) Middle-aged marathon runners have an increased risk of developing atrial fibrillation (AF). A previous study described that repetitive marathon running was associated with left atrial (LA) dysfunction. However, whether this change is common in marathon runners and which runners are at risk of LA dysfunction remain unknown. The purpose of this study was to determine which factors could predict LA dysfunction. We prospectively examined 12 healthy amateur volunteers (9 males, 31 ± 8 years old) who participated in a full marathon. All echocardiographic measurements and speckle-tracking echocardiography were performed before and after the marathon. The endpoint was defined as reduced LA reservoir strain 1 day after the marathon (non-responder group). Seven participants were in the non-responder group. Age (35 ± 9 vs. 26 ± 2 years, p = 0.020), augmentation index (76 ± 12 vs. 55 ± 8, p = 0.002), and diastolic blood pressures (83 ± 11 vs. 70 ± 7 mmHg, p = 0.021) in the non-responder group were significantly higher compared with the responder group. In multivariate linear regression analysis, only the augmentation index was an independent predictor of reduced LA reservoir function after the marathon (β = - 0.646, p = 0.023). The augmentation index was a predictive marker for reduction in LA reservoir function after a marathon in healthy amateur volunteers. (Keyword) Adaptation, Physiological / Adult / Atrial Fibrillation / Atrial Function, Left / Atrial Remodeling / Echocardiography, Doppler / female / Healthy Volunteers / Humans / male / Middle Aged / Physical Endurance / Prospective Studies / Risk Factors / Running / Time Factors / Young Adult (Tokushima University Institutional Repository) ● Metadata: 113069 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10554-018-1502-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30470971 ● Summary page in Scopus @ Elsevier: 2-s2.0-85057125051 (Tokushima University Institutional Repository: 113069, DOI: 10.1007/s10554-018-1502-2, PubMed: 30470971, Elsevier: Scopus)
69.	Shusuke Yagi, Daisuke Kondo, Takayuki Ise, Daiju Fukuda, Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, Hiroyuki Ito, Yoshihito Saijo, Hiromitsu Seno, Kumiko Sutou, Rie Ueno, Takafumi Todoroki, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome, Journal of Atherosclerosis and Thrombosis, Vol.26, No.3, 272-281, 2019. (Summary) It is speculated that statin therapy modulates the synthesis of polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, the data available on the effects of statin therapy on the serum levels of PUFA and the subsequent impact on in-stent restenosis (ISR) in patients with acute coronary syndrome (ACS) are limited. A total of 120 ACS patients who received emergent coronary stent implantation, follow-up coronary angiography to evaluate ISR, and new statin therapy were enrolled. We measured the serum levels of the PUFA and lipids at the onset of ACS and at the follow-up coronary angiography. The follow-up coronary angiography revealed 38 ISR cases. New statin therapy significantly reduced the serum levels of DHA and low-density lipoprotein cholesterol (LDL-C), while it did not affect EPA level. Single regression analysis revealed that a decreased serum level of LDL-C was associated with decreased DHA level. The multiple logistic regression analysis revealed that the decreased DHA level after statin therapy and low serum level of EPA on admission were determinants of prevalence of ISR. Statin therapy decreased the serum level of DHA with a parallel reduction in LDL-C level in patients with ACS. Decreased DHA level after statin therapy and low EPA level on admission are risk factors for ISR, indicating that in patients with ACS, decreased serum levels of DHA may be a residual target for the prevention of ISR. (Keyword) Acute Coronary Syndrome / Aged / Coronary Restenosis / Docosahexaenoic Acids / Eicosapentaenoic Acid / female / Follow-Up Studies / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / male / Prognosis / Retrospective Studies / Risk Factors / Stents (Tokushima University Institutional Repository) ● Metadata: 113220 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.44735 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30135329 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062425735 (Tokushima University Institutional Repository: 113220, DOI: 10.5551/jat.44735, PubMed: 30135329, Elsevier: Scopus)
70.	Shusuke Yagi, Seiichi Nishiyama, Toshio Abe and Masataka Sata : Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome, BMJ Case Reports, Vol.12, No.1, e227663, 2019. (Summary) Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thromboembolic events including venous thromboembolism (VTE) in association with the presence of antiphospholipid antibodies. The standard treatment of VTE historically consists of anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral anticoagulants, including rivaroxaban have become available for the treatment of VTE. However, the choice of anticoagulant, and the duration of anticoagulation in patients with APS has not been determined yet due to lack of evidence. Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary lifestyle in a patient with APS. We suggest that indefinite anticoagulation therapy might be needed even in low-risk APS cases. (Keyword) Aftercare / Antiphospholipid Syndrome / Factor Xa Inhibitors / Fibrin Fibrinogen Degradation Products / Humans / Male / Middle Aged / Pulmonary Embolism / Recurrence / Rivaroxaban / Tomography, X-Ray Computed / Treatment Outcome / Venous Thromboembolism / Venous Thrombosis (Tokushima University Institutional Repository) ● Metadata: 114198 (Link to Publication Site) ● Publication site (DOI): 10.1136/bcr-2018-227663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30635311 ● Summary page in Scopus @ Elsevier: 2-s2.0-85059843315 (Tokushima University Institutional Repository: 114198, DOI: 10.1136/bcr-2018-227663, PubMed: 30635311, Elsevier: Scopus)
71.	Mina Takahashi, Takeshi Tobiume, Kazuhisa Matsumoto, Tomomi Matsuura, Takeshi Soeki, 藤本裕太, 原田貴文, Zengu Robahto, 數藤久美子, 西條良仁, 上野理絵, Yutaka Kawabata, Mika Bando, nao Yamada, Hiroyuki Ito, 轟貴史, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : A successful case of catheter ablation against ventricular tachycardia storm due to old myocardial infarction in a patient with aortic valve replacement, Shikoku Acta Medica, Vol.74, No.56, 201-208, 2019. (Summary) A 68-year-old woman with VT storm and frequent appropriate ICD therapy was referred for catheter ablation. Her past history was notable for aortic valve replacement by mechanical valve due to infectious endocarditis 17 years prior to presentation and left ventricular apical old myocardial infarction with unknown onset. At 67 years old, She admitted to the prior hospital due to ventricular tachycardia with LBBB and superior axis at heart rate of 210 per minutes. Administration of amiodarone and magnesium sulfate was ineffective and cardioversion of 200J was successfully terminated the tachycardia. Intra-cardiac defibrillator was implanted and the administration of amiodarone and mexiletine was started. 5 months after, she admitted to the hospital due to the frequent appropriate shock against the same ventricular tachycardia. Administration of lidocaine, sotalol, pilsicainide, and magnesium sulfate could not control the tachycardia and she was referred to our hospital for catheter ablation. During the first session, ventricular tachycardia was easily induced and electroanatomical mapping was performed both during tachycardia and during sinus rhythm. Late diastolic potential preceding the onset of QRS wave by 45ms was detected at the infero-septal side of the apical aneurysm. 7 5s of the RF energy application at this site could terminate the tachycardia and thereafter no ventricular tachycardia was induced. But after dose-reduction or cessation of some anti-arrhythmic drugs, ventricular tachycardia was recurred and second session was performed. This time, no ventricular tachycardia was induced, then we performed isthmus transection and core isolation against the apical aneurysm. Thereafter no ventricular tachycardia was occurred in spite of dose-reduction or cessation of some anti-arrhythmic drugs. (Keyword) ventricular tachycardia / storm / old myocardial infarction / catheter ablation / aortic valve replacement (Tokushima University Institutional Repository) ● Metadata: 112988 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050001338015711104 (Tokushima University Institutional Repository: 112988, CiNii: 1050001338015711104)
72.	Shusuke Yagi, Robert Zheng, Seiichi Nishiyama, Yutaka Kawabata, Takayuki Ise, Kosuke Sugiura, Haruhiko Yoshinari, Toshihiko Nishisho, Yoshimi Bando, Kumiko Kagawa, Daiju Fukuda, Tomohiro Soga, Yoshihito Saijoh, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinji Kawahito, Masashi Akaike and Masataka Sata : Osteolytic primary bone lymphoma in the multiple bones, The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 347-350, 2019. (Summary) Primary non-Hodgkin bone lymphoma (PBL) can involve solitary or multiple destructive bone lesions such as those of the femur or pelvis humerus, and some cases have osteolytic lesions. PBL is a rare disease in adults. Thus, PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL can be underdiagnosed because patients do not experience symptoms or show objective abnormalities in the early stage. Here, we reported an elderly patient with PBL in multiple bones, including the cranial and femoral bones that were fractured due to falling. J. Med. Invest. 66 : 347-350, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114167 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.347 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656303 ● Summary page in Scopus @ Elsevier: 2-s2.0-85074142443 (Tokushima University Institutional Repository: 114167, DOI: 10.2152/jmi.66.347, PubMed: 31656303, Elsevier: Scopus)
73.	Shusuke Yagi, Itsuro Endo, Taichi Murakami, Tetsuya Hida, Yousuke Yamamoto, Tomohiro Soga, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinji Kawahito and Masataka Sata : Adult onset of Immunoglobulin A vasculitis - A case report,, The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 344-346, 2019. (Summary) Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, primarily occurs during childhood between the ages of 3 and 15 years and is the most common form of systemic vasculitis in children ; its occurrence in adults has been rarely reported. Such low incidence could be attributable to either under-diagnosis or misdiagnosis. Thus, not only pediatricians but also physicians should be able to diagnose IgAV accurately to manage the patients appropriately and avoid its associated complications. In addition, treatment of adult onset IgAV with renal involvement has not been fully established yet. We describe here a case of adult onset IgAV complicated by proteinuria and pharyngitis, which was cured by no specific treatment. J. Med. Invest. 66 : 344-346, August, 2019. (Keyword) Acetaminophen / Adult / Factor XIII / Humans / Immunoglobulin A / Male / Pharyngitis / Proteinuria / Purpura, Schoenlein-Henoch (Tokushima University Institutional Repository) ● Metadata: 114166 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.344 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656302 ● Search Scopus @ Elsevier (PMID): 31656302 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.344 (Tokushima University Institutional Repository: 114166, DOI: 10.2152/jmi.66.344, PubMed: 31656302)
74.	Shusuke Yagi, Kumiko Kagawa, Eiki Fujimoto, Masataka Sata and Yoshihito Saijoh : Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency, The Journal of Medical Investigation : JMI, Vol.66, No.1,2, 182-184, 2019. (Summary) Protein S (PS) deficiency is an inherited thrombophilia associated with an increased risk of venous thromboembolism (VTE). In Japan, unfractionated heparin followed by warfarin has been historically applied for the treatment of VTE. Recent evidence showed that direct oral anticoagulants (DOACs) were non-inferior to standard therapy with warfarin, with significantly less bleeding in patients with VTE. However, it is unknown whether DOACs are effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report a case of recurrent venous thrombosis during edoxaban therapy in a patient with protein S deficiency, which was successfully treated using high-dose apixaban therapy. J.Med. Invest. 66 : 182-184, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113418 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.182 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064935 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065794702 (Tokushima University Institutional Repository: 113418, DOI: 10.2152/jmi.66.182, PubMed: 31064935, Elsevier: Scopus)
75.	Shusuke Yagi, Rie Ueno, Kumiko Sutou, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshihito Saijo, Tomoya Hara, Takayuki Ise, Kenya Kusunose, Mika Bando, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Daiju Fukuda, Takeshi Soeki, Masashi Akaike and Masataka Sata : Lambda-like J wave due to acute myocardial infarction of the diagonal branch, The Journal of Medical Investigation : JMI, Vol.66, No.1,2, 185-187, 2019. (Summary) The culprit lesion of acute myocardial infarction could be predicted by electrocardiogram findings. However, we experienced some cases with coronary angiographic finding in the area of ST-T elevation that was different from that predicted. The lambda-like J wave could be caused by ischemia although the mechanism has not been fully elucidated. We report a case of acute myocardial infarction that showed discrepancy between ST-T elevation with lambda-like ischemic J wave in a broad area and coronary angiographical finding of diagonal branch occlusion. J. Med. Invest. 66 : 185-187, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113420 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.185 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064936 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065772885 (Tokushima University Institutional Repository: 113420, DOI: 10.2152/jmi.66.185, PubMed: 31064936, Elsevier: Scopus)
76.	Shusuke Yagi, Yoshihito Saijo, Taku Matsuda, Yasuhisa Kanematsu and Masataka Sata : Spontaneous arteriovenous fistula of the superficial temporal artery, The Journal of Medical Investigation : JMI, Vol.66, No.1,2, 209-210, 2019. (Summary) An arteriovenous fistula of the superficial temporal artery (STA) is a direct and abnormal communication between the STA, feeding artery, and superficial temporal vein, draining veins that bypass the capillary network. Several cases of trauma-induced or iatrogenic-induced arteriovenous fistula (AVF) of the STA have been reported ; however, spontaneous AVF of the STA not associated with trauma or medical treatment are extremely rare. Herein, we present a case of spontaneous AVF of the STA diagnosed in old age. J. Med. Invest. 66 : 209-210, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113475 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.209 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064944 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065788300 (Tokushima University Institutional Repository: 113475, DOI: 10.2152/jmi.66.209, PubMed: 31064944, Elsevier: Scopus)
77.	Shusuke Yagi and Masataka Sata : Rupture of pes anserine bursa in a patient with pes anserine pain syndrome due to osteoarthritis, The Journal of Medical Investigation : JMI, Vol.66, No.1,2, 211-212, 2019. (Summary) Pes anserinus pain syndrome is a common, clinically defined condition that is characterized by pain around the medial knee and tenderness over the upper medial tibia. The anserine bursa could be the site of proliferative and inflammatory conditions due to knee osteoarthritis, leading to pain and fluid retention. However, rupture of the pes anserinus is rare. Herein, we present a case of rupture of the pes anserine bursa in a patient with pes anserine pain syndrome and osteoarthritis. Physicians should consider rupture of the pes anserine bursa as a differential diagnosis of acute unilateral lower leg swelling. J. Med. Invest. 66 : 211-212, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113476 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064945 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065766564 (Tokushima University Institutional Repository: 113476, DOI: 10.2152/jmi.66.211, PubMed: 31064945, Elsevier: Scopus)
78.	Sachiko Nishimoto, Kunduziayi Aini, Daiju Fukuda, Yasutomi Higashikuni, Kimie Tanaka, Yoichiro Hirata, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia, Frontiers in Cardiovascular Medicine, Vol.5, 144, 2018. (Summary) Peripheral artery disease causes significant functional disability and results in impaired quality of life. Ischemic tissue injury releases various endogenous ligands for Toll-like receptors (TLRs), suggesting the involvement of TLRs in blood flow recovery. However, the role of TLR9, which was originally known as a sensor for bacterial DNA, remains unknown. This study investigated the role of TLR9 in blood flow recovery in the ischemic limb using a mouse hind-limb ischemia model. Unilateral femoral artery ligation was performed in TLR9-deficient () mice and wild-type mice. In wild-type mice, femoral artery ligation significantly increased mRNA expression of TLR9 in the ischemic limb ( < 0.001) and plasma levels of cell-free DNA (cfDNA) as determined by single-stranded DNA (ssDNA) ( < 0.05) and double-stranded DNA (dsDNA) ( < 0.01), which are endogenous ligands for TLR9, compared with the sham-operated group. Laser Doppler perfusion imaging demonstrated significantly improved ratio of blood flow in the ischemic to non-ischemic limb in mice compared with wild-type mice at 2 weeks after ligation ( < 0.05). mice showed increased capillary density and reduced macrophage infiltration in ischemic limb. Genetic deletion of TLR9 reduced the expression of TNF-α, and attenuated NF-κB activation in ischemic muscle compared with wild-type mice ( < 0.05, respectively) at 3 days after the surgery. ODN1826, a synthetic agonistic oligonucleotide for TLR9, or plasma obtained from mice with ischemic muscle promoted the expression of TNF-α in wild-type macrophages ( < 0.05), but not in macrophages. ODN1826 also activated NF-κB signaling as determined by the degradation of IκBα in wild-type macrophages ( < 0.05), but not in macrophages. In vitro experiments using human umbilical vein endothelial cells demonstrated that TNF-α, or conditioned medium obtained from wild-type macrophages treated with ODN1826 accelerated cell death as determined by MTS assay ( < 0.05 and < 0.01, respectively). Our results suggest that ischemic muscle releases cfDNA, which activates TLR9 and enhances inflammation, leading to impairment of blood flow recovery in the ischemic limb. cfDNA-TLR9 signaling may serve as a potential therapeutic target in ischemic limb disease. (Tokushima University Institutional Repository) ● Metadata: 113226 (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2018.00144 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30460242 ● Search Scopus @ Elsevier (PMID): 30460242 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2018.00144 (Tokushima University Institutional Repository: 113226, DOI: 10.3389/fcvm.2018.00144, PubMed: 30460242)
79.	B Ganbaatar, Daiju Fukuda, HM Salim, Sachiko Nishimoto, K Tanaka, Y Higashikuni, Y Hirata, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice., Atherosclerosis, Vol.275, 124-132, 2018. (Summary) Ticagrelor reduces cardiovascular events in patients with acute coronary syndrome (ACS). Recent studies demonstrated the expression of P2Y12 on vascular cells including endothelial cells, as well as platelets, and suggested its contribution to atherogenesis. We investigated whether ticagrelor attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein E-deficient (apoe) mice. Eight-week-old male apoe mice were fed a western-type diet (WTD) supplemented with 0.1% ticagrelor (approximately 120 mg/kg/day). Non-treated animals on WTD served as control. Atherosclerotic lesions were examined by en-face Sudan IV staining, histological analyses, quantitative RT-PCR analysis, and western blotting. Endothelial function was analyzed by acetylcholine-dependent vasodilation using aortic rings. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. Ticagrelor treatment for 20 weeks attenuated atherosclerotic lesion progression in the aortic arch compared with control (p < 0.05). Ticagrelor administration for 8 weeks attenuated endothelial dysfunction (p < 0.01). Ticagrelor reduced the expression of inflammatory molecules such as vascular cell adhesion molecule-1, macrophage accumulation, and lipid deposition. Ticagrelor decreased the phosphorylation of JNK in the aorta compared with control (p < 0.05). Ticagrelor and a JNK inhibitor ameliorated impairment of endothelium-dependent vasodilation by adenosine diphosphate (ADP) in wild-type mouse aortic segments. Furthermore, ticagrelor inhibited the expression of inflammatory molecules which were promoted by ADP in HUVEC (p < 0.001). Ticagrelor also inhibited ADP-induced JNK activation in HUVEC (p < 0.05). Ticagrelor attenuated vascular dysfunction and atherogenesis through the inhibition of inflammatory activation of endothelial cells. These effects might be a potential mechanism by which ticagrelor decreases cardiovascular events in patients with ACS. (Tokushima University Institutional Repository) ● Metadata: 114201 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2018.05.053 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29902700 ● Search Scopus @ Elsevier (PMID): 29902700 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2018.05.053 (Tokushima University Institutional Repository: 114201, DOI: 10.1016/j.atherosclerosis.2018.05.053, PubMed: 29902700)
80.	Yoshihito Saijo, Hirotsugu Yamada, Kenya Kusunose, Mika Bando, Susumu Nishio, Yuta Torii, Yukina Hirata, Hiromitsu Seno, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : A clinical application of preload stress echocardiography for predicting future hemodynamic worsening in patients with early-stage heart failure., Echocardiography, Vol.35, No.10, 1587-1595, 2018. (Summary) To improve the prognosis of patients with heart failure, risk stratification in their early stage is important. We assessed whether the change in transmitral flow (TMF) velocity pattern during preload augmentation can predict future hemodynamic worsening in early-stage heart failure patients with impaired relaxation TMF pattern. We designed a prospective cohort study that included 155 consecutive patients with impaired relaxation (IR) pattern at rest. Preload stress echocardiography was achieved using leg-positive pressure (LPP), and changes in TMF pattern during the LPP was observed during baseline echocardiographic examination. The patients whose TMF pattern developed to pseudonormal (PN) pattern throughout the study period were classified into the change to PN group, and patients whose TMF pattern stayed in IR pattern were classified into the stay in IR group. The median follow-up period was 17 months. The average age was 68 ± 11 years old, and 97 patients (63%) were male. Among 155 patients, 27 were classified into the change to PN group. A Cox proportional hazard analysis confirmed that the change in the peak atrial systolic TMF velocity during the LPP (ΔA, hazard ratio = 0.58 per 1SD; 95% CI = 0.39-0.88, P = 0.010) was the powerful independent predictor of change into PN pattern. Kaplan-Meier analysis revealed that the patients with ΔA -7 cm/s had more likely to develop into PN pattern than patients with ΔA > -7 cm/s (P = 0.001). Evaluation of a response in TMF during the LPP might provide an incremental diagnostic value to detect future overt heart failure in patients with early-stage heart failure. (Tokushima University Institutional Repository) ● Metadata: 112877 (Link to Publication Site) ● Publication site (DOI): 10.1111/echo.14098 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30005132 ● Summary page in Scopus @ Elsevier: 2-s2.0-85054773574 (Tokushima University Institutional Repository: 112877, DOI: 10.1111/echo.14098, PubMed: 30005132, Elsevier: Scopus)
81.	Kenya Kusunose, Hiromitsu Seno, Hirotsugu Yamada, Susumu Nishio, Yuta Torii, Yukina Hirata, Y Saijo, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Right Ventricular Function and Beneficial Effects of Cardiac Rehabilitation in Patients With Systolic Chronic Heart Failure., The Canadian Journal of Cardiology, Vol.34, No.10, 1307-1315, 2018. (Summary) It has been recognized that a comprehensive cardiac rehabilitation (CR) program improves mortality in patients with chronic heart failure. On the other hand, the magnitude of the improvement in exercise capacity after CR differs among individuals. The aim of this study was to assess the echocardiographic determinants of responders to CR using preload stress echocardiography. We prospectively enrolled 58 chronic heart failure patients with reduced left ventricular ejection fraction (aged 62 ± 11 years; 69% male; left ventricular ejection fraction 43% ± 7%) who had received optimized medical treatment in a CR program for 5 months. We performed preload echocardiographic studies using leg positive pressure (LPP) to assess the echocardiographic parameters during preload augmentation. We defined 41 patients as a development cohort to assess the predictive value of echocardiographic variables. Next, we validated results in the remaining 17 patients as a validation cohort. In the development cohort, significant improvement in peak oxygen uptake (VO) (>10%) after CR was observed in 58% patients. In a multivariable logistic regression model, the significant predictor of improvement in exercise capacity was right ventricular (RV) strain during LPP (odds ratio: 3.96 per 1 standard deviation; P = 0.01). An RV strain value of -16% during LPP had a good sensitivity of 0.79 and a specificity of 0.71 to identify patients with improvement in peak VO. In the validation cohort, an optimal cutoff value of RV strain value was the same (area under the curve: 0.77, sensitivity: 0.78, specificity: 0.65). RV strain during LPP may be an echocardiographic parameter for assessing beneficial effects of CR. (Tokushima University Institutional Repository) ● Metadata: 114204 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cjca.2018.06.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30146462 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052061274 (Tokushima University Institutional Repository: 114204, DOI: 10.1016/j.cjca.2018.06.003, PubMed: 30146462, Elsevier: Scopus)
82.	Takeshi Soeki, Tomomi Matsuura, Takeshi Tobiume, Sachiko Bando, Matsumoto Kazuhisa, Hiromi Nagano, Etsuko Uematsu, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Clinical, Electrocardiographic, and Echocardiographic Parameter Combination Predicts the Onset of Atrial Fibrillation., Circulation Journal, Vol.82, No.9, 2253-2258, 2018. (Summary) The ability to identify risk markers for new-onset atrial fibrillation (AF) is critical to the development of preventive strategies, but it remains unknown whether a combination of clinical, electrocardiographic, and echocardiographic parameters predicts the onset of AF. In the present study, we evaluated the predictive value of a combined score that includes these parameters.Methods and Results:We retrospectively studied 1,040 patients without AF who underwent both echocardiography and 24-h Holter electrocardiography between May 2005 and December 2010. During a median follow-up period of 68.4 months (IQR, 49.9-93.3 months), we investigated the incidence of new-onset AF. Of the 1,040 patients, 103 (9.9%) developed AF. Patients who developed AF were older than patients who did not. Total heart beats, premature atrial contraction (PAC) count, maximum RR interval, and frequency of sinus pause quantified on 24-h electrocardiography were associated with new-onset AF. LA diameter (LAD) on echocardiography was also associated with the development of AF. On multivariate Cox analysis, age 58 years, PAC count 80 beats/day, maximum RR interval 1.64 s, and LAD 4.5 cm were independently associated with the development of AF. The incidence rate of new-onset AF significantly increased as the combined score (i.e., the sum of the risk score determined using hazard ratios) increased. A combined score that includes age, PAC count, maximum RR interval, and LAD could help characterize the risk of new-onset AF. (Tokushima University Institutional Repository) ● Metadata: 113221 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-17-0758 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29848884 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052204332 (Tokushima University Institutional Repository: 113221, DOI: 10.1253/circj.CJ-17-0758, PubMed: 29848884, Elsevier: Scopus)
83.	Kageyuki Oba, Minetaka Maeda, Gulinu Maimaituxun, Satoshi Yamaguchi, Osamu Arasaki, Daiju Fukuda, Shusuke Yagi, Hirata Yukina, Susumu Nishio, Takashi Iwase, Shoichiro Takao, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada, Hiroaki Masuzaki, Masataka Sata and Michio Shimabukuro : Effect of the Epicardial Adipose Tissue Volume on the Prevalence of Paroxysmal and Persistent Atrial Fibrillation., Circulation Journal, Vol.82, No.7, 1778-1787, 2018. (Summary) Although increasing evidence suggests that epicardial adipose tissue volume (EATV) is associated with atrial fibrillation (AF), it is controversial whether there is a dose-response relationship of increasing EATV along the continuum of AF. We evaluated the effect of the EATV on the prevalence of paroxysmal AF (PAF) and persistent AF (PeAF) and the relationships with cardiac structure and functional remodeling.Methods and Results:Subjects who underwent multidetector computed tomography (MDCT) coronary angiography because of symptoms suggestive of coronary artery disease were divided into sinus rhythm (SR) (n=112), PAF (n=133), and PeAF (n=71) groups. The EATV index (EATV/body surface area, mL/m) was strongly associated with the prevalence of PAF and PeAF on the model adjusted for known AF risk factors. The effect of the EATV index on the prevalence of PeAF, but not on that of PAF, was modified by the left atrial (LA) dimension, suggesting that extension of the LA dimension is related to EATV expansion in PeAF. The cutoff value of the EATV index for the prevalence was higher in PeAF than in PAF (64 vs. 55 mL/m, P<0.01). The EATV index is associated with the prevalence of PAF and PeAF, and its cutoff values are predictive for PAF and PeAF development independently of other AF risk factors. (Tokushima University Institutional Repository) ● Metadata: 113224 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-18-0021 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29806623 ● Summary page in Scopus @ Elsevier: 2-s2.0-85049036945 (Tokushima University Institutional Repository: 113224, DOI: 10.1253/circj.CJ-18-0021, PubMed: 29806623, Elsevier: Scopus)
84.	Kenya Kusunose, Y Okushi, Hirotsugu Yamada, Susumu Nishio, Yuta Torii, Yukina Hirata, Y Saijo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Prognostic Value of Frailty and Diastolic Dysfunction in Elderly Patients., Circulation Journal, Vol.82, No.8, 2103-2110, 2018. (Summary) High prevalence of frailty and of diastolic dysfunction (DD) in heart failure and high mortality in frail adults have been noted. We characterized frailty by quantifying differences on echocardiography, and assessed the added prognostic utility of frailty and DD grade in an elderly population. One hundred and ninety-one patients 65 years who had at least 1 cardiovascular risk factor were prospectively recruited for clinically indicated echocardiography at the present institute. Weight loss, exhaustion, and deficits in physical activity, gait speed, and handgrip strength were used to categorize patients as frail (3 features), intermediately frail (1 or 2 features), or non-frail (0 features). DD grade 2 was defined as severe. Frailty was associated with larger left atrial volume, smaller stroke volume, and worse DD grade after adjustment for age. In a period of 14 months, 29 patients (15%) had cardiovascular events. The addition of frailty score and severe DD significantly improved the prognostic power of a model containing male gender (model 1, male gender, χ=6.4; model 2, model 1 plus frailty score, χ=16.7, P=0.004; model 3, model 2 plus severe DD, χ=25.5, P=0.015). Both frailty and DD grade were significantly associated with future cardiovascular events in an elderly population with preserved ejection fraction and 1 risk factor of cardiovascular disease. (Tokushima University Institutional Repository) ● Metadata: 113222 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-18-0017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29709994 ● Summary page in Scopus @ Elsevier: 2-s2.0-85050588123 (Tokushima University Institutional Repository: 113222, DOI: 10.1253/circj.CJ-18-0017, PubMed: 29709994, Elsevier: Scopus)
85.	Tomoya Hara, Pham Tran Phuong, Daiju Fukuda, Koji Yamaguchi, Chie Murata, Sachiko Nishimoto, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Soeki Takeshi, Tetsuzo Wakatsuki, Issei Imoto, Michio Shimabukuro and Masataka Sata : Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice., Circulation, Vol.138, No.16, 1706-1719, 2018. (Summary) -The coagulation system is closely linked with vascular inflammation, although the underlying mechanisms are still obscure. Recent studies show that protease-activated receptor (PAR)-2, a major receptor of activated factor X (FXa), are expressed in both vascular cells and leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis. -We generated apolipoprotein E-deficient ( ) mice lacking systemic PAR-2 expression ( ). mice which lack or express PAR-2 only in bone-marrow (BM) cells were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 weeks on a western-type diet (WTD) by histological analyses, quantitative RT-PCR, and western blotting. In vitro experiments using BM-derived macrophages were performed to confirm pro-inflammatory roles of PAR-2. The association between plasma FXa level and the severity of coronary atherosclerosis was also examined in humans who underwent coronary intervention. - mice showed reduced atherosclerotic lesions in the aortic arch (<0.05) along with features of stabilized atherosclerotic plaques such as less lipid deposition (<0.05), collagen loss (<0.01), macrophage accumulation (<0.05), and inflammatory molecule expression (<0.05) compared with mice. Systemic PAR2 deletion in mice significantly decreased the expression of inflammatory molecules in the aorta. The results of BM transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to atherogenesis in mice. PAR-2 deletion did not alter metabolic parameters. In vitro experiments demonstrated that FXa or a specific peptide agonist of PAR-2 significantly increased expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type mice compared with those from PAR-2-deficient mice. Activation of NF- κB signaling was involved in PAR-2-associated vascular inflammation and macrophage activation. In humans who underwent coronary intervention, plasma FXa level independently correlated with the severity of coronary atherosclerosis as determined by Gensini score (<0.05) and plaque volume (<0.01). -PAR-2 signaling activates macrophages and promotes vascular inflammation, increasing atherosclerosis in mice. This signaling pathway may also participate in atherogenesis in humans. (Tokushima University Institutional Repository) ● Metadata: 112891 (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCULATIONAHA.118.033544 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29700120 ● Summary page in Scopus @ Elsevier: 2-s2.0-85055611443 (Tokushima University Institutional Repository: 112891, DOI: 10.1161/CIRCULATIONAHA.118.033544, PubMed: 29700120, Elsevier: Scopus)
86.	Gulinu Maimaituxun, Michio Shimabukuro, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, Takashi Iwase, Shoichiro Takao, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada and Masataka Sata : Local Thickness of Epicardial Adipose Tissue Surrounding the Left Anterior Descending Artery Is a Simple Predictor of Coronary Artery Disease - New Prediction Model in Combination With Framingham Risk Score., Circulation Journal, Vol.82, No.5, 1369-1378, 2018. (Summary) Compared with global cardiac adiposity, the local accumulation of fat surrounding coronary arteries might have a more direct impact on coronary artery disease (CAD). Here, we compared the local epicardial adipose tissue (EAT) thickness and global cardiac adiposity volumes for predicting CAD.Methods and Results:A total of 197 consecutive subjects underwent 320-slice multi-detector computed tomography coronary angiography and were segregated into CAD (1 coronary artery branch stenosis 50%) and non-CAD groups. EAT thickness was measured at the right coronary artery (EAT), the left anterior descending artery (EAT), and the left circumflex artery (EAT). Although EATand EATwere similar between the 2 groups, EATwas larger in the CAD group than in the non-CAD group (5.45±2.16 mm vs. 6.86±2.19 mm, P<0.001). EAT, after correcting for confounding factors, was strongly associated with CAD (r=0.276, P<0.001) and Gensini score (r=0.239, P<0.001). On multiple regression analysis, Framingham risk score combined with EATwas a strong predictor of CAD (adjusted R=0.121; P<0.001). The local fat thickness surrounding the LAD is a simple and useful surrogate marker for estimating the presence, severity, and extent of CAD, independent of classical cardiovascular risk factors. (Tokushima University Institutional Repository) ● Metadata: 112879 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-17-1289 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29563352 ● Summary page in Scopus @ Elsevier: 2-s2.0-85045965929 (Tokushima University Institutional Repository: 112879, DOI: 10.1253/circj.CJ-17-1289, PubMed: 29563352, Elsevier: Scopus)
87.	Shusuke Yagi, Y. Yamamoto, S. Nishiyama and Masataka Sata : An Occluded Hooklet of an Embedded Inferior Vena Cava Filter, Internal Medicine, Vol.57, No.15, 2275-2276, 2018. (Tokushima University Institutional Repository) ● Metadata: 114206 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.0505-17 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29526958 ● CiNii @ National Institute of Informatics (CRID): 1390001288050194688 ● Search Scopus @ Elsevier (PMID): 29526958 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.0505-17 (Tokushima University Institutional Repository: 114206, DOI: 10.2169/internalmedicine.0505-17, PubMed: 29526958, CiNii: 1390001288050194688)
88.	Tomoya Hara, Daiju Fukuda, K Tanaka, Y Higashikuni, Yukina Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury., European Journal of Pharmacology, Vol.5, No.820, 222-228, 2018. (Summary) Accumulating evidence suggests that activated factor X (FXa), a key coagulation factor, plays an important role in the development of vascular inflammation through activation of many cell types. Here, we investigated whether pharmacological blockade of FXa attenuates neointima formation after wire-mediated vascular injury. Transluminal femoral artery injury was induced in C57BL/6 mice by inserting a straight wire. Rivaroxaban (5mg/kg/day), a direct FXa inhibitor, was administered from one week before surgery until killed. At four weeks after surgery, rivaroxaban significantly attenuated neointima formation in the injured arteries compared with control (P<0.01). Plasma lipid levels and blood pressure were similar between the rivaroxaban-treated group and non-treated group. Quantitative RT-PCR analyses demonstrated that rivaroxaban reduced the expression of inflammatory molecules (e.g., IL-1β and TNF-α) in injured arteries at seven days after surgery (P<0.05, respectively). In vitro experiments using mouse peritoneal macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., IL-1β and TNF-α), which was blocked in the presence of rivaroxaban (P<0.05). Also, in vitro experiments using rat vascular smooth muscle cells (VSMC) demonstrated that FXa promoted both proliferation and migration of this cell type (P<0.05), which were blocked in the presence of rivaroxaban. Inhibition of FXa by rivaroxaban attenuates neointima formation after wire-mediated vascular injury through inhibition of inflammatory activation of macrophages and VSMC. (Tokushima University Institutional Repository) ● Metadata: 114209 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2017.12.037 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29269019 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039155853 (Tokushima University Institutional Repository: 114209, DOI: 10.1016/j.ejphar.2017.12.037, PubMed: 29269019, Elsevier: Scopus)
89.	工藤萌宏, 待井典剛, 小野利夫, 大城義人, 高橋隆, 種田嘉信, 比嘉盛丈, Shusuke Yagi, 仲地健, 小林淳, 及川雅啓, Hirotsugu Yamada, 竹石恭知, Masataka Sata and Michio Shimabukuro : 時効型インスリン療法中の2型糖尿病患者におけるダパグリフロジンの血糖日内変動に及ぼす効果, Journal of Japan Society for the Study of Obesity, Vol.24, No.Suppl, 222, 2018.
90.	Hiromu Yamazaki, Shusuke Yagi, Yuta Torii, Rie Amano, Yasuyuki Oomichi, Teruaki Sangawa, Daiju Fukuda, Muneyuki Kadota, Takayuki Ise, Rie Ueno, Tomoya Hara, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels, Journal of Cardiology, Vol.71, No.3, 305-309, 2017. (Summary) It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown. We enrolled 57 patients with acute VTE with/without pulmonary embolism treated with edoxaban (n=37) or warfarin (n=20) in a clinical setting. Before treatment and 2 weeks after treatment, we evaluated thrombotic burden using ultrasound or computed tomography angiography. We also evaluated thrombin generation, represented by prothrombin fragment F1+2; thrombus degradation, represented by D-dimer; and levels of anticoagulants, including protein C, protein S, and antithrombin III. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer. Edoxaban treatment preserved protein C and protein S levels. In contrast, warfarin decreased protein C and protein S levels. Neither treatment affected antithrombin III. Edoxaban improves VTE while preserving protein C and protein S levels, thereby indicating that edoxaban improves thrombotic burden while maintaining levels of anticoagulants. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2017.09.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29100817 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032912457 (DOI: 10.1016/j.jjcc.2017.09.009, PubMed: 29100817, Elsevier: Scopus)
91.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus., Advances in Therapy, Vol.35, No.1, 124-134, 2017. (Summary) Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12325-017-0639-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29185199 ● Summary page in Scopus @ Elsevier: 2-s2.0-85035102977 (DOI: 10.1007/s12325-017-0639-z, PubMed: 29185199, Elsevier: Scopus)
92.	Shusuke Yagi, Takeshi Soeki, Ken-Ichi Aihara, Daiju Fukuda, Takayuki Ise, Muneyuki Kadota, Sachiko Bando, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Kenya Kusunose, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome, International Heart Journal, Vol.58, No.5, 720-723, 2017. (Summary) The n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antiarrhythmic effects, possibly via modulation of the cardiac ion channels. Nevertheless, it is unknown whether low serum levels of n-3 PUFAs are risk factors for ventricular fibrillation in patients with Brugada syndrome (BrS). We retrospectively reviewed data from 62 men with BrS and evaluated their serum levels of EPA and DHA, and the risk factors for sudden cardiac death, including a history of cardiogenic syncope. Nineteen patients had a history of cardiogenic syncope, and their EPA and DHA levels were significantly lower than those of the patients without syncope. Multivariate logistic regression analysis revealed that low EPA and DHA levels were associated with the incidence of syncope. The receiver-operator characteristic curve showed the area under the curves of EPA and DHA for history of syncope were 0.84 and 0.72, respectively. In conclusion, low levels of EPA and DHA are risk factors for cardiogenic syncope in patients with BrS, which suggests that n-3 PUFAs play important roles in preventing ventricular fibrillation in BrS. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers / Brugada Syndrome / Chromatography, Gas / Docosahexaenoic Acids / Eicosapentaenoic Acid / Electrocardiography / Follow-Up Studies / Humans / Incidence / Japan / Male / Middle Aged / Prevalence / ROC Curve / Retrospective Studies / Risk Assessment / Risk Factors / Syncope / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-278 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28966307 ● CiNii @ National Institute of Informatics (CRID): 1390282680202467328 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032215381 (DOI: 10.1536/ihj.16-278, PubMed: 28966307, CiNii: 1390282680202467328, Elsevier: Scopus)
93.	Yuriko Takagawa, Shusuke Yagi, Takayuki Ise, Ayumi Ishii, Koji Nishikawa, Daiju Fukuda, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Shinsuke Katoh, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Improved Exercise Capacity After Cardiac Rehabilitation Is Associated with Reduced Visceral Fat in Patients with Chronic Heart Failure., International Heart Journal, Vol.58, No.5, 746-751, 2017. (Summary) Participation in a comprehensive cardiac rehabilitation (CR) program has been shown to reduce mortality and improve exercise capacity and symptoms in patients with chronic heart failure (CHF). Reduced exercise capacity leads to a concomitant reduction of skeletal muscle mass and accumulation of body fat. However, it is currently unknown whether CR reduces visceral adipose tissue (VAT) and/or subcutaneous abdominal adipose tissue (SAT) in patients with CHF. In addition, the body composition associated with improved exercise capacity after CR in patients with CHF has not been previously studied. Nineteen CHF patients who were categorized as NYHA functional class II or III and had received optimal medical treatment including a CR program for 5 months were enrolled in this study. The CR program significantly increased peak VO and reduced B-type natriuretic peptide. In addition, fat and body composition analysis showed reductions in the visceral fat tissue (VAT) area, subcutaneous abdominal adipose tissue (SAT) area, body weight, and total fat weight after CR. There were no changes in total water weight and total muscle weight. Single regression analysis revealed that the amelioration of reduced exercise capacity seen after CR is associated with reduced VAT area but not with SAT area or body weight. In conclusion, CR reduces VAT and improves exercise capacity in patients with CHF. This suggests that reducing VAT is important for CR to be most effective in the treatment of CHF. (Keyword) Body Composition / Cardiac Rehabilitation / Exercise Tolerance / Female / Follow-Up Studies / heart failure / Humans / Intra-Abdominal Fat / Male / Middle Aged / obesity / oxygen consumption / Prognosis / Retrospective Studies / Weight Loss (Tokushima University Institutional Repository) ● Metadata: 110111 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-454 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28966316 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032221042 (Tokushima University Institutional Repository: 110111, DOI: 10.1536/ihj.16-454, PubMed: 28966316, Elsevier: Scopus)
94.	Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Salim Masdan Hotimah, G Maimaituxun, Susumu Nishio, Yuriko Takagawa, Saori Hama, Tomomi Matsuura, Koji Yamaguchi, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike, Michio Shimabukuro and Masataka Sata : Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus., Diabetology & Metabolic Syndrome, Vol.9, 78, 2017. (Summary) It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327). (Tokushima University Institutional Repository) ● Metadata: 114544 (Link to Publication Site) ● Publication site (DOI): 10.1186/s13098-017-0275-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29034006 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030465923 (Tokushima University Institutional Repository: 114544, DOI: 10.1186/s13098-017-0275-4, PubMed: 29034006, Elsevier: Scopus)
95.	Shusuke Yagi, Daiju Fukuda, KI Aihara, Masashi Akaike, Michio Shimabukuro and Masataka Sata : n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease., Journal of Atherosclerosis and Thrombosis, Vol.24, No.10, 999-1010, 2017. (Summary) The adoption of the Western-style diet, with decreased fish intake and lack of exercise, has increased the prevalence of cardiovascular disease (CVD) in Japan. Statin treatment has been established to reduce the risk of cardiovascular events; however, 60%-70% of these events occur despite its use. Thus, the residual risk for CVD should be identified and resolved to reduce further cardiovascular events. The serum levels of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid and docosahexaenoic acid, are reportedly associated with an increased incidence of cardiovascular events and mortality, whereas the addition of n-3 PUFA treatment to the statin treatment decreases cardiovascular events. Similar to statins, n-3 PUFAs have pleiotropic effects in addition to lipid-modifying effects. Pre-clinical and clinical studies have shown that n-3 PUFAs prevent cardiovascular events by ameliorating endothelial function and attenuating lipid accumulation, vascular inflammation, and macrophage recruitment, thereby causing coronary plaque development and rupture. Taken together, n-3 PUFAs are comprehensively able to attenuate the atherogenic response. Therefore, n-3 PUFA intake is recommended to prevent cardiovascular events, particularly in patients with multiple cardiovascular risk factors. (Tokushima University Institutional Repository) ● Metadata: 115484 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.RV17013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28835582 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030703516 (Tokushima University Institutional Repository: 115484, DOI: 10.5551/jat.RV17013, PubMed: 28835582, Elsevier: Scopus)
96.	Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yuta Torii, Yukina Hirata, Hiromitsu Seno, Yoshihito Saijo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Preload Stress Echocardiography Predicts Outcomes in Patients With Preserved Ejection FractionandLow-GradientAorticStenosis, Circulation. Cardiovascular Imaging, Vol.10, No.10, 2017. (Summary) The projected aortic valve area (AVA) at a normal transvalvular flow rate using dobutamine is helpful to determine the actual severity of aortic stenosis (AS) and to predict risk of adverse events in low-gradient AS cases with unclear surgical indication. Our study aimed to identify the independent and incremental value of preload stress echocardiography-derived AVA to predict outcomes in patients with preserved ejection fraction and low-gradient AS. We prospectively performed echocardiographic studies in 79 patients with low-gradient AS (age, 77±7 years; 30% men) with preload stress echocardiography using leg positive pressure. AVA was calculated using AVA and transvalvular flow rate at baseline and during leg positive pressure. The primary end point was the decision for aortic valve surgery or cardiac death. During a median period of 19 months, 23 patients had the decision for aortic valve surgery, and none died during follow-up. In a stepwise multivariable analysis, indexed AVA (AVAi; hazard ratio, 2.00 per 0.1 cm/m decrease; 95% confidence interval, 1.36-2.96; <0.001) was associated with the primary end point. Using a receiver operating characteristic curve analysis, the best cutoff value of AVAi for predicting cardiac events was <0.72 cm/m. By incorporating AVAi into AVAi at baseline, continuous net reclassification index for cardiac events was 0.48 (=0.04). In patients with low-gradient AS, indexed AVA derived from preload stress echocardiography can be useful to predict risk of adverse events. The present article should be considered as a proof of concept study, and we think that larger multicenter studies are warranted. (Keyword) Aged / Aged, 80 and over / Aortic Valve / Aortic Valve Stenosis / Area Under Curve / Disease Progression / Disease-Free Survival / Echocardiography, Stress / Female / Humans / Kaplan-Meier Estimate / Male / Models, Cardiovascular / Predictive Value of Tests / Prospective Studies / ROC Curve / Severity of Illness Index / Stroke Volume / Time Factors / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCIMAGING.117.006690 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29021259 ● Summary page in Scopus @ Elsevier: 2-s2.0-85031850278 (DOI: 10.1161/CIRCIMAGING.117.006690, PubMed: 29021259, Elsevier: Scopus)
97.	Susumu Nishio, Kenya Kusunose, Hirotsugu Yamada, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Echocardiographic Epicardial Adipose Tissue Thickness Is Associated with Symptomatic Coronary Vasospasm during Provocative Testing., Journal of the American Society of Echocardiography, Vol.30, No.10, 1021-1027, 2017. (Summary) Epicardial adipose tissue (EAT) is the ectopic visceral fat surrounding the heart, which plays an important role in atherosclerosis of the coronary arteries via endothelial damage. Several studies have also suggested that vasospasm with angina (VSA) causes endothelial dysfunction in the coronary arteries. The aim of this study was to evaluate the thickness of EAT in the anterior interventricular groove (EAT-AIG) using echocardiography in patients who had no obstructive coronary artery disease and were suspected of having VSA. Sixty-five patients who underwent intracoronary acetylcholine provocation testing for clinical indications were prospectively enrolled. VSA was diagnosed by coronary artery stenosis increase of >90% and the presentation of chest pain with ischemic changes on electrocardiography. Subjects were divided into two groups, with and without significant coronary spasm (VSA group, 30 patients; non-VSA group, 35 patients), consistent with acetylcholine provocation testing. EAT-AIG thickness was significantly greater in the VSA group than in the non-VSA group (8.2 2.7 vs 6.1 2.5 mm, P = .002). By receiver operating characteristic analysis, EAT-AIG thickness had a high C statistic (area under the curve = 0.81, P < .001) after adjustment for conventional risk factors (smoking, diabetes mellitus, and dyslipidemia). EAT-AIG thickness had incremental diagnostic value over other conventional risk factors (area under the curve = 0.81 vs 0.64, P for comparison = .020). EAT-AIG thickness, which is noninvasively and easily measured using transthoracic echocardiography, can be one of multiple clinical variables associated with VSA. (Tokushima University Institutional Repository) ● Metadata: 110928 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.echo.2017.06.024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28843368 ● Search Scopus @ Elsevier (PMID): 28843368 ● Search Scopus @ Elsevier (DOI): 10.1016/j.echo.2017.06.024 (Tokushima University Institutional Repository: 110928, DOI: 10.1016/j.echo.2017.06.024, PubMed: 28843368)
98.	Shusuke Yagi, Minoru Mitsugi, Teruaki Sanagawa, Masashi Akaike and Masataka Sata : Paget-Schroetter Syndrome in a Baseball Pitcher., International Heart Journal, Vol.58, No.4, 637-640, 2017. (Summary) Paget-Schroetter syndrome (PSS) is thrombosis of the deep veins draining the upper extremity due to anatomic abnormalities of the thoracic outlet that cause subclavian compression and subsequent thrombosis, leading to thrombus formation in the subclavian vein. Vigorous arm activity in sports is a known risk factor. Here, we report a case of Paget-Schroetter syndrome in a 31-year-old male non-professional baseball pitcher. (Keyword) Adult / Baseball / Fibrinolytic Agents / Humans / Male / Thrombolytic Therapy / Tomography, X-Ray Computed / Upper Extremity Deep Vein Thrombosis (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-447 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28701678 ● Summary page in Scopus @ Elsevier: 2-s2.0-85026825932 (DOI: 10.1536/ihj.16-447, PubMed: 28701678, Elsevier: Scopus)
99.	Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Hiromitsu Seno, Y Saijo, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma), The American Journal of Cardiology, Vol.120, No.2, 315-321, 2017. (Summary) Change in 6-minute walk distance (6MWD) has been used as a clinical marker in pulmonary hypertension. Determinants and worsening of 6MWD remain a matter of debate because nonpulmonary factors have an impact on the 6MWD. We hypothesized that future reduction of 6MWD in patients with systemic sclerosis (SSc) was more closely associated with cardiac dysfunction. We prospectively performed standard clinical and echocardiographic evaluations in SSc patients with the 6-minute walk test at enrollment. Features associated with the 6MWD were sought in a multiple linear regression analysis and compared using standardized . Worsening of the 6MWD was defined as a 15% reduction and served as the primary outcome. Eighty-one patients were included. In the multivariate analysis, baseline 6MWD was related to SSc severity score ( = -0.250, p = 0.024), left atrial volume index ( = -0.222, p = 0.046), right ventricular fractional area change ( = 0.252, p = 0.025), and the ratio of mean pulmonary artery pressure and cardiac output ( = -0.31, p = 0.002). During follow-up, 20 patients reached the primary outcome. In sequential Cox models, a model based on right ventricular fractional area change at baseline (chi-square 4.8) was improved by left atrial volume index (chi-square 10.3, p = 0.007). In conclusion, determinants and worsening of 6MWD are explained by cardiac factors. When using the 6MWD as a clinical marker in pulmonary hypertension patients, their left ventricular diastolic function and right ventricular systolic function should be taken into consideration. (Keyword) Diastole / Disease Progression / Echocardiography, Doppler / Female / Follow-Up Studies / Humans / Hypertension, Pulmonary / Male / Middle Aged / Predictive Value of Tests / Prospective Studies / Scleroderma, Systemic / Stroke Volume / Systole / Time Factors / Ventricular Function, Left / Ventricular Function, Right / Walking (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjcard.2017.04.024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28532772 ● Search Scopus @ Elsevier (PMID): 28532772 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjcard.2017.04.024 (DOI: 10.1016/j.amjcard.2017.04.024, PubMed: 28532772)
100.	Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Ayumi Ishii, Yukina Hirata, Hiromitsu Seno, Yoshihito Saijo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : RV Myocardial Strain During Pre-Load Augmentation Is Associated With Exercise Capacity in Patients With Chronic HF, JACC. Cardiovascular Imaging, Vol.10, No.10, 1240-1249, 2017. (Summary) The aim of this study was to assess the relationship between right ventricular (RV) function during pre-load augmentation and exercise tolerance. Peak oxygen uptake (VO2) is a strong predictor of mortality in chronic heart failure. Cardiac function during pre-load augmentation is an important part of the phenomenon in the evaluation of exercise capacity. We prospectively performed echocardiographic studies in 68 chronic heart failure patients with cardiopulmonary exercise testing (mean age 60 ± 12 years; 69% male). After resting evaluations, echocardiographic parameters were repeated during leg positive pressure (LPP). Exercise capacity was assessed by peak VO2 in all patients (left ventricular ejection fraction: 43 ± 15%). Patients with severely reduced exercise capacity (peak VO2 <14 ml/kg/min) had significantly lower stroke volume index, left ventricular global longitudinal strain and RV strain and higher filling pressure (E/e' and pulmonary arterial systolic pressure) than the remainder. Stroke volume index ( = 0.49), global longitudinal strain ( = -0.61), E/e' ( = -0.32), pulmonary arterial systolic pressure ( = -0.57), and RV strain ( = -0.66) during LPP were independently correlated to peak VO2 (all p < 0.01). RV strain during LPP was the most powerful predictor in identifying patients with severely reduced exercise capacity (cut off value: -17%; sensitivity: 81%; specificity: 88%; areas under the curve: 0.88; p < 0.001) compared with other variables including resting parameters. RV strain during pre-load augmentation correlated independently to peak VO2 and was a powerful predictor in identifying patients with severely reduced exercise capacity. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2017.03.022 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28734918 ● Summary page in Scopus @ Elsevier: 2-s2.0-85025467938 (DOI: 10.1016/j.jcmg.2017.03.022, PubMed: 28734918, Elsevier: Scopus)
101.	Maimaituxun Gulinu, Michio Shimabukuro, Hotimah Masdan Salim, Minoru Tabata, Daisuke Yuji, Yoshihisa Morimoto, Takeshi Akasaka, Tomomi Matsuura, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Takaki Sugimoto, Masashi Tanaka, Shuichiro Takanashi and Masataka Sata : Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery, PLoS ONE, Vol.12, No.6, e0177170, 2017. (Summary) Traditional and non-traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) are different between men and women. Gender-linked impact of epicardial adipose tissue volume (EATV) in patients undergoing coronary artery bypass grafting (CABG) remains unknown. Gender-linked impact of EATV, abdominal fat distribution and other traditional ASCVD risk factors were compared in 172 patients (men: 115; women: 57) who underwent CABG or non-coronary valvular surgery (non-CABG). In men, EATV, EATV index (EATV/body surface area) and the markers of adiposity such as body mass index, waist circumference and visceral fat area were higher in the CABG group than in the non-CABG group. Traditional ASCVD risk factors were also prevalent in the CABG group. In women, EATV and EATV index were higher in the CABG group, but other adiposity markers were comparable between CABG and non-CABG groups. Multivariate logistic regression analysis showed that in men, CABG was determined by EATV Index and other ASCVD risk factors including hypertension, dyslipidemia, adiponectin, high sensitive C-reactive protein (hsCRP) and type 2 diabetes mellitus (Corrected R2 = 0.262, p < 0.0001), while in women, type 2 diabetes mellitus is a single strong predictor for CABG, excluding EATV Index (Corrected R2 = 0.266, p = 0.005). Our study found that multiple risk factors, including epicardial adipose tissue volume and traditional ASCVD factors are determinants for CABG in men, but type 2 diabetes mellitus was the sole determinant in women. Gender-specific disparities in risk factors of CABG prompt us to evaluate new diagnostic and treatment strategies and to seek underlying mechanisms. (Tokushima University Institutional Repository) ● Metadata: 112321 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0177170 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28594865 ● Summary page in Scopus @ Elsevier: 2-s2.0-85020391442 (Tokushima University Institutional Repository: 112321, DOI: 10.1371/journal.pone.0177170, PubMed: 28594865, Elsevier: Scopus)
102.	Takeshi Mitsuhashi, Ryoko Uemoto, Kazue Ishikawa, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi, Toshio Matsumoto, Masashi Akaike and Ken-ichi Aihara : Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice., Journal of Atherosclerosis and Thrombosis, 2017. (Summary) Pitavastatin exerts eNOS-independent protective effects against atherogenesis and hind-limb ischemia in mice, which may occur via modifications on key molecules such as AMPK and diverse molecules. (Tokushima University Institutional Repository) ● Metadata: 115483 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.37747 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28592707 ● Search Scopus @ Elsevier (PMID): 28592707 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.37747 (Tokushima University Institutional Repository: 115483, DOI: 10.5551/jat.37747, PubMed: 28592707)
103.	S Bando, Takeshi Soeki, Tomomi Matsuura, Takeshi Tobiume, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro, Naoki Muguruma, Tetsuji Takayama, I Kishimoto, Kenji Kangawa and Masataka Sata : Plasma brain natriuretic peptide levels are elevated in patients with cancer, PLoS ONE, Vol.12, No.6, e0178607, 2017. (Summary) Natriuretic peptides have been proposed as biomarkers of cardiovascular disease, especially heart failure. Brain natriuretic peptide (BNP) has also been shown to be upregulated at the transcriptional and translational levels by pro-inflammatory cytokines in cardiac myocytes. Although we often measure plasma BNP levels in cancer patients, it remains unknown whether cancer-related inflammation affects the plasma BNP levels. We investigated the relationship between the BNP and human cancers. We retrospectively studied 2,923 patients in whom the plasma BNP levels and serum C-reactive protein (CRP) were measured and echocardiography was performed. Patients with clinically evident heart failure (NYHA II or higher), heart disease requiring medical treatment or surgery, renal dysfunction, and inflammatory disease were excluded. There were 234 patients in the final analysis. Blood sampling was performed before surgery and chemotherapy. In addition, we evaluated the relationship between the inflammation and plasma BNP levels in mouse models of colon cancer. Of the 234 patients, 80 were diagnosed with cancer. Both the plasma BNP and serum CRP levels were significantly higher in cancer patients than those without. There were no significant differences in the echocardiographic parameters. There was a significant positive correlation between the plasma BNP and serum CRP levels in cancer patients (r = 0.360, P<0.01) but not in those without. In cancer patients, only the CRP correlated with the BNP independent of the age, creatinine level, hypertension, and body mass index. In addition, in nude mice with subcutaneous colon cancer, the plasma BNP level was elevated compared with that in non-cancer mice, and there was a significant relationship between the plasma BNP and serum levels of the inflammatory markers. In cancer patients, as well as colon cancer model mice, the plasma BNP levels were elevated, possibly due to cancer-related inflammation. The effect of cancer on the BNP levels should be considered when using BNP as an indicator of heart failure in cancer patients. (Tokushima University Institutional Repository) ● Metadata: 112318 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0178607 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28570595 ● Search Scopus @ Elsevier (PMID): 28570595 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0178607 (Tokushima University Institutional Repository: 112318, DOI: 10.1371/journal.pone.0178607, PubMed: 28570595)
104.	Salim Masdan Hotimah, Daiju Fukuda, Yasutomi Higashikuni, Kimie Tanaka, Yoichiro Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice., Vascular Pharmacology, Vol.96-98, No.16, 19-25, 2017. (Summary) Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects that are associated with vascular protection. Here, we examined whether teneligliptin alters the pro-inflammatory phenotype of perivascular adipose tissue (PVAT) and inhibits atherogenesis. Teneligliptin (60mg/kg/day) was administered orally to apolipoprotein-E-deficient (ApoE(-/-)) mice for 20weeks. Teneligliptin significantly inhibited the development of atherosclerosis in the aortic arch compared with vehicle (P<0.05), without alteration of blood glucose level or blood pressure. Histological analyses demonstrated that teneligliptin decreased lipid deposition and MCP-1 expression (P<0.05, respectively), and tended to decrease macrophage accumulation in atherosclerotic plaques. The results of quantitative RT-PCR analysis demonstrated that teneligliptin reduced the expression of inflammatory molecules such as TNF- and MCP-1 in the abdominal aorta. Furthermore, teneligliptin reduced the expression of a macrophage marker and Nox-4, a major NADPH oxidase subunit in adipocytes, in PVAT around the aortic arch. Administration of teneligliptin for 8weeks ameliorated endothelium-dependent vasodilation and reduced oxidative stress as determined by urinary 8-OHdG excretion (P<0.05) compared with vehicle. In vitro experiments demonstrated that exendin-4 (Ex-4), a GLP-1 analog, decreased the expression of inflammatory molecules in RAW264.7 cells. Also, Ex-4 decreased Nox4 expression in 3T3-L1 adipocytes. Teneligliptin inhibited atherogenesis with attenuation of the inflammatory phenotype in PVAT. A GLP-1 analog suppressed pro-inflammatory activation of macrophages and adipocytes. Suppression of the pro-inflammatory phenotype of PVAT might contribute, at least partially, to the cardioprotective effects of teneligliptin. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.vph.2017.03.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28347868 ● Summary page in Scopus @ Elsevier: 2-s2.0-85016431523 (DOI: 10.1016/j.vph.2017.03.003, PubMed: 28347868, Elsevier: Scopus)
105.	Kenya Kusunose, Yuta Torii, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Hiromitsu Seno, Yoshihito Saijo, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF., JACC. Cardiovascular Imaging, Vol.10, No.2, 118-126, 2017. (Summary) Objectives: The aim of this study was to assess the time course of presumptive TIC and the predictors of LV functional recovery in such patients.Background: Tachycardia-induced cardiomyopathy (TIC) is a potentially reversible cardiomyopathy with effective treatment of the tachyarrhythmia. However, cases without improvement of left ventricular (LV) systolic function were found occasionally. The diagnosis of TIC can be challenging, and the role of echocardiographic imaging in the prediction of LV functional recovery is limited.Methods: LV segmental longitudinal strains (LS) were evaluated by 2-dimensional speckle tracking in 71 consecutive patients (65±16 years; 61% men) with tachyarrhythmia and reduced LV ejection fraction (EF) without any other known cardiovascular disease, and 30 age and gender matched control subjects. Relative apical LS ratio (RALSR) was defined using the equation: average apical LS / (average basal LS + average mid LS) as a marker of strain distribution.Results: Compared to control subjects, patients with tachyarrhythmia had significantly lower global LS. Improvement in LVEF within 6 months after treatment of index arrhythmia was observed in 41 patients, and LVEF did not improve in 30 patients. In univariate analysis, lower LVEF at baseline (hazard ratio: HR: 0.59 per 1SD, p=0.04) and higher RALSR (HR: 11.2 per 1SD, p <0.001) were associated with no recovery in LVEF during follow-up. In a multivariate logistic regression model, the significant predictor of LV systolic functional recovery was RALSR (HR: 22.9 per 1SD, p=0.001). A RALSR of 0.61 was sensitive (71%) and specific (90%) in differentiating LV systolic functional recovery (area under the curve: 0.88).Conclusions: The RALSR was associated with LV systolic functional recovery. This information might be useful for clinical evaluation and follow-up in patients with reduced LVEF. (Keyword) tachycardia induced cardiomyopathy / strain imaging / functional recovery (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2016.03.019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27665160 ● Summary page in Scopus @ Elsevier: 2-s2.0-84994494325 (DOI: 10.1016/j.jcmg.2016.03.019, PubMed: 27665160, Elsevier: Scopus)
106.	K Sai, K Kajinami, H Akao, M Iwadare, R Sato-Ishida, Y Kawai, K Takeda, T Tanimoto, T Yamano, T Akasaka, T Ishida, K Hirata, K Saku, Shusuke Yagi, Takeshi Soeki, Masataka Sata, M Ueno, S Miyazaki, A Shiraki, J Oyama, K Node, K Sugamura, H Ogawa, K Kurose, K Maekawa, Y Matsuzawa, T Imatoh, R Hasegawa, Consortium Pharmacogenomics Data Science Japanese and Y Saito : A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metabolism and Pharmacokinetics, Vol.31, No.6, 467-470, 2016. (Keyword) Genetic polymorphism / HLA / Myopathy / Rhabdomyolysis / Statin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.dmpk.2016.09.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27839692 ● Search Scopus @ Elsevier (PMID): 27839692 ● Search Scopus @ Elsevier (DOI): 10.1016/j.dmpk.2016.09.002 (DOI: 10.1016/j.dmpk.2016.09.002, PubMed: 27839692)
107.	HM Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse., Frontiers in Cardiovascular Medicine, Vol.3, 43, 2016. (Summary) BACKGROUND: Endothelial dysfunction caused by increased oxidative stress is a critical initiator of macro- and micro-vascular disease development in diabetic patients. Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. The aim of this study was to examine whether ipragliflozin attenuates endothelial dysfunction in diabetic mice.METHODS: Eight-week-old male C57BL/6 mice were treated with streptozotocin (150mg/kg) by a single intraperitoneal injection to induce diabetes mellitus. At 3days of injection, ipragliflozin (3mg/kg/day) was administered via gavage for 3weeks. Vascular function was assessed by isometric tension recording. Human umbilical vein endothelial cells (HUVEC) were used for in vitro experiments. RNA and protein expression were examined by quantitative RT-PCR (qPCR) and western blot, respectively. Oxidative stress was determined by measuring urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) level.RESULTS: Ipragliflozin administration significantly reduced blood glucose level (P<0.001) and attenuated the impairment of endothelial function in diabetic mice, as determined by acetylcholine-dependent vasodilation (P<0.001). Ipragliflozin did not alter metabolic parameters, such as body weight and food intake. Ipragliflozin administration ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta and reduced reactive oxygen species generation as determined by urinary excretion of 8-OHdG in diabetic mice. Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P<0.05). In in vitro studies, incubation with methylglyoxal, one of the advanced glycation end products, significantly impaired phosphorylation of Akt and eNOSSer1177 (P<0.01) and increased the expression of MCP-1, VCAM-1, and ICAM-1 in HUVEC.CONCLUSION: Ipragliflozin improved hyperglycemia and prevented the development of endothelial dysfunction under a hyperglycemic state, at least partially by attenuation of oxidative stress. (Keyword) SGLT2 inhibitor / endothelial function / hyperglycemia / inflammation / oxidative stress (Tokushima University Institutional Repository) ● Metadata: 114485 (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2016.00043 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27833913 ● Search Scopus @ Elsevier (PMID): 27833913 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2016.00043 (Tokushima University Institutional Repository: 114485, DOI: 10.3389/fcvm.2016.00043, PubMed: 27833913)
108.	A Takashima, Shusuke Yagi, Koji Yamaguchi, S Watanabe, N Yamamoto, H Ito, M Kadota, T Hara, H Yamazaki, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Purulent pericarditis accompanying pericardial abscess induced by nocardia in an immunocompromised patient., Circulation Journal, Vol.80, No.11, 2409-2411, 2016. (Keyword) Abscess / Aged, 80 and over / Echocardiography / Female / Humans / Immunocompromised Host / Nocardia / Nocardia Infections / Pericarditis / Pericardium / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-16-0531 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27628220 ● Summary page in Scopus @ Elsevier: 2-s2.0-84992462594 (DOI: 10.1253/circj.CJ-16-0531, PubMed: 27628220, Elsevier: Scopus)
109.	A Takashima, Daiju Fukuda, K Tanaka, Y Higashikuni, Y Hirata, S Nishimoto, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Yutaka Taketani, Michio Shimabukuro and Masataka Sata : Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation., Atherosclerosis, Vol.254, 142-150, 2016. (Summary) BACKGROUND AND AIMS: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are major components of n-3 polyunsaturated fatty acids (n-3 PUFAs) which inhibit atherogenesis, although few studies have examined the effects of the combination of EPA and DHA on atherogenesis. The aim of this study was to investigate whether DHA has additional anti-atherosclerotic effects when combined with EPA.METHODS: Male 8-week-old apolipoprotein E-deficient (Apoe-/-) mice were fed a western-type diet supplemented with different amounts of EPA and DHA; EPA (2.5%, w/w), low-dose EPA + DHA (2.5%, w/w), or high-dose EPA + DHA (5%, w/w) for 20 weeks. The control group was fed a western-type diet containing no n-3 PUFA. Histological and gene expression analysis were performed in atherosclerotic lesions in the aorta. To address the mechanisms, RAW264.7 cells were used.RESULTS: All n-3 PUFA treatments significantly attenuated the development and destabilization of atherosclerotic plaques compared with the control. The anti-atherosclerotic effects were enhanced in the high-dose EPA + DHA group (p < 0.001), whereas the pure EPA group and low-dose EPA + DHA group showed similar results. EPA and DHA additively attenuated the expression of inflammatory molecules in RAW264.7 cells stimulated with LPS. DHA or EPA + DHA suppressed LPS-induced toll-like receptor 4 (TLR4) expression in lipid rafts on RAW264.7 cells (p < 0.05). Lipid raft disruption by methyl--cyclodextrin suppressed mRNA expression of inflammatory molecules in LPS-stimulated macrophages.CONCLUSION: n-3 PUFAs suppressed atherogenesis. DHA combined with EPA had additional anti-inflammatory effects and inhibited atherogenesis in Apoe-/- mice. The reduction of TLR4 expression in lipid rafts in macrophages by DHA might be involved in this mechanism, at least partially. (Keyword) Atherosclerosis / Inflammation / Lipid raft / Macrophage / Toll-like receptor 4 / n-3 poly unsaturated fatty acid (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2016.10.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27744130 ● Summary page in Scopus @ Elsevier: 2-s2.0-84991678518 (DOI: 10.1016/j.atherosclerosis.2016.10.002, PubMed: 27744130, Elsevier: Scopus)
110.	M Kadota, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, R Ueno, Y Kawabata, T Hara, K Ogasawara, Mika Bando, S Bando, Tomomi Matsuura, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin., International Heart Journal, Vol.57, No.4, 461-465, 2016. (Summary) The renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP) regulate body fluids. Although conventional diuretics have been used for treating heart failure, they activate RAAS and exacerbate renal function. Tolvaptan, a newly developed vasopressin-2 receptor antagonist, elicits aquaresis and improves volume overload in heart failure patients, however, the predictors of tolvaptan effectiveness and the influence on the RAAS and renal function according to tolvaptan therapy are not established. We evaluated 26 chronic heart failure patients receiving therapy with 15 mg/day tolvaptan and examined their laboratory and urinary data before and after tolvaptan therapy. A response to tolvaptan was defined as a body weight decrease by more than 2 kg in a week and a urine volume increase by 500 mL/ day compared with that before tolvaptan administration. Body weight, urine volume, and brain natriuretic peptide levels significantly improved (P < 0.05), without any worsening of renal function represented by serum creatinine, sodium, and potassium. Moreover, no significant changes were observed in the plasma renin activity and plasma aldosterone concentration (PAC). In the responder group, urine osmolality before tolvaptan administration was significantly higher (P < 0.05) but declined significantly after tolvaptan administration (P < 0.05). The AVP/PAC ratio before administration was positively correlated with the efficacy of tolvaptan. Tolvaptan treatment could prevent RAAS activation in chronic heart failure patients. Moreover, monitoring the AVP/PAC ratio may be useful in predicting the tolvaptan response. (Keyword) Adult / Aged / Aged, 80 and over / Antidiuretic Hormone Receptor Antagonists / Arginine Vasopressin / Benzazepines / Body Mass Index / Female / Heart Failure / Humans / Male / Middle Aged / Prospective Studies / Renin-Angiotensin System / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 109694 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.15-491 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27357439 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979587993 (Tokushima University Institutional Repository: 109694, DOI: 10.1536/ihj.15-491, PubMed: 27357439, Elsevier: Scopus)
111.	Michio Shimabukuro, H Sato, Hirofumi Izaki, Daiju Fukuda, E Uematsu, Y Hirata, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Hiro-omi Kanayama, H Masuzaki and Masataka Sata : Depot- and gender-specific expression of NLRP3 inflammasome and toll-like receptors in adipose tissue of cancer patients., BioFactors, Vol.42, No.4, 397-406, 2016. (Keyword) obesity / inflammation / gender (Link to Publication Site) ● Publication site (DOI): 10.1002/biof.1287 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27086574 ● Summary page in Scopus @ Elsevier: 2-s2.0-84982113330 (DOI: 10.1002/biof.1287, PubMed: 27086574, Elsevier: Scopus)
112.	Michio Shimabukuro, C Okawa, Hirotsugu Yamada, S Yanagi, E Uematsu, N Sugasawa, Hirotsugu Kurobe, Y Hirata, JR Kim-Kaneyama, XF Lei, S Takao, Y Tanaka, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuya Kitagawa, H Masuzaki, M Sato and Masataka Sata : The pathophysiological role of oxidized cholesterols in epicardial fat accumulation and cardiac dysfunction: A study in swine fed a high caloric diet with an inhibitor of intestinal cholesterol absorption, ezetimibe., The Journal of Nutritional Biochemistry, Vol.35, 66-73, 2016. (Summary) Oxidized cholesterols (oxycholesterols) in food have been recognized as strong atherogenic components, but their tissue distributions and roles in cardiovascular diseases remain unclear. To investigate whether accumulation of oxycholesterols is linked to cardiac morphology and function, and whether reduction of oxycholesterols can improve cardiac performance, domestic male swine were randomized to a control diet (C), high caloric diet (HCD) or HCD+Ezetimibe, an inhibitor of intestinal cholesterol absorption, group (HCD+E) and evaluated for: (1) distribution of oxycholesterol components in serum and tissues, (2) levels of oxycholesterol-related enzymes, (3) paracardial and epicardial coronary fat thickness, and (4) cardiac performance. Ezetimibe treatment for 8weeks attenuated increases in oxycholesterols in the HCD group almost completely in liver, but reduced only levels of 4β-hydroxycholesterol in left ventricular (LV) myocardium. Ezetimibe treatment altered the expression of genes for cholesterol and fatty acid metabolism and decreased the expression of CYP3A46, which catabolizes cholesterol to 4β-hydroxycholesterol, strongly in liver. An increase in epicardial fat thickness and impaired cardiac performance in the HCD group were improved by ezetimibe treatment, and the improvement was closely related to the reduction in levels of 4β-hydroxycholesterol in LV myocardium. In conclusion, an increase in oxycholesterols in the HCD group was closely related to cardiac hypertrophy and dysfunction, as well as an increase in epicardial fat thickness. Ezetimibe may directly reduce oxycholesterol in liver and LV myocardium, and improve cardiac morphology and function. (Keyword) Cardiac function / Cardiac hypertrophy / Epicardial fat / Obesity / Oxycholesterol (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jnutbio.2016.05.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27416363 ● Search Scopus @ Elsevier (PMID): 27416363 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jnutbio.2016.05.010 (DOI: 10.1016/j.jnutbio.2016.05.010, PubMed: 27416363)
113.	HM Salim, Daiju Fukuda, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice., Vascular Pharmacology, Vol.79, 16-23, 2016. (Summary) Background; The dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects. This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina), suppresses atherogenesis in non-diabetic apolipoprotein-E deficient (ApoE-/-) mice and examined its effects on endothelial function. Methods and Results; Lina (10 mg/kg/day) was administered orally to ApoE-/- mice for 20 weeks. Lina reduced atherogenesis without the alteration of metabolic parameters including blood glucose level compared with the control (P<0.05). Results of immunohistochemistry and quantitative RT-PCR demonstrated that Lina significantly decreased inflammatory molecule expression and macrophage infiltration in atherosclerotic aorta. Lina administration to ApoE-/- mice for 9 weeks ameliorated endothelium-dependent vasodilation compared with non-treated mice. Plasma active glucagon-like peptide-1 (GLP-1) level was significantly higher in the treated group (P<0.05). Exendin-4 (Ex-4), a GLP-1 analogue, ameliorated endothelium-dependent vasodilation impaired by palmitic acid (PA) in wild-type mouse aortic segments. Ex-4 promoted phosphorylation of eNOSSer1177 and Akt which are abrogated by PA in human umbilical vein endothelial cells. In addition, Lina administration to ApoE-/- mice decreased oxidative stress as determined by urinary 8-OHdG secretion and NADPH oxidase subunit expression in the abdominal aorta.Conclusion; Lina inhibited atherogenesis in non-diabetic ApoE-/- mice. Amelioration of endothelial dysfunction associated with the reduction of oxidative stress by GLP-1 contributes to the atheroprotective effects of Lina. (Keyword) DPP-4 inhibitor / linagliptin / GLP-1 / endothelial function / inflammation / oxidative stress (Tokushima University Institutional Repository) ● Metadata: 110139 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.vph.2015.08.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26277250 ● Search Scopus @ Elsevier (PMID): 26277250 ● Search Scopus @ Elsevier (DOI): 10.1016/j.vph.2015.08.011 (Tokushima University Institutional Repository: 110139, DOI: 10.1016/j.vph.2015.08.011, PubMed: 26277250)
114.	Takeshi Soeki, Tomomi Matsuura, Sachiko Bando, Takeshi Tobiume, Etsuko Uematsu, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation., Journal of Cardiology, Vol.68, No.6, 472-477, 2016. (Summary) BACKGROUND: The underlying mechanism of atrial substrate remodeling in atrial fibrillation (AF) remains unknown. In this study, we investigated whether local and systemic levels of microRNA (miR) might be associated with the presence of AF and with left atrial (LA) substrate properties.METHODS: Blood from the periphery, pulmonary vein (PV), and left atrial appendage (LAA) was sampled from 30 patients with AF undergoing PV isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome and without AF. We measured peripheral, PV, and LAA plasma levels of miR-1, -26, -133a, -328, and -590 by reverse transcription-polymerase chain reaction. LA global contact mapping during sinus rhythm was performed before PV isolation.RESULTS: Plasma levels of miR-328 were higher in patients with AF than in control subjects. Plasma miR-328 levels were significantly higher in the LAA than in the periphery and PV in patients with AF, but not in control subjects. Plasma miR-1 levels were also higher in the LAA than in the PV in AF patients. Interestingly, LAA plasma levels of miR-328 showed a positive correlation with the LA voltage zone index (area with voltage <0.5mV divided by total LA surface area) and a weak correlation with LA volume.CONCLUSION: Local production of miR-328 in the left atrium may be involved in the process of atrial remodeling in patients with AF. (Keyword) Atrial fibrillation / Left atrium / MicroRNA / Remodeling / Substrate (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2015.12.007 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26987792 ● Summary page in Scopus @ Elsevier: 2-s2.0-84960969355 (DOI: 10.1016/j.jjcc.2015.12.007, PubMed: 26987792, Elsevier: Scopus)
115.	Akira Takashima, Shusuke Yagi, Koji Yamaguchi, Eri Takagi, Tamotsu Kanbara, Hirohisa Ogawa, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Tetsuya Kitagawa and Masataka Sata : Vegetation in the coronary sinus that concealed the presence of a coronary arteriovenous fistula in a patient with infectious endocarditis., International Journal of Cardiology, Vol.207, 266-268, 2016. (Keyword) Coronary sinus / Fistula / Infectious endocarditis / Vegetation (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2016.01.057 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26808990 ● Summary page in Scopus @ Elsevier: 2-s2.0-84958019532 (DOI: 10.1016/j.ijcard.2016.01.057, PubMed: 26808990, Elsevier: Scopus)
116.	Shusuke Yagi, Ken-ichi Aihara, Daiju Fukuda, Akira Takashima, Mika Bando, Tomoya Hara, Sachiko Nishimoto, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome., Nutrition Journal, Vol.14, No.1, 111, 2015. (Summary) BACKGROUND: The hospitalization rate for acute coronary syndrome (ACS) for people aged 50 has remained stable over the past decade. Increased serum levels of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a decreased incidence of cardiovascular events and mortality in older patients; however, it is currently unknown whether reduced serum levels of n-3 PUFAs is also a risk factor for ACS in patients aged 50 years.METHODS AND RESULTS: We retrospectively reviewed 102 (male/ female 73/29) Japanese ACS patients whose serum levels of EPA/arachidonic acid (AA) and DHA/AA were evaluated on admission. The EPA/AA ratio was the lowest in patients aged 50 compared to patients aged 51-74 and 75. Pearson correlation analysis showed that early ACS onset was associated with low EPA/AA and DHA/AA ratios, and multiple regression analysis determined that decreased ratios of EPA/AA and DHA/AA, and male sex, current smoker status, increased body mass index and triglyceride levels, independently correlated with early ACS onset. Conversely, low-density and high-density lipoproteins, glycated hemoglobin, and hypertension did not correlate with early ACS onset. Subgroup analyses of male patients revealed that decreased ratios of EPA/AA and DHA/AA independently correlated with early ACS onset.CONCLUSION: Decreased EPA/AA and DHA/AA ratios may be risk factors for early onset of ACS, suggesting that reduced EPA/AA and DHA/AA may represent targets for preventing ACS in Japanese young people. (Link to Publication Site) ● Publication site (DOI): 10.1186/s12937-015-0102-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26514181 ● Summary page in Scopus @ Elsevier: 2-s2.0-84945959581 (DOI: 10.1186/s12937-015-0102-4, PubMed: 26514181, Elsevier: Scopus)
117.	S Bando, Daiju Fukuda, Takeshi Soeki, S Nishimoto, E Uematsu, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis., Atherosclerosis, Vol.242, No.2, 407-414, 2015. (Summary) ObjectivesThe promotion of adipose tissue inflammation by lifestyle-related diseases such as obesity and diabetes accelerates atherogenesis; however, the underlying mechanisms remain incompletely understood. Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome contributes to chronic inflammation in adipose tissue. Here, we investigated the link between NLRP3 expression in subcutaneous adipose tissue (SAT) and the severity of coronary atherosclerosis.Methods and resultsSAT was obtained from 72 patients who underwent heart device implantation and coronary angiography. Expression of NLRP3 inflammasome-related molecules (NLRP3, IL-1 and IL-18) in SAT were evaluated by quantitative RT-PCR. Laboratory markers related to lifestyle-related diseases were measured. Patients with obesity, dyslipidemia (P < 0.05, respectively), diabetes or hyperuricemia (P < 0.01, respectively) had significantly higher expression of NLRP3. Multivariate analysis demonstrated that body mass index and serum level of uric acid were predictors of NLRP3 expression in SAT. The expression of NLRP3 in SAT correlated negatively with serum adiponectin level (r = 0.23, P < 0.05). Patients with coronary artery disease showed higher NLRP3 expression than patients without significant stenosis (P < 0.01). Furthermore, the expression of NLRP3 in SAT correlated positively with the severity of coronary atherosclerosis as determined by Gensini score (r = 0.47, P < 0.0001) or SYNTAX score (r = 0.55, P < 0.0001). Multiple regression analysis revealed that the expression of NLRP3 in SAT remains as an independent predictors for the severity of coronary atherosclerosis.ConclusionsThe expression of NLRP3 in SAT, which is affected by lifestyle-related diseases, is associated with the severity of coronary atherosclerosis. Our results suggest that NLRP3 inflammasome in SAT may have a role in atherogenesis. (Keyword) Atherosclerosis / Adipose tissue / Inflammation / NLRP3 inflammasome / Lifestyle-related disease (Tokushima University Institutional Repository) ● Metadata: 109532 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2015.07.043 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26282945 ● Search Scopus @ Elsevier (PMID): 26282945 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2015.07.043 (Tokushima University Institutional Repository: 109532, DOI: 10.1016/j.atherosclerosis.2015.07.043, PubMed: 26282945)
118.	Hara Tomoya, Daiju Fukuda, Tanaka Kimie, Higashikuni Yasutomi, Hirata Yoichiro, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice., Atherosclerosis, Vol.242, No.2, 639-646, 2015. (Summary) OBJECTIVE: Activated factor X (FXa) plays a key role in the coagulation cascade, whereas accumulating evidence suggests that it also contributes to the pathophysiology of chronic inflammation on the vasculature. In this study, we assessed the hypothesis that rivaroxaban (Riv), a direct FXa inhibitor, inhibits atherogenesis by reducing macrophage activation.METHODS AND RESULTS: Expression levels of PAR-1 and PAR-2, receptors for FXa, increased in the aorta of apolipoprotein E-deficient (ApoE(-/-)) mice compared with wild-type mice (P < 0.01, P < 0.05, respectively). Administration of Riv (5 mg/kg/day) for 20 weeks to 8-week-old ApoE(-/-) mice reduced atherosclerotic lesion progression in the aortic arch as determined by en-face Sudan IV staining compared with the non-treated group (P < 0.05) without alteration of plasma lipid levels and blood pressure. Histological analyses demonstrated that Riv significantly decreased lipid deposition, collagen loss, macrophage accumulation and matrix metallopeptidase-9 (MMP-9) expression in atherosclerotic plaques in the aortic root. Quantitative RT-PCR analyses using abdominal aorta revealed that Riv significantly reduced mRNA expression of inflammatory molecules, such as MMP-9, tumor necrosis factor- (TNF-). In vitro experiments using mouse peritoneal macrophages or murine macrophage cell line RAW264.7 demonstrated that FXa increased mRNA expression of inflammatory molecules (e.g., interleukin (IL)-1 and TNF-), which was blocked in the presence of Riv.CONCLUSIONS: Riv attenuates atherosclerotic plaque progression and destabilization in ApoE(-/-) mice, at least in part by inhibiting pro-inflammatory activation of macrophages. These results indicate that Riv may be particularly beneficial for the management of atherosclerotic diseases, in addition to its antithrombotic activity. (Keyword) Activated factor X / atherosclerosis / Coagulation / inflammation / Macrophages / Rivaroxaban (Tokushima University Institutional Repository) ● Metadata: 109485 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2015.03.023 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25817329 ● Summary page in Scopus @ Elsevier: 2-s2.0-84941742835 (Tokushima University Institutional Repository: 109485, DOI: 10.1016/j.atherosclerosis.2015.03.023, PubMed: 25817329, Elsevier: Scopus)
119.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, HM Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto and Masataka Sata : Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus., Diabetes & Metabolism Journal, Vol.39, No.4, 342-347, 2015. (Summary) BACKGROUND: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.METHODS: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.RESULTS: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.CONCLUSION: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment. (Keyword) Coronary artery disease / diabetes mellitus / Dipeptidyl-peptidase IV inhibitors / Obese / Predictive factors (Link to Publication Site) ● Publication site (DOI): 10.4093/dmj.2015.39.4.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26301197 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939780057 (DOI: 10.4093/dmj.2015.39.4.342, PubMed: 26301197, Elsevier: Scopus)
120.	Kenya Kusunose, Hirotsugu Yamada, Junko Hotsuchi, Mika Bando, Susumu Nishio, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Jun Kishi and Masataka Sata : Prediction of Future Overt Pulmonary Hypertension by 6-Min Walk Stress Echocardiography in Patients With Connective Tissue Disease., Journal of the American College of Cardiology, Vol.66, No.4, 376-384, 2015. (Summary) BACKGROUND: Early detection of pulmonary hypertension (PH) in connective tissue disease (CTD) is crucial to ensuring that patients receive timely treatment for this progressive disease. Exercise stress tests have been used to screen patients in an attempt to identify early-stage PH. Recent studies have described abnormal mean pulmonary artery pressure (mPAP)-cardiac output (Q) responses as having the potential to assess the disease state.OBJECTIVES: This study hypothesized that pulmonary circulation pressure-flow relationships obtained by 6-min walk (6MW) stress echocardiography would better delineate differential progression of PH and predict development of PH during follow-up.METHODS: We prospectively performed 6MW stress echocardiographic studies in 78 CTD patients (age 58 ± 12 years; 9% male) at baseline and follow-up. All patients underwent yearly echocardiographic follow-up studies for up to 5 years.RESULTS: During a median period of 32 months (range: 15 to 62 months), 16 patients reached the clinical endpoint of development of PH and none died during follow-up. PH was confirmed by right heart catheterization in all 16 patients (mPAP 25 mm Hg and pulmonary capillary wedge pressure 15 mm Hg). In a Cox proportional-hazards survival model, 6MW distance (hazard ratio [HR]: 0.99; p = 0.010), early diastolic tricuspid annulus motion velocity (HR: 0.79; p = 0.025), and mPAP/Q by 6MW stress (HR: 1.10; p = 0.005) were associated with development of PH. In sequential Cox models, a model on the basis of 6MW distance (chi-square, 6.6) was improved by mPAP/Q (chi-square: 14.4; p = 0.019). Using a receiver-operating characteristic curve, we found that the best cutoff value of mPAP/Q for predicting development of pulmonary hypertension was >3.3 mm Hg/l/min.CONCLUSIONS: The 6MW stress echocardiography noninvasively provides an incremental prognostic value of PH development in CTD. This is a single-center prospective cohort study. Larger multicenter studies are warranted to confirm this result. (Keyword) lupus erythematosus / mixed connective tissue disease / pulmonary circulation / systemic scleroderma (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jacc.2015.05.032 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26205595 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937681606 (DOI: 10.1016/j.jacc.2015.05.032, PubMed: 26205595, Elsevier: Scopus)
121.	Hiromu Yamazaki, Koji Yamaguchi, Takeshi Soeki, Tetsuzo Wakatsuki, Toshiyuki Niki, Yoshio Taketani, Atsunori Kitaoka, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada and Masataka Sata : Impact of indoxyl sulfate, a uremic toxin, on non-culprit coronary plaque composition assessed by integrated backscatter intravascular ultrasound., Circulation Journal, Vol.79, No.8, 1773-1779, 2015. (Summary) BACKGROUND: Uremic toxin has emerged as an important determinant of cardiovascular risk. The aim of this study was to examine the relationship between serum uremic toxin and coronary plaque composition on integrated backscatter intravascular ultrasound (IB-IVUS).MethodsandResults:IB-IVUS was performed in 47 patients with planned treatment for angina pectoris. Non-culprit intermediate plaque analyzed in this study had to be >5 mm apart from the intervention site. 3-D IB-IVUS analysis was performed to determine percent lipid volume (LV) and fibrous volume (FV). We also measured serum uremic toxins (indoxyl sulfate [IS], asymmetric dimethylarginine [ADMA], and p-cresol [PC]). Glomerular filtration rate correlated with IS (r=-0.329, P=0.04), but did not correlate with ADMA or PC. Percent LV correlated with IS (r=0.365, P=0.02), but did not correlate with ADMA or PC. Percent FV also correlated with IS (r=-0.356, P=0.03), but did not correlate with ADMA or PC. On multivariate regression, only IS was associated with percent LV (r=0.359, P=0.04) and percent FV (r=-0.305, P=0.04) independently of potentially confounding coronary risk factors.CONCLUSIONS: Among the uremic toxins, serum IS might be a novel useful biomarker to detect and monitor lipid-rich coronary plaque on IB imaging. (Circ J 2015; 79: 1773-1779). (Keyword) Coronary plaque / Indoxyl sulfate / Integrated backscatter intravascular ultrasound (Tokushima University Institutional Repository) ● Metadata: 109533 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-15-0019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25971408 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937904061 (Tokushima University Institutional Repository: 109533, DOI: 10.1253/circj.CJ-15-0019, PubMed: 25971408, Elsevier: Scopus)
122.	Tomoya Hara, Shusuke Yagi, Masashi Akaike and Masataka Sata : Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection., International Journal of Cardiology, Vol.198, 220-221, 2015. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2015.06.112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26173061 ● Summary page in Scopus @ Elsevier: 2-s2.0-84940416779 (DOI: 10.1016/j.ijcard.2015.06.112, PubMed: 26173061, Elsevier: Scopus)
123.	Kenya Kusunose, Junko Hotsuchi, Y Takagawa, S Nishio, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Serial imaging changes during treatment of immunoglobulin G4-related disease with multiple pseudotumors., Circulation, Vol.131, No.21, 1882-1883, 2015. (Keyword) Aged, 80 and over / Antibodies, Anti-Idiotypic / Arteries / Cardiomegaly / Coronary Aneurysm / Eyelid Diseases / Fluorodeoxyglucose F18 / Humans / Immunoglobulin G / Male / Paraproteinemias / Plasma Cells / Positron-Emission Tomography / Radiopharmaceuticals / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCULATIONAHA.115.015638 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26015466 ● Summary page in Scopus @ Elsevier: 2-s2.0-84936080389 (DOI: 10.1161/CIRCULATIONAHA.115.015638, PubMed: 26015466, Elsevier: Scopus)
124.	Shusuke Yagi, Ken-ichi Aihara, Daiju Fukuda, Akira Takashima, Tomoya Hara, Junko Hotsuchi, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Effects of docosahexaenoic acid on the endothelial function in patients with coronary artery disease., Journal of Atherosclerosis and Thrombosis, Vol.22, No.5, 447-454, 2015. (Summary) AIM: The consumption of n-3 polyunsaturated fatty acids (PUFA), including docosahexaenoic acid DHA), reduces the incidence of cardiovascular events, and reduced serum levels of n-3 PUFA may be associated with an increased risk of cardiovascular events. However, controversy remains regarding which components of PUFA are associated with the endothelial function in patients with coronary artery disease (CAD). We therefore examined the associations between the n-3 and n-6 PUFA levels and CAD.METHODS: We retrospectively reviewed 160 consecutive Japanese patients with CAD whose endothelial function was measured according to the percent change in flow-mediated dilation (FMD) and the serum levels of n-3 PUFA, including eicosapentaenoic acid (EPA) and DHA, and n-6 PUFA, including arachidonic acid (AA) and dihomo-gamma-linolenic acid (DHLA).RESULTS: A single regression analysis showed no relationships between the FMD and the serum levels of PUFA, including EPA, DHA, AA and DHLA. In contrast, a multiple regression analysis showed that the DHA level was a positive (P0.01) and age was a negative (P0.001) contributor to an increased FMD; however, sex, body mass index, systolic and diastolic blood pressure, current/past smoking and the levels of HbA1c, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, EPA, AA and DHLA did not significantly affect the outcome.CONCLUSIONS: The serum level of DHA is associated with the endothelial function evaluated according to the FMD in patients with CAD, thus suggesting that a low serum level of DHA may be a predictive biomarker for endothelial dysfunction. (Keyword) Flow-mediated dilation / n-3 polyunsaturated fatty acids / Docosahexaenoic acid (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.26914 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25342567 ● CiNii @ National Institute of Informatics (CRID): 1390282679408260352 ● Summary page in Scopus @ Elsevier: 2-s2.0-84929412906 (DOI: 10.5551/jat.26914, PubMed: 25342567, CiNii: 1390282679408260352, Elsevier: Scopus)
125.	Toshiyuki Niki, Takeshi Soeki, Koji Yamaguchi, Yoshio Taketani, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis., International Heart Journal, Vol.56, No.3, 269-272, 2015. (Summary) Several studies have shown that various chemokines are more highly expressed in atherosclerotic plaques than in normal vessel walls. In the present study, we investigated the relationship between coronary atherosclerosis and noteworthy chemokines, including interferon-inducible protein of 10 kD (IP-10); monocyte chemoattractant protein 1 (MCP-1); regulated on activation, normal T-cell expressed and secreted (RANTES); and high-sensitivity C-reactive protein (hsCRP), an established marker of atherosclerotic disease. We studied 28 patients who underwent coronary angiography because of suspected coronary artery disease (CAD). CAD was defined as stenosis of more than 50% of the vessel diameter on coronary angiograms. Blood samples were obtained both from the aorta and the coronary sinus (CS) just before coronary angiography. Relative to CAD (-) patients, those who were CAD (+) tended to have higher plasma concentrations of IP-10 in the aorta, as well as significantly higher transcoronary concentration gradients of circulating IP-10. There were no significant differences between the two groups in aortic plasma concentrations or transcoronary concentration gradients of MCP-1, RANTES, and hsCRP. Furthermore, both the aortic plasma concentrations and transcoronary concentration gradients of IP-10 correlated with the Gensini score (r = 0.58 and r = 0.63, respectively, P < 0.01), while the plasma MCP-1, RANTES, and serum hsCRP concentrations did not. This study suggests that IP-10 is a good surrogate marker of coronary atherosclerosis. (Keyword) Coronary artery disease / Coronary circulation / Chemokine (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.14-300 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25902883 ● Search Scopus @ Elsevier (PMID): 25902883 ● Search Scopus @ Elsevier (DOI): 10.1536/ihj.14-300 (DOI: 10.1536/ihj.14-300, PubMed: 25902883)
126.	Takeshi Soeki, Koji Yamaguchi, Toshiyuki Niki, E Uematsu, S Bando, T Matsuura, Takayuki Ise, Kenya Kusunose, Junko Hotsuchi, Takeshi Tobiume, Shusuke Yagi, Daiju Fukuda, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Plasma microRNA-100 is associated with coronary plaque vulnerability., Circulation Journal, Vol.79, No.2, 413-418, 2015. (Summary) BACKGROUND: Although numerous studies have reported altered plasma levels of various microRNAs (miRNAs) in patients with cardiovascular disease, there are no data on the relationship between plasma miRNAs and vulnerable coronary plaque. In this study, we investigated whether plasma miRNAs might be a sensitive marker of coronary plaque vulnerability.MethodsandResults:Integrated backscatter intravascular ultrasound (IB-IVUS) was performed in 32 consecutive patients with angina pectoris who underwent percutaneous coronary intervention. Three-dimensional analysis of IB-IVUS was performed to determine the percentage of lipid volume (%LV) and fibrous volume (%FV). Circulating miRNAs were measured in EDTA-plasma simultaneously obtained from the aorta and the coronary sinus (CS). Muscle-enriched (miR-133a, miR-208a, miR-499), vascular-enriched (miR-92a, miR-100, miR-126, miR-127, miR-145), and myeloid cell-enriched miRNAs (miR-155, miR-223) were measured. Plasma miR-100 was higher in the CS than in the aorta, but there were no significant differences in the levels of other miRNAs between the aorta and CS. Plasma miR-100 in the aorta was positively correlated with %LV (r=0.48, P<0.01) and negatively correlated with %FV (r=-0.41, P<0.05). Importantly, transcoronary concentration gradient of circulating miR-100 was more strongly correlated with %LV (r=0.53, P<0.01) and %FV (r=-0.56, P<0.01).CONCLUSIONS: miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease. (Circ J 2015; 79: 413-418). (Keyword) Coronary artery disease / Coronary circulation / Intravascular ultrasound / MicroRNA (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-14-0958 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25519160 ● CiNii @ National Institute of Informatics (CRID): 1390001205108464000 ● Summary page in Scopus @ Elsevier: 2-s2.0-84928251309 (DOI: 10.1253/circj.CJ-14-0958, PubMed: 25519160, CiNii: 1390001205108464000, Elsevier: Scopus)
127.	S Kimura, Yuka Ueda, Takayuki Ise, Shusuke Yagi, Takashi Iwase, K Nishikawa, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike, Natsuo Yasui and Masataka Sata : Impact of supervised cardiac rehabilitation on urinary albumin excretion in patients with cardiovascular disease., International Heart Journal, Vol.56, No.1, 105-109, 2015. (Summary) Urinary albumin excretion is a predictor of cardiovascular death. Cardiac rehabilitation (CR) with exercise training (ET) has been shown to improve exercise capacity and prognosis in patients with cardiovascular disease (CVD). However, it remains unclear whether CR reduces urinary albumin excretion in CVD patients. We performed a retrospective, observational study using data obtained from 98 male CVD patients without macroalbuminuria and estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m(2) who participated in CR with ET during hospitalization. Twenty-three patients continued supervised ET for 6 months (supervised group) and 75 patients quit supervised ET (non-supervised group). The supervised ET program consisted of 60 minutes of supervised sessions 1-3 times a week and 30-60 minutes of home exercise at least twice a week. Urinary albumin/creatinine ratio (ACR) was significantly decreased in the supervised group at 6 months after enrollment (43 ± 71 mg/g to 17 ± 20 mg/g creatinine, P < 0.05) but not in the non-supervised group. eGFR was unchanged in the supervised group but was significantly decreased in the non-supervised group (72 ± 18 mL/minute/1.73 m(2) to 67 ± 17 mL/minute/1.73 m(2), P < 0.001). The results of multiple regression analysis showed that only supervised ET was an independent contributor to ACR. CR with supervised ET decreased urinary albumin excretion without deterioration of renal function. These findings suggest that continuation of a supervised ET program is associated with reduction in the development of CVD and reduction in cardiovascular morbidity and mortality in CVD patients. (Keyword) Cardiac rehabilitation / Renal function / Cardiovascular disease (Tokushima University Institutional Repository) ● Metadata: 109367 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.14-161 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25742947 ● Search Scopus @ Elsevier (PMID): 25742947 ● Search Scopus @ Elsevier (DOI): 10.1536/ihj.14-161 (Tokushima University Institutional Repository: 109367, DOI: 10.1536/ihj.14-161, PubMed: 25742947)
128.	Shusuke Yagi, A Takashima, M Mitsugi, T Wada, Junko Hotsuchi, Ken-ichi Aihara, T Hara, Masayoshi Ishida, Daiju Fukuda, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension., Therapeutics and Clinical Risk Management, Vol.11, 83-88, 2015. (Summary) Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension. (Keyword) blood pressure / combination tablet / uric acid / low-density lipoprotein cholesterol / high-density lipoprotein cholesterol (Link to Publication Site) ● Publication site (DOI): 10.2147/TCRM.S72299 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25624765 ● Summary page in Scopus @ Elsevier: 2-s2.0-84921260560 (DOI: 10.2147/TCRM.S72299, PubMed: 25624765, Elsevier: Scopus)
129.	Shusuke Yagi, T Hara, R Ueno, Ken-ichi Aihara, Daiju Fukuda, A Takashima, Junko Hotsuchi, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease., Nutrition Journal, Vol.13, No.1, 112, 2014. (Summary) BACKGROUND: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.METHODS: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the other parameters were evaluated.RESULTS: Pearson correlation analysis showed that EPA (R =0.25, P <0.01), EPA/AA ratio (R =0.22, P =0.01), and left ventricular ejection fraction (R =0.15, P =0.04) were positively associated with MMSE score, and that age (R = -0.20, P <0.01) and brain natriuretic peptide levels (R = -0.28, P <0.01) were inversely associated with MMSE score. Multiple regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically excluded.CONCLUSIONS: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients. (Keyword) Aged / Arachidonic Acid / Cognition / Cognition Disorders / Coronary Disease / Eicosapentaenoic Acid / Fatty Acids, Omega-3 / Female / Humans / Japan / Male / Middle Aged / Retrospective Studies / Risk Factors / Stroke Volume (Link to Publication Site) ● Publication site (DOI): 10.1186/1475-2891-13-112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25471307 ● Summary page in Scopus @ Elsevier: 2-s2.0-84926465688 (DOI: 10.1186/1475-2891-13-112, PubMed: 25471307, Elsevier: Scopus)
130.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, S Nishimoto, C Kozuka, Daiju Fukuda, Takeshi Soeki, H Masuzaki, M Tsutsui and Masataka Sata : MicroRNA-378 regulates adiponectin expression in adipose tissue: A new plausible mechanism., PLoS ONE, Vol.9, No.11, e111537, 2014. (Summary) AIMS: Mechanisms regulating adiponectin expression have not been fully clarified. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are involved in biological processes, including obesity and insulin resistance. We evaluated whether the miRNA-378 pathway is involved in regulating adiponectin expression.METHODS AND RESULTS: First, we determined a putative target site for miRNA-378 in the 3 prime untranslated region (3'UTR) of the adiponectin gene by in silico analysis. The levels of adiponectin mRNA and protein were decreased in 3T3-L1 cells overexpressing the mimic of miRNA-378. Luminescence activity in HEK293T cells expressing a renilla-luciferase-adiponectin-3'UTR sequence was inhibited by overexpressing the mimic of miRNA-378, and the decrease was reversed by adding the inhibitor of miRNA-378. Moreover, we confirmed the inhibitory effects of the mimic were cancelled in a deleted mutant of the miR-378 3'-UTR binding site. Addition of tumor necrosis factor- (TNF) led a upregulation of miR-378 and downregulation of adiponectin at mRNA and protein levels in 3T3-L1 cells. Level of miR-378 was higher and mRNA level of adiponectin was lower in diabetic ob/ob mice than those of normal C57BL/6 mice and levels of miR378 and adiponectin were negatively well correlated (r=-0.624, p=0.004).CONCLUSIONS: We found that levels of miRNA-378 could modulate adiponectin expression via the 3'UTR sequence-binding site. Our findings warrant further investigations into the role of miRNAs in regulating the adiponectin expression. (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0111537 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25379946 ● Search Scopus @ Elsevier (PMID): 25379946 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0111537 (DOI: 10.1371/journal.pone.0111537, PubMed: 25379946)
131.	A Takashima, Takayuki Ise, Shusuke Yagi, Takashi Iwase, S Kimura, Yuka Ueda, K Nishikawa, A Ishii, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike and Masataka Sata : Cardiac rehabilitation reduces serum levels of oxidized low-density lipoprotein., Circulation Journal, Vol.78, No.11, 2682-2687, 2014. (Summary) BACKGROUND: Oxidized low-density lipoprotein (oxLDL) levels have been found to play an important role in the progression of atherosclerosis. However, methods for effectively reducing oxLDL levels have not been established. Comprehensive cardiac rehabilitation (CR) with exercise training prevents the progression of atherosclerosis, and might reduce oxLDL levels.MethodsandResults:We measured the serum levels of malondialdehyde-modified LDL (MDA-LDL), a marker of oxLDL, in 136 patients who were enrolled in a 6-month CR program. Peak oxygen consumption (VO2) and MDA-LDL levels were analyzed, before and 6 months after enrolment. In total, 67 patients completed the CR program (CR group) and 69 patients failed to complete the program (non-CR group). Peak VO2increased significantly in the CR group (P<0.01). The levels of MDA-LDL decreased significantly in the CR group (P<0.01) but not in the non-CR group. VO2(peak VO2after CR-peak VO2before CR) was negatively associated with MDA-LDL (MDA-LDL after CR-MDA-LDL before CR) (R(2)=0.11, P=0.01). Multiple regression analysis showed that continuing CR was an independent determining factor for lowering MDA-LDL levels.CONCLUSIONS: CR decreases oxLDL levels in patients with cardiovascular diseases. Moreover, CR may prevent cardiovascular events through an antioxidative effect. (Circ J 2014; 78: 2682-2687). (Keyword) Cardiac rehabilitation / Lipoproteins / Oxidative stress (Tokushima University Institutional Repository) ● Metadata: 109368 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-14-0532 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25241889 ● Search Scopus @ Elsevier (PMID): 25241889 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-14-0532 (Tokushima University Institutional Repository: 109368, DOI: 10.1253/circj.CJ-14-0532, PubMed: 25241889)
132.	Takeshi Soeki, S Bando, E Uematsu, T Matsuura, Toshiyuki Niki, Takayuki Ise, Kenya Kusunose, Junko Hotsuchi, Yuka Ueda, N Tomita, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Pentraxin 3 is a local inflammatory marker in atrial fibrillation., Heart and Vessels, Vol.29, No.5, 653-658, 2014. (Summary) Increasing evidence indicates that inflammation contributes to the pathogenesis of atrial fibrillation (AF). Pentraxin 3 (PTX3) is produced abundantly in local inflammatory lesions while C-reactive protein (CRP) is produced mainly in the liver. In this study, we investigated whether a local level of PTX3 might be a sensitive marker for the local inflammation of AF. Blood from the periphery and left atrial appendage (LAA) was sampled from 23 patients with AF undergoing pulmonary vein isolation, and from 10 control subjects with Wolff-Parkinson-White syndrome. We measured peripheral and LAA plasma concentrations of CRP, interleukin-6 (IL-6), tumor necrosis factor- (TNF-), and PTX3. Plasma PTX3 concentrations in both locations were higher in patients with AF than in control subjects. PTX3 concentrations were significantly higher in the LAA than the periphery in patients with AF (3.7 ± 1.4 vs 3.3 ± 1.2 ng/ml, P < 0.01), but not in control subjects (2.4 ± 0.5 vs 2.4 ± 0.5 ng/ml, not significant). Patients and controls showed no significant differences in CRP, IL-6, or TNF- concentrations between the periphery and LAA. Interestingly, there was a significant positive correlation between LAA plasma concentrations of PTX3 and left atrial volume (r = 0.55, P < 0.01). These data demonstrate that Local PTX3 production in the left atrium might reflect the local inflammation of AF. (Keyword) Pentraxin 3 / Atrial fibrillation / inflammation (Link to Publication Site) ● Publication site (DOI): 10.1007/s00380-013-0400-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23979265 ● Summary page in Scopus @ Elsevier: 2-s2.0-84929517476 (DOI: 10.1007/s00380-013-0400-8, PubMed: 23979265, Elsevier: Scopus)
133.	Shusuke Yagi, M Fujimura, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, M Tada, Yuka Ueda, Takayuki Ise, Koji Yamaguchi, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis., Journal of Cardiology Cases, Vol.10, No.2, 54-57, 2014. (Summary) Rates of morbidity and mortality from cardiovascular disease are high in patients with rheumatoid arthritis (RA); however, the mechanisms and biomarkers that reflect coronary plaque vulnerability have not yet been established. We present a case of acute coronary syndrome (ACS) presumably caused by exacerbation of chronic inflammation of RA, in which an abrupt increase in serum triglyceride was seen on the day of onset of ACS but not during effort angina. This case suggests that RA patients with an abrupt increase in triglyceride need intensive care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.<Learning objective: Triglyceride might be a sensitive biomarker of activated macrophages and plaque vulnerability in patients with RA. RA patients with an abrupt increase in triglyceride might need intensive care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.> (Keyword) Acute coronary syndrome / Triglyceride / Tumor necrosis factor- / Biomarker (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jccase.2014.04.009 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84905378195 (DOI: 10.1016/j.jccase.2014.04.009, Elsevier: Scopus)
134.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Itsuro Endo, Junko Hotsuchi, Takayuki Ise, Takashi Iwase, Masashi Akaike, Toshio Matsumoto and Masataka Sata : High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients., Endocrine Journal, Vol.61, No.7, 727-733, 2014. (Summary) Excess parathyroid hormone (PTH), known as primary hyperparathyroidism (pHPT), results in hypercalcemia and bone loss. Recent studies have shown that PTH is associated with the occurrence of hypertension in Western countries; however, controversy remains regarding high serum levels of PTH and calcium as risk factors for hypertension in Japanese patients. We retrospectively enrolled 114 consecutive Japanese patients who visited our hospital for examination and treatment of hypercalcemia and/or hypertension with serum calcium levels ≥ 9.8 mg/dL. To estimate the prevalence of hypertension, the patients were categorized according to calcium levels into hypercalcemic (10.2-13.4 mg/dL) and normocalcemic (9.8-10.1 mg/dL) groups, which were further categorized into high PTH (50-440 pg/mL) and low PTH (8-49 pg/mL) groups. The prevalence of hypertension was higher in patients with hypercalcemia than in patients with normocalcemia in both the high and low PTH groups. The prevalence of hypertension was higher in patients with high serum PTH levels than in patients with low serum PTH levels in both the hypercalcemic and normocalcemic groups. Logistic multiple regression analysis determined that serum calcium (P < 0.05) and PTH (P < 0.01) levels were positive contributors to hypertension. In conclusion, high serum levels of PTH and calcium are risk factors for hypertension in Japanese patients. (Keyword) parathyroid hormone / calcium / hypertension (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ14-0004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24849536 ● CiNii @ National Institute of Informatics (CRID): 1390001206300211712 ● Summary page in Scopus @ Elsevier: 2-s2.0-84905190698 (DOI: 10.1507/endocrj.EJ14-0004, PubMed: 24849536, CiNii: 1390001206300211712, Elsevier: Scopus)
135.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, Mika Bando, Junko Hotsuchi, S Hayashi, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Pre-load stress echocardiography for predicting the prognosis in mild heart failure., JACC. Cardiovascular Imaging, Vol.7, No.7, 641-649, 2014. (Keyword) Doppler echocardiography / heart failure / leg-positive pressure / stress echocardiography / survival (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2014.04.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24954460 ● Summary page in Scopus @ Elsevier: 2-s2.0-84904576445 (DOI: 10.1016/j.jcmg.2014.04.009, PubMed: 24954460, Elsevier: Scopus)
136.	Takayuki Ise, Takashi Iwase, S Masuda, Shusuke Yagi, Masashi Akaike, S Nishio, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute pulmonary thromboembolism from deep vein thrombosis induced by trauma to the popliteal vein with a tennis racket., Journal of Cardiology Cases, Vol.9, No.4, 162-164, 2014. (Summary) Acute pulmonary thromboembolism (PTE) is mainly caused by deep vein thrombosis (DVT) and sometimes leads to a fatal outcome. Few cases of sport-related lower extremity DVT, involving direct external trauma, have been reported. A 58-year-old man, without any risk factors for thromboembolism suffered acute PTE from DVT after playing tennis. A detailed history revealed that he had hit his popliteal vein with each swing of his tennis racket and the site of the trauma, at popliteal fossa, was exactly the same as the site of the DVT formation. Therefore, the cause of DVT was suspected to be the repeated trauma to the popliteal vein. The repeated external trauma to the popliteal vein may have caused vascular endothelial damage, leading to DVT. (Keyword) Acute pulmonary thromboembolism / Deep vein thrombosis / Trauma (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jccase.2014.01.001 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84897413698 (DOI: 10.1016/j.jccase.2014.01.001, Elsevier: Scopus)
137.	Shusuke Yagi, Kadota Muneyuki, Ken-ichi Aihara, Nishikawa Koji, Hara Tomoya, Takayuki Ise, Yuka Ueda, Takashi Iwase, Masashi Akaike, Michio Shimabukuro, Shinsuke Katoh and Masataka Sata : Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men, Diabetology & Metabolic Syndrome, Vol.6, No.1, 27, 2014. (Summary) A high-calorie diet and physical inactivity, an imbalance between caloric intake and energy consumption, are major causes of metabolic syndrome (MetS), which manifests as accumulation of visceral fat and insulin resistance. However, the lifestyle-related factors associated with visceral fat mass in healthy men are not fully understood. We evaluated visceral fat area (VFA), skeletal muscle mass, caloric intake, and energy expenditure in 67 healthy male participants (mean age, 36.9 ± 8.8 years; body mass index 23.4 ± 2.5 kg/m2). Multiple regression analysis showed that the total skeletal muscle mass (P < 0.001) were negatively and age (P < 0.001) were positively associated with VFA. Lower limb muscle mass (P < 0.001) was strongly associated with VFA. However, total caloric intake, total energy expenditure, and energy expenditure during exercise were not associated with VFA. Skeletal muscle mass especially lower limb muscle mass negatively contributes to visceral fat mass in healthy men. Therefore, maintaining lower limb muscular fitness through daily activity may be a useful strategy for controlling visceral obesity and metabolic syndrome. (Link to Publication Site) ● Publication site (DOI): 10.1186/1758-5996-6-27 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24571923 ● Summary page in Scopus @ Elsevier: 2-s2.0-84896075201 (DOI: 10.1186/1758-5996-6-27, PubMed: 24571923, Elsevier: Scopus)
138.	Takeshi Soeki, Toshiyuki Niki, E. Uematsu, S. Bando, T. Matsuura, Kenya Kusunose, Takayuki Ise, Yuka Ueda, N. Tomita, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Daiju Fukuda, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Michio Shimabukuro, I. Kishimoto, Kenji Kangawa and Masataka Sata : Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein., Heart and Vessels, Vol.28, No.6, 795-801, 2013. (Summary) Vagal nerve stimulation has been postulated to confer an antifibrillatory effect. We studied whether ghrelin administration would exert an antiarrhythmic effect via modulation of autonomic nerve activity in rats after acute myocardial ischemia (MI). Male Sprague-Dawley rats were exposed to 30 min of ischemia following ligation of the left coronary artery. Animals were then randomized to receive either ghrelin (n = 26) or saline (n = 26) during the period of coronary ligation. Power spectral analysis of heart-rate variability revealed that the administration of ghrelin increased the high-frequency (HF) power and decreased the low-frequency (LF)/HF ratio. Ventricular tachyarrhythmias were less frequent in rats after MI who received ghrelin in comparison with rats that received saline. Immunoblotting and immunohistochemistry revealed that rats given saline alone during MI exhibited a marked reduction in phosphorylated connexin-43 within the left ventricle, whereas those that received ghrelin displayed only minor reductions in comparison with sham-operated rats. These effects of ghrelin were diminished by the coadministration of atropine or the blockade of vagal afferents. These data demonstrate that the beneficial effect of ghrelin might be mediated by modulation of cardiac autonomic nerve activity. (Keyword) Animals / Anti-Arrhythmia Agents / Atropine / Connexin 43 / Disease Models, Animal / Ghrelin / Heart Rate / Heart Ventricles / Male / Muscarinic Antagonists / Myocardial Ischemia / Phosphorylation / Rats / Rats, Sprague-Dawley / Tachycardia, Ventricular / Time Factors / Vagotomy / Vagus Nerve (Link to Publication Site) ● Publication site (DOI): 10.1007/s00380-013-0333-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23494606 ● Search Scopus @ Elsevier (PMID): 23494606 ● Search Scopus @ Elsevier (DOI): 10.1007/s00380-013-0333-2 (DOI: 10.1007/s00380-013-0333-2, PubMed: 23494606)
139.	Shusuke Yagi, Masashi Akaike, Takayuki Ise, Yuka Ueda, Takashi Iwase and Masataka Sata : Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment., Hypertension Research, Vol.36, No.9, 753-758, 2013. (Summary) Because dementia is associated with both deterioration in the quality of life and poor prognosis, the prevention of cognitive impairment (CI) is a critical problem in public health promotion. Hypertension is a risk factor for the aggravation of CI, and the renin-angiotensin-aldosterone system (RAAS) is a key player in the increased incidence and development of hypertension. Therefore, the RAAS is considered to be a promoting factor for CI development. Conversely, recent studies have shown that lowering blood pressure with RAAS inhibitors decreases the incidence of CI, dementia and cardiovascular disease. Blood-brain barrier-penetrating RAAS inhibitors appear to have advantages in preventing cognitive decline because they can suppress the RAAS in the hippocampus, which has an important role in cognition. Thus, RAAS blockage is a notable strategy for preventing CI. (Keyword) Angiotensin-Converting Enzyme Inhibitors / Cognition / Cognition Disorders / Humans / Hypertension / Renin-Angiotensin System / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2013.51 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23698805 ● Summary page in Scopus @ Elsevier: 2-s2.0-84883885656 (DOI: 10.1038/hr.2013.51, PubMed: 23698805, Elsevier: Scopus)
140.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Yuka Sumitomo-Ueda, Ryoko Uemoto, Kazue Ishikawa, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Yasuhiro Mouri, Matomo Sakari, Takahiro Matsumoto, Ken-ichi Takeyama, Masashi Akaike, Mitsuru Matsumoto, Masataka Sata, Kenneth Walsh, Shigeaki Kato and Toshio Matsumoto : Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling., Circulation, Vol.128, No.1, 60-71, 2013. (Summary) These results document a physiological role of AR in sex-independent angiogenic potency and provide evidence of novel cross-talk between the androgen/AR signaling and VEGF/kinase insert domain protein receptor signaling pathways. (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCULATIONAHA.113.001533 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23723256 ● Search Scopus @ Elsevier (PMID): 23723256 ● Search Scopus @ Elsevier (DOI): 10.1161/CIRCULATIONAHA.113.001533 (DOI: 10.1161/CIRCULATIONAHA.113.001533, PubMed: 23723256)
141.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Daiju Fukuda, Masayoshi Ishida, Takayuki Ise, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems., Acta Cardiologica Sinica, Vol.29, No.3, 201-207, 2013. (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84878307366 (Elsevier: Scopus)
142.	Michio Shimabukuro, Chisayo Kozuka, Shin-ichiro Taira, Kouichi Yabiku, Munkhbaatar Dagvasumberel, Masayoshi Ishida, Sachiko Matsumoto, Shusuke Yagi, Daiju Fukuda, Ken Yamakawa, Moritake Higa, Takeshi Soeki, Hisashi Yoshida, Hiroaki Masuzaki and Masataka Sata : Ectopic fat deposition and global cardiometabolic risk: New paradigm in cardiovascular medicine., The Journal of Medical Investigation : JMI, Vol.60, No.1, 2, 1-14, 2013. (Summary) The obesity epidemic is a global public health concern that increases the likelihood of morbidity and mortality of metabolic and cardiovascular disease (CVD) and threatens to reduce life expectancy around the world. The concept of the metabolic syndrome (MetS) takes into account that visceral fat plays an essential role in the development of metabolic and cardiovascular diseases. However, MetS cannot be used to assess global CVD risk but is at best one more modifiable CVD risk factor. Thus, global cardiometabolic risk (the global risk of cardiovascular disease resulting from traditional risk factors combined with the additional contribution of the metabolic syndrome and/or insulin resistance) should be considered individually. There is solid evidence supporting the notion that excess abdominal fat is predictive of insulin resistance and the presence of related metabolic abnormalities currently referred to as MetS. Despite the fact that abdominal obesity is a highly prevalent feature of MetS, the mechanisms by which abdominal obesity is causally related to MetS are not fully elucidated. Besides visceral fat accumulation, ectopic lipid deposition, especially in liver and skeletal muscle, has been implicated in the pathophysiology of diabetes, insulin resistance and obesity-related disorders. Also, ectopic fat deposition could be deteriorated in the heart components such as (1) circulatory and locally recruited fat, (2) intra- and extra-myocellular fat, (3) perivascular fat, and (4) pericardial fat. In this review, the contribution of ectopic lipid deposition to global cardiometabolic risk is reviewed and also discussed are potential underlying mechanisms including adipocytokine, insulin resistance and lipotoxicity. J. Med. Invest. 60: 1-14, February, 2013. (Keyword) obesity / insulin resistance / cardiovascular disease / diabetes mellitus (Tokushima University Institutional Repository) ● Metadata: 106036 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614905 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876035311 (Tokushima University Institutional Repository: 106036, DOI: 10.2152/jmi.60.1, PubMed: 23614905, Elsevier: Scopus)
143.	高島啓, Takayuki Ise, Yuka Ueda, Takashi Iwase, Shusuke Yagi, 前田香代子, 西川幸治, 小笠原梢, Mika Bando, 坂東左知子, 冨田紀子, Toshiyuki Niki, 發知淳子, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike, Natsuo Yasui and Masataka Sata : Cardiac rehabilitation reduces level of oxidized LDL, 心臓リハビリテーション, Vol.18, No.1, 130-133, 2013. (Keyword) 酸化LDL / 心臓リハビリテーション / 心肺運動負荷試験 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381154583040 (CiNii: 1520010381154583040)
144.	Hirata Yoichiro, Hirotsugu Kurobe, Uematsu Etsuko, Shusuke Yagi, Takeshi Soeki, Hirotsugu Yamada, Daiju Fukuda, Michio Shimabukuro, Nakayama Mizuho, Matsumoto Kunio, Sakai Yoshiki, Tetsuya Kitagawa and Masataka Sata : Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model., European Journal of Pharmacology, Vol.699, No.1-3, 81-87, 2013. (Summary) Injury to the heart can result in cardiomyocyte hypertrophy, fibrosis, and cell death. Myocarditis sometimes progresses to dilated cardiomyopathy. We previously reported that ONO-1301, a synthetic prostacyclin agonist with thromboxane-synthase inhibitory activity, promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig. Here, we investigated the therapeutic efficacy of ONO-1301 in a rat model of myosin-induced experimental autoimmune myocarditis, in which the heart transits from an acute inflammatory phase to a chronic dilated cardiomyopathy phase. Four weeks after myosin injection to Lewis rats, ONO-1301 (6 mg/kg/day) was orally administered for 4 weeks (ONO-1301 group). Hemodynamic parameters and plasma brain natriuretic peptide (BNP) level were significantly improved by ONO-1301. Histological analysis revealed that capillary density in the myocardium was significantly increased by ONO-1301. ONO-1301 increased circulating endothelial progenitor cells (EPC) as determined by FACS analysis. These beneficial effects of ONO-1301 were partially abrogated by a neutralizing anti-HGF antibody (8 mg/kg/dose). These findings indicate beneficial effects of ONO-1301 in a rat experimental autoimmune myocarditis model. (Keyword) heart failure / HGF / dilated cardiomyopathy / experimental autoimmune myocarditis (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2012.11.045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23219794 ● Search Scopus @ Elsevier (PMID): 23219794 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2012.11.045 (DOI: 10.1016/j.ejphar.2012.11.045, PubMed: 23219794)
145.	Munkhbaatar Dagvasumberel, Michio Shimabukuro, Nishiuchi Takeshi, Junji Ueno, Shoichiro Takao, Daiju Fukuda, Hirata Yoichiro, Hirotsugu Kurobe, Takeshi Soeki, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Shusuke Yagi, Tomita Noriko, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masafumi Harada, Tetsuya Kitagawa and Masataka Sata : Gender disparities in the association between epicardial adipose tissue volume and coronary atherosclerosis: A 3-dimensional cardiac computed tomography imaging study in Japanese subjects., Cardiovascular Diabetology, Vol.11, No.1, 106, 2012. (Summary) Growing evidence suggests that epicardial adipose tissue (EAT) may contribute to the development of coronary artery disease (CAD). In this study, we explored gender disparities in EAT volume (EATV) and its impact on coronary atherosclerosis. The study population consisted of 90 consecutive subjects (age: 63 ± 12 years; men: 47, women: 43) who underwent 256-slice multi-detector computed tomography (MDCT) coronary angiography. EATV was measured as the sum of cross-sectional epicardial fat area on CT images, from the lower surface of the left pulmonary artery origin to the apex. Subjects were segregated into the CAD group (coronary luminal narrowing > 50%) and non-CAD group. EATV/body surface area (BSA) was higher among men in the CAD group than in the non-CAD group (62 ± 13 vs. 33 ± 10 cm3/m2, p < 0.0001), but did not differ significantly among women in the 2 groups (49 ± 18 vs. 42 ± 9 cm3/m2, not significant). Multivariate logistic analysis showed that EATV/BSA was the single predictor for >50% coronary luminal narrowing in men (p < 0.0001). Predictors excluded were age, body mass index, hypertension, diabetes mellitus, and hyperlipidemia. Increased EATV is strongly associated with coronary atherosclerosis in men. (Keyword) Adipose Tissue / Age Factors / Aged / Asian Continental Ancestry Group / Body Surface Area / Chi-Square Distribution / Coronary Angiography / Coronary Artery Disease / Coronary Stenosis / Female / Health Status Disparities / Humans / Japan / Logistic Models / Male / Middle Aged / Multidetector Computed Tomography / Multivariate Analysis / Pericardium / Predictive Value of Tests / Risk Assessment / Risk Factors / Severity of Illness Index / Sex Factors (Link to Publication Site) ● Publication site (DOI): 10.1186/1475-2840-11-106 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22963346 ● Search Scopus @ Elsevier (PMID): 22963346 ● Search Scopus @ Elsevier (DOI): 10.1186/1475-2840-11-106 (DOI: 10.1186/1475-2840-11-106, PubMed: 22963346)
146.	Takeshi Soeki, Mitsuhiro Kitani, Kenya Kusunose, Shusuke Yagi, Yoshio Taketani, Kunihiko Koshiba, Tetsuzo Wakatsuki, Shunsuke Orino, Kazuhiro Kawano and Masataka Sata : Renoprotective and antioxidant effects of cilnidipine in hypertensive patients., Hypertension Research, Vol.35, No.11, 1058-1062, 2012. (Summary) Cilnidipine, an L/N-type calcium channel blocker (CCB), has been reported to have more beneficial effects on proteinuria progression in hypertensive patients than amlodipine, an L-type CCB. The N-type calcium channel blockade that inhibits renal sympathetic nerve activity might reduce glomerular hypertension by facilitating vasodilation of the efferent arterioles. However, the precise mechanism of the renoprotective effect of cilnidipine remains unknown. Because cilnidipine exerted significantly higher antioxidant activity than amlodipine in cultured human mesangial cells, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing oxidative stress. A total of 35 hypertensive patients receiving a renin-angiotensin system inhibitor were randomly assigned to a cilnidipine (n=18; 10 mg per day cilnidipine titrated to 20 mg per day) or amlodipine (n=17; 5 mg per day amlodipine titrated to 10 mg per day) group; the target blood pressure (BP) was set at 130/85 mmHg. After 6 months of treatment, systolic and diastolic BPs were significantly reduced in both of the groups, without any significant difference between the groups. The urinary albumin, 8-hydroxy-2'-deoxyguanosine (OHdG) and liver-type fatty-acid-binding protein (L-FABP) to creatinine ratios significantly decreased in the cilnidipine group (P<0.05) compared with those in the amlodipine group. The reductions in urinary albumin, 8-OHdG and L-FABP were not correlated with the change in systolic BP. In conclusion, cilnidipine, but not amlodipine, ameliorated urinary albumin excretion and decreased urinary 8-OHdG and L-FABP in the hypertensive patients. Cilnidipine probably exerts a greater renoprotective effect through its antioxidative properties.Hypertension Research advance online publication, 5 July 2012; doi:10.1038/hr.2012.96. (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2012.96 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22763473 ● Search Scopus @ Elsevier (PMID): 22763473 ● Search Scopus @ Elsevier (DOI): 10.1038/hr.2012.96 (DOI: 10.1038/hr.2012.96, PubMed: 22763473)
147.	Koji Yamaguchi, Tetsuzo Wakatsuki, Toshiyuki Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina., International Journal of Cardiology, Vol.153, No.3, 272-276, 2011. (Summary) Late stent thrombosis (LST) after sirolimus-eluting stent (SES) implantation has been demonstrated previously. Although incomplete neointimal coverage after SES implantation has been reported, local long-term hypercoagulability remains unknown. We evaluated the local persistent coagulative response in eighty-three consecutive patients with stable angina, treated with either SES (n=51) or BMS (n=32) implantation for isolated de novo left anterior descending (LAD) stenosis. We measured prothrombin fragment F1+2 (frF1+2) and D-dimer levels sampled in the coronary sinus (CS) and sinus of Valsalva (V). The transcardiac gradient (Δ) was defined as the CS level minus V level. The ΔfrF1 + 2 and ΔD-dimer were significantly greater in the SES group than in the BMS group (0.50 ± 0.35 vs -0.14 ± 0.15 nmol/l, p=0.009 and 0.24 ± 0.21 vs -0.05 ± 0.16 μg/ml, p=0.041, respectively). We selected the hypocoagulative [ΔfrF1 + 2<0.15 (mean value-SD) nmol/l, n=21] and hypercoagulative [ΔfrF1 + 2>0.85 (mean value+SD) nmol/l, n=14] groups out of the SES patients. Multivariate analysis was performed to identify independent predictors of local hypercoagulability. Total SES length was the only independent predictor of local hypercoagulability. There was a significant positive correlation between the ΔfrF1 + 2 and total stent length in the SES group (r=0.57, p<0.05). An increased local coagulative response was observed in the convalescent phase after SES implantation as compared to BMS. Careful long-term follow-up of patients after longer SES implantation is recommended in order to avoid LST. (Keyword) Aged / Angina, Stable / Cohort Studies / Coronary Thrombosis / Drug-Eluting Stents / Female / Humans / Male / Middle Aged / Sirolimus / Thrombophilia / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2010.08.014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20826025 ● Search Scopus @ Elsevier (PMID): 20826025 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2010.08.014 (DOI: 10.1016/j.ijcard.2010.08.014, PubMed: 20826025)
148.	Takeshi Soeki, Toshiyuki Niki, Kenya Kusunose, Sachiko Bando, Yoichiro Hirata, Noriko Tomita, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability., Journal of Cardiology, Vol.58, No.2, 151-157, 2011. (Summary) Inflammation is a critical contributing factor to the development and progression of atherosclerosis. Pentraxin 3 (PTX3) is produced abundantly in atherosclerotic lesions while C-reactive protein (CRP) is mainly produced in the liver. In this study, we investigated whether plasma levels of PTX3 might be a sensitive marker both for the severity of coronary artery disease and vulnerable plaques. Next, we determined whether assays for inflammatory molecules can be used to monitor the therapeutic effects of telmisartan on stabilization of vulnerable atherosclerotic plaques. We measured PTX3 concentrations in the peripheral and coronary sinus plasma of 40 patients with angina pectoris (AP) and 20 control subjects. Next, in 28 patients with AP, we determined the correlation between levels of inflammatory molecules and the computed tomography (CT) density of plaques as a quantitative index of plaque vulnerability. There was no significant difference in peripheral plasma PTX3 concentrations between patients with AP and control subjects, while coronary sinus plasma PTX3 concentrations were significantly higher in AP patients than control subjects. The concentrations of PTX3 in coronary sinus and peripheral plasma correlated with Gensini scores as an index of severity of coronary atherosclerosis. Interestingly, there was a significantly negative correlation between plasma PTX3 concentrations and CT density (r=-0.67, p<0.01). On the other hand, CT density did not correlate with the peripheral plasma concentrations of monocyte chemoattractant protein-1 (MCP-1) or high-sensitivity CRP (hsCRP). Furthermore, telmisartan treatment for 6 months decreased plasma concentrations of PTX3 but not those of MCP-1 or hsCRP in 12 patients with essential hypertension. Multivariate regression analysis revealed that changes in PTX3 levels were independent of blood pressure changes. PTX3 is likely more specific than hsCRP as an indicator of coronary plaque vulnerability that could lead to plaque rupture. (Keyword) Aged / Angina Pectoris / Angiotensin II Type 1 Receptor Blockers / Benzimidazoles / Benzoates / Biological Markers / C-Reactive Protein / Coronary Artery Disease / Coronary Sinus / Disease Progression / Drug Monitoring / Female / Humans / Inflammation Mediators / Male / Middle Aged / Plaque, Atherosclerotic / Serum Amyloid P-Component / Severity of Illness Index / Tomography, Spiral Computed (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2011.04.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21676590 ● Search Scopus @ Elsevier (PMID): 21676590 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jjcc.2011.04.005 (DOI: 10.1016/j.jjcc.2011.04.005, PubMed: 21676590)
149.	Shusuke Yagi and Masataka Sata : 鉱質コルチコイドの作用と機序, ICUとCCU, Vol.35, No.8, 605-611, 2011. (Keyword) ICU / CCU / steroid / 使用 / 鉱質コルチコイド / 作用 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521699230403961728 (CiNii: 1521699230403961728)
150.	Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Comparison of chronic-stage histopathological findings among 3 coronary stents implanted in the same patient., International Journal of Cardiology, Vol.150, No.1, e25-e27, 2011. (Summary) A 73-year-old woman suffering from anterior thoracic pain on exertion presented to our hospital. We performed coronary angiography and noted three stenotic legions in each coronary artery. For each angiographic finding, we implanted a bare metal stent (BMS), sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) into the right coronary artery, left anterior descending and left circumflex coronary arteries, respectively. Nine months later, she died of lung disease, and we could compare the histopathological findings among the three coronary stents. In the drug-eluting stents, very thin intima, infiltration of inflammatory cells, and fibrin deposition were observed, while thick intima and no inflammatory findings were observed in the BMS. Fibrin deposition was more marked in the PES than in the SES. This report shows marked differences in the subsequent pathological course among three stents in the same patient. (Keyword) Aged / Coronary Stenosis / Drug-Eluting Stents / Female / Humans / Paclitaxel / Sirolimus / Stents (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2009.08.032 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19735952 ● Search Scopus @ Elsevier (PMID): 19735952 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2009.08.032 (DOI: 10.1016/j.ijcard.2009.08.032, PubMed: 19735952)
151.	Kenya Kusunose, Hirotsugu Yamada, Noriko Tomita, Susumu Nishio, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Serial imaging changes during treatment of Takayasu arteritis with pulmonary artery stenosis., International Journal of Cardiology, Vol.148, No.3, 47-50, 2011. (Summary) Most cases of chronic stenosis or occlusive lesions of the pulmonary arteries are attributed to thromboembolism, and pulmonary arteritis is extremely rare as the primary cause of these entities. We report a case of pulmonary stenosis and occlusion caused by Takayasu arteritis. The patient was a 54-year-old woman who presented with dyspnea. Total occlusion of the left pulmonary artery and significant stenosis of the right pulmonary artery caused by Takayasu arteritis were confirmed by various imaging modalities including pulmonary angiography, (18)fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging and real-time three-dimensional transesophageal echocardiography. After 6 weeks of steroid therapy, follow-up imaging studies showed that the stenotic lesion had resolved. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2009.02.036 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19299026 ● Search Scopus @ Elsevier (PMID): 19299026 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2009.02.036 (DOI: 10.1016/j.ijcard.2009.02.036, PubMed: 19299026)
152.	Shusuke Yagi and Masataka Sata : アルドステロンと認知機能, 血圧, Vol.18, No.5, 8(440)-9(441), 2011.
153.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute hemodynamic effects of adaptive servo ventilation in patients with pulmonary hypertension., International Journal of Cardiology, Vol.148, No.1, 125-127, 2011. (Keyword) Aged / Aged, 80 and over / Female / Hemodynamics / Humans / Hypertension, Pulmonary / Intermittent Positive-Pressure Ventilation / Male / Middle Aged / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2011.01.074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21334081 ● Search Scopus @ Elsevier (PMID): 21334081 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2011.01.074 (DOI: 10.1016/j.ijcard.2011.01.074, PubMed: 21334081)
154.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Kazue Ishikawa, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia., The American Journal of Cardiology, Vol.107, No.11, 1644-1649, 2011. (Summary) The aim of the present study was to evaluate the factors that modulate the protective action of statins on cardiorenal function, regardless of the lipid-lowering effect. To treat abnormal serum lipid profiles, low-dose pitavastatin (1.0 mg/day) was administered to 65 hyperlipidemic patients. The exclusion criteria included left ventricular ejection fraction <40% and apparent renal disease. Age- and gender-matched patients with hyperlipidemia (n = 40) served as the controls. After 12 to 16 weeks of pitavastatin treatment, pitavastatin had decreased low-density lipoprotein cholesterol (from 143.5 ± 31.4 to 98.2 ± 19.4 mg/dl, p <0.01), triglycerides (from 157.7 ± 57.2 to 140.5 ± 60.7 mg/dl, p <0.01), E/e' (from 10.8 ± 6.2 to 9.0 ± 4.5, p <0.05), a parameter of left ventricular diastolic function, and albuminuria (from 47.6 ± 55.9 to 28.5 ± 40.0 mg/g creatinine, p <0.01). Furthermore, pitavastatin decreased serum transforming growth factor-1 (from 709 ± 242 to 550 ± 299 pg/ml, p <0.01), urinary 8-hydroxy-2'-deoxyguanosine (from 6.6 ± 4.1 to 5.0 ± 3.1 g/g creatinine, p <0.01), an oxidative stress marker, and increased urinary nitrate and nitrite (from 22.5 ± 14.6 to 29.4 ± 27.6 nmol/g creatinine, p <0.05). No such changes were observed in the controls. Multiple regression analysis in the pitavastatin group revealed the effect of pitavastatin on cardiorenal function was associated with suppression of oxidative stress, but not on low-density lipoprotein cholesterol reduction. In conclusion, pitavastatin decreases E/e' and albuminuria, which is associated with suppression of oxidative stress. (Keyword) Aged / Albuminuria / Case-Control Studies / Cholesterol, LDL / Diastole / Female / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hyperlipidemias / Male / Middle Aged / Quinolines / Treatment Outcome / Triglycerides / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjcard.2011.01.054 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21458773 ● Search Scopus @ Elsevier (PMID): 21458773 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjcard.2011.01.054 (DOI: 10.1016/j.amjcard.2011.01.054, PubMed: 21458773)
155.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Yuka Sumitomo-Ueda, Sumiko Yoshida, Toshio Matsumoto and Masataka Sata : Bosentan improves systemic sclerosis-related peripheral circulation insufficiency., International Journal of Cardiology, Vol.147, No.3, 472-475, 2011. (Keyword) Adult / Aged / Blood Circulation / Female / Humans / Middle Aged / Pain Measurement / Raynaud Disease / Scleroderma, Systemic / Sulfonamides (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2011.01.025 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21296436 ● Search Scopus @ Elsevier (PMID): 21296436 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2011.01.025 (DOI: 10.1016/j.ijcard.2011.01.025, PubMed: 21296436)
156.	Shunji Hashizume, Masashi Akaike, Hiroyuki Azuma, Kazue Ishikawa, Sumiko Yoshida, Yuka Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Ken-ichi Aihara, Masahiro Abe, Masataka Sata and Toshio Matsumoto : Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets., Journal of Atherosclerosis and Thrombosis, Vol.18, No.2, 138-147, 2011. (Summary) Platelet-derived growth factor (PDGF)-BB plays a crucial role in atherosclerosis and vascular remodeling by promoting the migration and proliferation of vascular smooth muscle cells. The objective of this study was to clarify the pleiotropic effect of peroxisome proliferator-activated receptor α (PPARα) activators on PDGF-BB expression in megakaryocytes and platelets. The expression of PPARα in a human erythroleukemia (HEL) cells was clearly detected by reverse transcriptase-PCR and immunofluorescence microscopy. The expression level of PPARα in HEL cells was unchanged regardless of differentiation into megakaryocytic cells by treatment with phorbol 12-myristate 13 acetate (TPA). The TPA-induced expression of PDGF-B mRNA and PDGF-BB protein levels in culture media was significantly decreased by treatment with PPARα activators, Wy14643 and fenofibric acid, in a dose-dependent manner. PDGF-BB expression induced by inflammatory cytokines, including interleukin-1β or interleukin-6, was also significantly suppressed by treatment with PPARα activators. Immunohistochemistry of human bone marrow showed the expression of PPARα in both the nucleus and cytoplasm of megakaryocytes. In addition, PDGF-BB levels in platelets were significantly decreased from 1,800±870 to 1,470±840 pg/10(5) platelets (mean±SD, p<0.05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia. Activation of PPARα in megakaryocytes reduces PDGF-BB expression in platelets. PPARα activators may exert vasculo-protective action through suppression of PDGF-BB production in a megakaryocyte/platelet pathway. (Keyword) Adult / Blood Platelets / cell differentiation / Cell Line, Tumor / Dyslipidemias / Female / Fenofibrate / gene expression / Humans / immunohistochemistry / Lipids / Male / Megakaryocytes / Middle Aged / PPAR alpha / Platelet-Derived Growth Factor / Pyrimidines / RNA, Messenger / Tetradecanoylphorbol Acetate (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.5868 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21060209 ● Search Scopus @ Elsevier (PMID): 21060209 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.5868 (DOI: 10.5551/jat.5868, PubMed: 21060209)
157.	Takayuki Ise, Ken-ichi Aihara, Yuka Ueda, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors., Hypertension Research, Vol.34, No.2, 225-231, 2010. (Summary) Thrombin has a crucial role in cardiac remodeling through protease-activated receptor-1 activation in cardiac fibroblasts and cardiomyocytes. As heparin cofactor II (HCII) inhibits the action of tissue thrombin in the cardiovascular system, it is possible that HCII counteracts the development of cardiac remodeling. We investigated the relationships between plasma HCII activity and surrogate markers of cardiac geometry, including left atrial volume index (LAVI), relative wall thickness (RWT) and left ventricular mass index, and deceleration time (DcT) and the ratio of peak E velocity to early diastolic mitral annulus velocity (E/e' ratio) as surrogate markers of left ventricular diastolic dysfunction measured using echocardiography in 304 Japanese elderly individuals without systolic heart failure (169 men and 135 women; mean age: 65.4 ± 11.8 years). Mean plasma HCII activity in all participants was 95.8 ± 17.0% and there was no difference between the mean plasma HCII activities in males and females. Multiple regression analysis revealed that there were significant inverse relationships between plasma HCII activity and LAVI (coefficient: -0.2302, P<0.001), between HCII activity and RWT (coefficient: -0.0007, P<0.05), between HCII activity and DcT (coefficient: -0.5189, P<0.05) and between HCII activity and E/e' ratio (coefficient: -0.0558, P<0.01). Plasma HCII activity was independently and inversely associated with the development of cardiac remodeling, including cardiac concentric change, left atrial enlargement and left ventricular diastolic dysfunction. These findings suggest that cardiac tissue thrombin inactivation by HCII is a novel therapeutic target for cardiac remodeling and atherosclerosis. (Keyword) Aged / Cross-Sectional Studies / Female / Heparin Cofactor II / Humans / Male / Middle Aged / Risk Factors / Ventricular Dysfunction / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2010.211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21107326 ● Search Scopus @ Elsevier (PMID): 21107326 ● Search Scopus @ Elsevier (DOI): 10.1038/hr.2010.211 (DOI: 10.1038/hr.2010.211, PubMed: 21107326)
158.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Sumiko Yoshida, Yuka Sumitomo-Ueda, Ken-ichi Aihara, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis., Internal Medicine, Vol.49, No.21, 2309-2312, 2010. (Summary) Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis. Bosentan is used in patients with symptomatic PAH; however, it has not been established whether or not bosentan ameliorates the progression of PAH in patients with no PAH-related symptoms. We present a case of systemic sclerosis with no PAH-related symptoms in which bosentan ameliorated exercise-induced PAH evaluated by 6-minute walk stress echocardiography, brachial flow-mediated dilation, and skin temperature of hands and feet. The results suggest that administration of bosentan in patients with early-stage PAH ameliorates pulmonary arterial vasodilatation through improvement of endothelial function. (Keyword) Exercise / Exercise Test / Female / Humans / Hypertension, Pulmonary / Middle Aged / Scleroderma, Systemic / Sulfonamides (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.49.3812 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21048365 ● CiNii @ National Institute of Informatics (CRID): 1390282679847104768 ● Search Scopus @ Elsevier (PMID): 21048365 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.49.3812 (DOI: 10.2169/internalmedicine.49.3812, PubMed: 21048365, CiNii: 1390282679847104768)
159.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Sumiko Yoshida, Yuka Ueda, Yasumasa Ikeda, Kazue Ishikawa, Toshio Matsumoto and Masataka Sata : High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension., Hypertension Research, Vol.34, No.1, 74-78, 2010. (Summary) Cognitive impairment leading to dementia is associated with high prevalence of hypertension, decreased quality of life and poor prognosis. Aldosterone is known as a risk factor for cardiovascular and cerebrovascular diseases. In addition, mineral corticoid receptors are abundantly expressed in the hippocampus, which plays a pivotal role in cognitive function; however, it has not been determined whether plasma aldosterone level is associated with cognitive impairment in patients with hypertension. We enrolled 68 patients with essential hypertension and assessed their cardiovascular risk factors, including blood pressure, hyperlipidemia, diabetes mellitus, obesity, smoking, history of cerebral infarction, renal function, parameters of inflammation, oxidative stress and nitric oxide bioavailability, a parameter of cerebral blood flow and carotid plaque by ultrasound examination, plasma renin activity and plasma aldosterone concentration (PAC). The mini-mental state examination (MMSE) was used to evaluate cognitive function. The relevance of cardiovascular risk factors and MMSE score was statistically evaluated. Multiple regression analysis showed that age (P<0.01), PAC (P<0.01) and history of cerebral infarction (P<0.05) were inversely and independently associated with MMSE score. Mineral corticoid receptor antagonists, including spironolactone and eplerenone, increased MMSE score in seven patients with hypertension, but not in the controls. In conclusion, increased PAC is associated with impaired cognitive function and mineral corticoid receptor blockade may protect against not only cardiovascular mortality, but also cognitive impairment in patients with hypertension.Hypertension Research advance online publication, 23 September 2010; doi:10.1038/hr.2010.179. (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2010.179 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20861841 ● Search Scopus @ Elsevier (PMID): 20861841 ● Search Scopus @ Elsevier (DOI): 10.1038/hr.2010.179 (DOI: 10.1038/hr.2010.179, PubMed: 20861841)
160.	Yuka Sumitomo-Ueda, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Yasumasa Ikeda, Ryoko Uemoto, Shusuke Yagi, Takashi Iwase, Kazue Ishikawa, Yoichiro Hirata, Masashi Akaike, Masataka Sata, Shigeaki Kato and Toshio Matsumoto : Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice., Hypertension, Vol.56, No.3, 430-436, 2010. (Summary) Heparin cofactor II (HCII), a serine protease inhibitor, inhibits tissue thrombin action after binding with dermatan sulfate proteoglycans in the extracellular matrix of the vascular system. We previously reported that heterozygous HCII-deficient (HCII(+/-)) humans and mice demonstrate acceleration of vascular remodeling, including atherosclerosis. However, the action of HCII on cardiac remodeling never has been determined. HCII(+/+) and HCII(+/-) mice at age 25 weeks were infused with angiotensin II (Ang II; 2.0 mg/kg/d) for 2 weeks by an osmotic mini-pump. Echocardiography revealed acceleration of cardiac concentric remodeling in HCII(+/-) mice and larger left atrial volume in HCII(+/-) mice than in HCII(+/+) mice. Histopathologic studies showed more prominent interstitial fibrosis in both the left atrium and left ventricle in HCII(+/-) mice than in HCII(+/+) mice. Daily urinary excretion of 8-hydroxy-2'-deoxyguanosine, a parameter of oxidative stress, and dihydroethidium-positive spots, indicating superoxide production in the myocardium, were markedly increased in Ang II-treated HCII(+/-) mice compared to those in HCII(+/+) mice. Cardiac gene expression levels of atrial natriuretic peptides and brain natriuretic peptides, members of the natriuretic peptide family, Nox 4, Rac-1, and p67(phox) as components of NAD(P)H oxidase, and transforming growth factor-beta1 and procollagen III were more augmented in HCII(+/-) mice than in HCII(+/+) mice. However, administration of human HCII protein attenuated all of those abnormalities in Ang II-treated HCII(+/-) mice. Moreover, human HCII protein supplementation almost abolished cardiac fibrosis in Ang II-treated HCII(+/+) mice. The results indicate that HCII has a protective role against Ang II-induced cardiac remodeling through suppression of the NAD(P)H oxidase-transforming growth factor-beta1 pathway. (Keyword) Analysis of Variance / Angiotensin II / Animals / Atrial Natriuretic Factor / Cardiomegaly / Echocardiography / Fibrosis / Heart Atria / Heparin Cofactor II / Mice / Mice, Transgenic / Myocardium / Natriuretic Peptide, Brain / Oxidative Stress / Transforming Growth Factor beta1 / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1161/HYPERTENSIONAHA.110.152207 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20660821 ● Search Scopus @ Elsevier (PMID): 20660821 ● Search Scopus @ Elsevier (DOI): 10.1161/HYPERTENSIONAHA.110.152207 (DOI: 10.1161/HYPERTENSIONAHA.110.152207, PubMed: 20660821)
161.	Sumiko Yoshida, Ken-ichi Aihara, Hiroyuki Azuma, Ryoko Uemoto, Yuka Sumitomo-Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Susumu Nishio, Hiromi Kawano, Junko Miki, Hirotsugu Yamada, Yoichiro Hirata, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function., Atherosclerosis, Vol.212, No.1, 310-315, 2010. (Summary) BACKGROUND: Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. However, its biological significance in atherosclerosis remains controversial. Therefore, the aim of this study was to determine whether DHEAS is associated with development of carotid atherosclerosis in subjects with cardiovascular risk factors. SUBJECTS AND METHODS: A total of 419 Japanese individuals (208 males and 211 females) were recruited from Tokushima University Hospital, Japan. In all subjects, maximum intima-media thickness (max-IMT) in all carotid arteries, and mean-IMT and mean blood flow volume (BFV) in the common carotid arteries (CCA) were measured by ultrasonography; endothelial function was assessed by flow-mediated vasodilation of the brachial artery (%FMD). Serum DHEAS and classical cardiovascular risk factors were also evaluated. Statistical significance was determined by multiple regression analysis to elucidate independent determinants of max-IMT, mean-IMT, mean CCA-BFV, and %FMD. RESULTS: Serum DHEAS levels were higher in males than in females. Multiple regression analysis revealed that DHEAS was an independent negative factor for both max-IMT and mean-IMT in males but not in females. In contrast, DHEAS was the sole positive factor for mean CCA-BFV in females but not in males. In addition, there was no significant relationship between %FMD and DHEAS regardless of sex and other confounding factors. CONCLUSION: Although DHEAS is not involved in endothelial function, DHEAS is inversely associated with sex-dependent diverse carotid atherosclerosis such as increased max-IMT and mean-IMT in males and decreased CCA-BFV in females. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2010.05.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20627295 ● Search Scopus @ Elsevier (PMID): 20627295 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2010.05.011 (DOI: 10.1016/j.atherosclerosis.2010.05.011, PubMed: 20627295)
162.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, Takashi Sato, Kazue Ishikawa, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Yuka Ueda, Sumiko Yoshida, Hiroyuki Azuma, Kenneth Walsh, Toshiaki Tamaki, Shigeaki Kato and Toshio Matsumoto : Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice., Molecular Endocrinology, Vol.24, No.7, 1338-1348, 2010. (Summary) Doxorubicin (Dox) has been used as a potent anticancer agent, but serious cardiotoxicity precludes its use in a wide range of patients. We have reported that the androgen-androgen receptor (AR) system plays important roles in cardiac growth and protection from angiotensin II-induced cardiac remodeling. The present study was undertaken to clarify whether the androgen-AR system exerts a cardioprotective effect against Dox-induced cardiotoxicity. Male AR knockout (ARKO) and age-matched littermate male wild-type (WT) mice at 25 wk of age were given ip injections of Dox (20 mg/kg) or a vehicle. The survival rate and left ventricular function in Dox-treated male ARKO mice were reduced compared with those in Dox-treated male WT mice. Electron microscopic study showed prominent vacuole formation of myocardial mitochondria in Dox-treated male ARKO mice. Cardiac oxidative stress and apoptosis of cardiomyocytes were increased more prominently by Dox treatment in male ARKO mice than in male WT mice. In addition, Dox-induced reduction in the expression of cardiac mitochondria transcription factor A (Tfam) and phosphorylation of serine-threonine kinase (Akt) was more pronounced in male ARKO mice than in male WT mice. In cardiac myoblast cells, testosterone up-regulated Akt phosphorylation and Tfam expression and exerted an antiapoptotic effect against Dox-induced cardiotoxicity. Collectively, the results demonstrate that Dox-induced cardiotoxicity is aggravated in male ARKO mice via exacerbation of mitochondrial damage and superoxide generation, leading to enhanced apoptosis of cardiomyocytes. Thus, the androgen-AR system is thought to counteract Dox-induced cardiotoxicity partly through activation of the Akt pathway and up-regulation of Tfam to protect cardiomyocytes from mitochondrial damage and apoptosis. (Keyword) Androgens / Animals / Antineoplastic Agents / Apoptosis / Blotting, Western / Cell Line / Cell Survival / DNA-Binding Proteins / Doxorubicin / Echocardiography / High Mobility Group Proteins / Immunoprecipitation / In Situ Nick-End Labeling / Male / Mice / Mice, Knockout / Microscopy, Electron / Myocardium / Myocytes, Cardiac / Oxidative Stress / Phosphorylation / Protein-Serine-Threonine Kinases / Rats / Receptors, Androgen / Superoxides / Testosterone / Thiobarbituric Acid Reactive Substances / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1210/me.2009-0402 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20501642 ● Search Scopus @ Elsevier (PMID): 20501642 ● Search Scopus @ Elsevier (DOI): 10.1210/me.2009-0402 (DOI: 10.1210/me.2009-0402, PubMed: 20501642)
163.	Shusuke Yagi, Masashi Akaike, Mitsunori Fujimura, Takehiko Kimura, Takeshi Nishiuchi, Takashi Iwase, Ken-ichi Aihara, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Congenital ventricular aneurysm as an unexpected complication of monomorphic premature ventricular contractions., Internal Medicine, Vol.49, No.10, 907-912, 2010. (Summary) Congenital ventricular diverticulum (CVD) in adults is a rare cardiac malformation, which includes fibrous type congenital ventricular aneurysm (CVA). CVA is often clinically asymptomatic and shows no abnormality in the electrocardiogram or chest X-ray. However, some cases of sudden death resulting from ventricular tachycardia, cardiac embolism or ventricular rupture have been reported. Therefore, physicians should perform further cardiac imaging studies to detect a CVA if ventricular arrhythmia originating from the left ventricle is observed. Here, we report two successfully followed cases of CVA which were diagnosed from premature ventricular contractions. (Keyword) congenital ventricular aneurysm / congenital ventricular diverticulum / ventricular arrythmia (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.49.3008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20467175 ● CiNii @ National Institute of Informatics (CRID): 1390001204871212928 ● Search Scopus @ Elsevier (PMID): 20467175 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.49.3008 (DOI: 10.2169/internalmedicine.49.3008, PubMed: 20467175, CiNii: 1390001204871212928)
164.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Kazue Ishikawa, Takashi Iwase, Yasumasa Ikeda, Takeshi Soeki, Sumiko Yoshida, Yuka Sumitomo-Ueda, Toshio Matsumoto and Masataka Sata : Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury., Hypertension, Vol.55, No.4, 918-923, 2010. (Summary) Activation of the renin-angiotensin system exacerbates atrial remodeling, leading to atrial fibrillation and thrombosis, especially in a condition with decreased NO bioavailability. Recently, it has been reported that statins reduce the incidence of atrial fibrillation through attenuation of atrial remodeling; however, the mechanisms have not been completely elucidated. Therefore, we aimed to clarify the beneficial effect of statin on atrial remodeling in condition with reduced NO bioavailability. Endothelial NO synthase(-/-) mice were sham operated or infused with angiotensin II (Ang II) via an osmotic minipump for 2 weeks, and Ang II-infused mice were divided into 3 treatment groups: pitavastatin, Tempol (a free radical scavenger), or vehicle. Echocardiography and electrocardiography showed that Ang II infusion caused left atrial enlargement and a high incidence of atrial fibrillation, whereas pitavastatin and Tempol prevented these abnormalities. In histological analysis, Ang II-induced atrial interstitial fibrosis, perivascular fibrosis, and cardiomyocyte hypertrophy were all attenuated by pitavastatin and Tempol. Immunohistochemical staining showed that Ang II downregulated thrombomodulin and tissue factor pathway inhibitor and upregulated tissue factor and plasminogen activator inhibitor 1 in the left atrium and that pitavastatin and Tempol corrected the thrombogenic condition. Moreover, pitavastatin and Tempol reduced Ang II-induced atrial superoxide production and atrial transforming growth factor-beta1 expression and Smad 2/3 phosphorylation. Atrial rac1-GTPase activity, known to activate NADPH oxidase, was attenuated by pitavastatin but not by Tempol. In conclusion, pitavastatin exerts endothelial NO synthase-independent protective actions against Ang II-induced atrial remodeling and atrial fibrillation with enhanced thrombogenicity through suppression of oxidant injury. (Keyword) Analysis of Variance / Angiotensin II / Animals / Antioxidants / Atrial Fibrillation / Blood Pressure / Blotting, Western / Cardiomegaly / Cyclic N-Oxides / Echocardiography / Fibrosis / Heart Atria / Heart Rate / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Male / Mice / Mice, Knockout / Myocytes, Cardiac / Nitric Oxide Synthase Type III / Oxidative Stress / Quinolines / Renin-Angiotensin System / Reverse Transcriptase Polymerase Chain Reaction / Signal Transduction / Smad2 Protein / Smad3 Protein / Spin Labels / Transforming Growth Factor beta1 (Link to Publication Site) ● Publication site (DOI): 10.1161/HYPERTENSIONAHA.109.146076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20194307 ● Search Scopus @ Elsevier (PMID): 20194307 ● Search Scopus @ Elsevier (DOI): 10.1161/HYPERTENSIONAHA.109.146076 (DOI: 10.1161/HYPERTENSIONAHA.109.146076, PubMed: 20194307)
165.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Kazue Ishikawa, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia., Journal of Atherosclerosis and Thrombosis, Vol.17, No.2, 173-180, 2010. (Summary) AIM: Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, has been shown to reduce the intestinal absorption of cholesterol. We investigated whether it also has beneficial effects on metabolic disorder and/or renal insufficiency in patients with hypercholesterolemia. METHODS: Ezetimibe was administered to 38 Japanese patients with hypercholesterolemia to obtain appropriate low-density lipoprotein cholesterol (LDL-chol) levels. Age- and sex-matched patients with hypercholesterolemia (n=38) were the controls. We evaluated the effects of ezetimibe before and 4 to 8 weeks after ezetimibe treatment. RESULTS: Ezetimibe significantly decreased LDL-chol levels and metabolic syndrome-related factors, including body weight, waist circumference, blood pressure; homeostasis model assessment insulin resistance (HOMA-IR), and urinary albumin excretion, were significantly reduced. In addition, it decreased the level of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, the urinary excretion of 8-hydroxy-2'-deoxyguanosine, a parameter of oxidative stress, and increased the urinary excretion of nitrate and nitrite (NOx). In the controls we observed no such changes. Excepting the decrease in the serum TNF-alpha level, the effects of ezetimibe were not correlated with decreased LDL-chol levels. CONCLUSION: Ezetimibe ameliorated the status of metabolic syndrome and microalbuminuria, reduced inflammation and oxidative stress, and increased nitric oxide bioavailability in a LDL-chol reduction-dependent and -independent manner. (Keyword) Aged / Albuminuria / Anticholesteremic Agents / Azetidines / C-Reactive Protein / Case-Control Studies / Cholesterol, LDL / Deoxyguanosine / Female / Humans / Hypercholesterolemia / Male / Metabolic Diseases / Metabolic Syndrome X / Middle Aged / Nitrates / Nitrites / Oxidative Stress / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.2378 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20150722 ● Search Scopus @ Elsevier (PMID): 20150722 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.2378 (DOI: 10.5551/jat.2378, PubMed: 20150722)
166.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo-Ueda, Shusuke Yagi, T Niki, Kenya Kusunose, N Tomita, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, KI Aihara, Masafumi Harada, H Nishitani and Masataka Sata : Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy., Heart Asia, Vol.2, 52-55, 2010. (Link to Publication Site) ● Publication site (DOI): 10.1136/ha.2010.002006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27325943 ● Search Scopus @ Elsevier (PMID): 27325943 ● Search Scopus @ Elsevier (DOI): 10.1136/ha.2010.002006 (DOI: 10.1136/ha.2010.002006, PubMed: 27325943)
167.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, K Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Y Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical Utility of Single Beat E/e' Obtained by Simultaneous Recording of Flow and Tissue Doppler Velocities in Atrial Fibrillation with Preserved Systolic Function., JACC. Cardiovascular Imaging, Vol.2, No.10, 1147-1156, 2009. (Summary) We evaluated the usefulness of the ratio of the early diastolic transmitral flow velocity (E) to the mitral annular velocity (e') calculated from simultaneously recorded E and e' in atrial fibrillation (AF). The ratio of the E to the e' (E/e') has been reported as a useful index even in AF patients. However, E and e' were measured during different beats in the previous studies. Fifty-six AF patients with preserved systolic function (mean age 66 +/- 11 years) underwent routine echocardiographic study. The E/e' was calculated from the E and e' simultaneously recorded by the dual Doppler echocardiography. A single-beat E/e' was calculated from simultaneously recorded E and e' when the preceding RR interval/pre-preceding RR interval = 1. Brain natriuretic peptide (BNP) levels were also examined. Twenty-one patients underwent simultaneous pulmonary artery catheterization. The single-beat lateral E/e' correlated with pulmonary capillary wedge pressure (PCWP) (r = 0.74, p < 0.001). The single-beat lateral E/e' of >or=11 could predict elevated PCWP (>or=15 mm Hg) with a sensitivity of 90% and a specificity of 90%. The single-beat lateral E/e' also correlated well with the log BNP concentration. The single-beat lateral E/e' of >or=9.2 predicted a plasma BNP level of >or=200 pg/ml with 88% sensitivity and 84% specificity. The single-beat lateral E/e' correlated with plasma BNP level and PCWP in AF patients with preserved systolic function. In addition, the single-beat lateral E/e' (>or=11) was a good predictor of elevated PCWP (>or=15 mm Hg). Dual Doppler echocardiography offers an advantage of providing the single-beat lateral E/e' correctly even in AF patients, for the evaluation of left ventricular diastolic function. (Keyword) Adult / Aged / Aged, 80 and over / Atrial Fibrillation / Biological Markers / Catheterization, Swan-Ganz / Coronary Circulation / Diastole / Echocardiography, Doppler, Color / Echocardiography, Doppler, Pulsed / Female / Heart Rate / Humans / Linear Models / Male / Middle Aged / Mitral Valve / Natriuretic Peptide, Brain / Predictive Value of Tests / Pulmonary Wedge Pressure / Sensitivity and Specificity / Systole / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2009.05.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19833302 ● Search Scopus @ Elsevier (PMID): 19833302 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcmg.2009.05.013 (DOI: 10.1016/j.jcmg.2009.05.013, PubMed: 19833302)
168.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Nobuyuki Takamori, Yasumasa Ikeda, Yuka Sumitomo, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Kazue Ishikawa, Masataka Sata, Tetsuya Kitagawa and Toshio Matsumoto : Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors., Journal of Atherosclerosis and Thrombosis, Vol.16, No.2, 127-134, 2009. (Summary) AIM: Heparin cofactor II (HCII) specifically inactivates thrombin action at the injured vascular wall. We have reported that HCII is a protective factor against coronary in-stent restenosis and carotid atherosclerosis; however, it is unclear whether there is any correlation between plasma HCII levels and the development of peripheral arterial disease (PAD). METHODS: Plasma HCII activity and the ankle brachial pressure index (ABI) were determined in 494 elderly subjects with cardiovascular risk factors. PAD was diagnosed by ABI below 0.9, and 62 subjects were diagnosed with PAD. The relationship between factors that affect cardiovascular events and the prevalence of PAD was statistically evaluated. RESULTS: Mean HCII activity in PAD subjects was significantly lower than in non-PAD subjects (87.5+/-19.7% v.s. 94.6+/-17.8%, p=0.009). Multivariate logistic regression analysis showed that age (odds ratio [OR]: 1.062, p=0.0016), current smoking (OR 3.028, p=0.002) and diabetes mellitus (OR 2.656, p=0.008) were independent and progressive determinants of PAD. In contrast, HCII was an independent inhibitory factor of PAD (OR: 0.982, p=0.048). CONCLUSIONS: Plasma HCII activity is inversely related to the prevalence of PAD. HCII may function as the sole protective factor against PAD in elderly people with cardiovascular risk factors. (Keyword) Aged / Aged, 80 and over / Cardiovascular Diseases / Female / Heparin Cofactor II / Humans / Male / Middle Aged / Peripheral Vascular Diseases / Prevalence / Protective Agents / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.E695 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19403987 ● Search Scopus @ Elsevier (PMID): 19403987 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.E695 (DOI: 10.5551/jat.E695, PubMed: 19403987)
169.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Yuka Ueda, Sumiko Yoshida, Takayuki Ise, Shusuke Yagi, Takashi Iwase, 近藤彰, 田村克也 and Toshio Matsumoto : アンジオテンシンII受容体拮抗薬バルサルタンのNO bioavailability改善効果に関する臨床的検討, Progress in Medicine, Vol.29, No.7, 1777-1782, 2009. (Summary) バルサルタンの降圧作用，動脈硬化抑制作用および糖代謝改善作用に一酸化窒素(NO)のバイオアベイラビリティの改善効果が関与しているか検討した．高血圧治療目的で通院加療中の42例を対象とした．バルサルタン投与にて，BMIやリポプロテイン(a)を含む脂質プロファイルに有意な変化は認めなかったが，収縮期血圧，脈圧，baPWVおよびHbA1cは有意に低下した．投与3ヵ月後には投与前と比較して，NOのバイオアベイラビリティのマーカーである血清硝酸/亜硝酸イオン(NOx)は約1.5倍に増加した．血清NOxの増加が，他の測定因子にどのように影響を与えているか，単変量および多変量解析を用いて解析し，血清NOxの増加量は収縮期血圧の低下と脈圧の減少との間においてそれぞれ有意な相関がみられた．また，HbA1cはバルサルタン投与3ヵ月後に有意に低下していたが，その変化はNOxの増加量と有意な相関がみられた． (Keyword) Nitrogen Oxides(血液) Glycosylated Hemoglobin A 降圧剤(治療的利用,薬理学) 高血圧(薬物療法) 生物学的利用率動脈硬化症-アテローム性(予防,診断) 経口投与一酸化窒素 Valsartan(治療的利用,薬理学) Angiotensin II Type 1 Receptor Blockers(治療的利用,薬理学) 脈波伝播速度ヒト中年(45~64) 高齢者(65~79) 男女
170.	Kenya Kusunose, Hirotsugu Yamada, Takashi Todoroki, Susumu Nishio, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Tetsuya Kitagawa and Masataka Sata : Platypnea-orthodeoxia syndrome associated with patent foramen ovale and aortic ectasia., Echocardiography, Vol.26, No.1, 114-117, 2008. (Summary) A 59-year-old man was admitted for dyspnea on exertion and edema. The patient did not have any pulmonary diseases that could cause dyspnea. Transesophageal echocardiography on the tilting bed with contrast infusion revealed a right-to-left shunt through the patent foramen ovale. Therefore, he was diagosed as platypnea-orthodeoxia syndrome due to the patent foramen ovale. Surgical closure was done and all of his symptoms had improved. (Keyword) Aortic Diseases / Dyspnea / transesophageal echocardiography / Edema, Cardiac / Foramen Ovale, Patent / Humans / Male / Middle Aged / syndrome / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1540-8175.2008.00780.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19017323 ● Search Scopus @ Elsevier (PMID): 19017323 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1540-8175.2008.00780.x (DOI: 10.1111/j.1540-8175.2008.00780.x, PubMed: 19017323)
171.	Shusuke Yagi, Masahi Akaike, Mitsunori Fujimura, Takayuki Ise, Sumiko Yoshida, Yuka Sumitomo, Yasumasa Ikeda, Takashi Iwase, Ken-ichi Aihara, Hiroyuki Azuma, Atsushi Kurushima, Youichi Ichikawa, Tetsuya Kitagawa, Takehiko Kimura, Takeshi Nishiuchi and Toshio Matsumoto : Infective endocarditis caused by lactobacillus., Internal Medicine, Vol.47, No.12, 1113-1116, 2008. (Summary) Lactobacillus (LB) is a gram-positive rod-shaped bacterium that inhabits the oral cavity, gastrointestinal tract, vagina and nasal cavity. Although LB plays a role in the prevention of infections caused by pathogenic bacteria, it causes some critical infectious diseases such as infective endocarditis (IE). IE due to LB is rare; however, early diagnosis and early treatment are important because of its high mortality rate. We report the onset of IE after otologic treatment in a heavy drinker of alcohol, the second case of IE due to LB in Japan. (Keyword) Adult / Alcoholism / Endocarditis, Bacterial / Gram-Positive Bacterial Infections / Heart Valve Prosthesis Implantation / Humans / Immunocompromised Host / Lactobacillus / Male / Mitral Valve Insufficiency (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.47.0744 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18552468 ● Search Scopus @ Elsevier (PMID): 18552468 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.47.0744 (DOI: 10.2169/internalmedicine.47.0744, PubMed: 18552468)
172.	Masashi Akaike, 小原卓爾, 日浅光春, 藤村光則, 加藤みどり, 横井健治, 小島章裕, 岡崎誠司, 井内貴彦, 井上利彦, 住友由佳, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Ken-ichi Aihara and Hiroyuki Azuma : 高コレステロール血症患者に対するピタバスタチンの有効性総合的脂質プロファイルに関する検討, Progress in Medicine, Vol.28, No.11, 2745-2751, 2008. (Summary) 高コレステロール血症患者を対象にピタバスタチンを投与し，総合的脂質プロファイルへの影響について検討した．高コレステロール血症と診断され，ピタバスタチンを投与した87例を対象とした．ピタバスタチン投与によりTC，LDL-Cは有意に低下した．HDL-Cは有意な上昇，TGは有意な低下を認めた．ピタバスタチンを新規に投与した症例で，TC，LDL-Cは有意かつ良好な低下作用を認めた．また，HDL-Cは有意な上昇，TGは有意な低下作用を示した．Non HDL-Cは有意に低下し，LDL-C/HDL-C比は有意に減少した．動脈硬化指数は，いずれも有意に改善した．投与前後でLp(a)を測定した76例で，有意な変化は認めなかった．投与前後におけるALT，ASTの平均変化量に，有意な変化は認めなかった．CKも有意な変化は認めなかった．治療上，問題となる副作用は認めなかった． (Keyword) Cholesterol(血液) HDL Cholesterol(血液) LDL Cholesterol(血液) Triglycerides(血液) 高コレステロール血症(薬物療法) Lipoprotein(a)(血液) 治療成績 Pitavastatin(治療的利用) ヒト中年(45~64) 高齢者(65~79) 男女
173.	Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, Yuka Sumitomo, Sumiko Yoshida, Takayuki Ise, Takashi Iwase, Kazue Ishikawa, Hiroyuki Azuma, Masashi Akaike and Toshio Matsumoto : Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency., Circulation Research, Vol.102, No.1, 68-76, 2007. (Summary) Angiotensin II (Ang II) plays a pivotal role in cardiovascular remodeling leading to hypertension, myocardial infarction, and stroke. Pitavastatin, an HMG-CoA reductase inihibitor, is known to have pleiotropic actions against the development of cardiovascular remodeling. The objectives of this study were to clarify the beneficial effects as well as the mechanism of action of pitavastatin against Ang II-induced organ damage. C57BL6/J mice at 10 weeks of age were infused with Ang II for 2 weeks and were simultaneously administered pitavastatin or a vehicle. Pitavastatin treatment improved Ang II-induced left ventricular hypertrophy and diastolic dysfunction and attenuated enhancement of cardiac fibrosis, cardiomyocyte hypertrophy, coronary perivascular fibrosis, and medial thickening. Ang II-induced oxidative stress, cardiac TGFbeta-1 expression, and Smad 2/3 phosphorylation were all attenuated by pitavastatin treatment. Pitavastatin also reduced Ang II-induced cardiac remodeling and diastolic dysfunction in eNOS-/- mice as in wild-type mice. In eNOS-/- mice, the Ang II-induced cardiac oxidative stress and TGF-beta-Smad 2/3 signaling pathway were enhanced, and pitavastatin treatment attenuated the enhanced oxidative stress and the signaling pathway. Moreover, pitavastatin treatment reduced the high mortality rate and improved renal insufficiency in Ang II-treated eNOS-/- mice, with suppression of glomerular oxidative stress and TGF-beta-Smad 2/3 signaling pathway. In conclusion, pitavastatin exerts eNOS-independent protective actions against Ang II-induced cardiovascular remodeling and renal insufficiency through inhibition of the TGF-beta-Smad 2/3 signaling pathway by suppression of oxidative stress. (Keyword) Angiotensin II / Animals / Cardiotonic Agents / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypertrophy, Left Ventricular / Mice / Mice, Inbred C57BL / Mice, Knockout / Nitric Oxide Synthase Type III / Oxidative Stress / Quinolines / Renal Insufficiency / Signal Transduction / Smad2 Protein / Smad3 Protein / Transforming Growth Factor beta / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCRESAHA.107.163493 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17967781 ● Search Scopus @ Elsevier (PMID): 17967781 ● Search Scopus @ Elsevier (DOI): 10.1161/CIRCRESAHA.107.163493 (DOI: 10.1161/CIRCRESAHA.107.163493, PubMed: 17967781)
174.	Yasumasa Ikeda, Ken-ichi Aihara, Takashi Sato, Masashi Akaike, Masanori Yoshizumi, Yuki Suzaki, Yuki Izawa-Ishizawa, Mitsunori Fujimura, Shunji Hashizume, Midori Kato, Shusuke Yagi, Toshiaki Tamaki, Hirotaka Kawano, Takahiro Matsumoto, Hiroyuki Azuma, Shigeaki Kato and Toshio Matsumoto : Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis., The Journal of Biological Chemistry, Vol.280, No.33, 29661-29666, 2005. (Summary) Androgen has anabolic effects on cardiac myocytes and has been shown to enhance left ventricular enlargement and function. However, the physiological and patho-physiological roles of androgen in cardiac growth and cardiac stress-induced remodeling remains unclear. We aimed to clarify whether the androgen-nuclear androgen receptor (AR) system contributes to the cardiac growth and angiotensin II (Ang II)-stimulated cardiac remodeling by using systemic AR-null male mice. AR knock-out (ARKO) male mice, at 25 weeks of age, and age-matched wild-type (WT) male mice were treated with or without Ang II stimulation (2.0 mg/kg/day) for 2 weeks. ARKO mice with or without Ang II stimulation showed a significant reduction in the heart-to-body weight ratio compared with those of WT mice. In addition, echocardiographic analysis demonstrated impairments of both the concentric hypertrophic response and left ventricular function in Ang II-stimulated ARKO mice. Western blot analysis of the myocardium revealed that activation of extracellular signal-regulated kinases (ERK) 1/2 and ERK5 by Ang II stimulation were lower in ARKO mice than those of WT mice. Ang II stimulation caused more prominent cardiac fibrosis in ARKO mice than in WT mice with enhanced expression of types I and III collagen and transforming growth factor-beta1 genes and with increased Smad2 activation. These results suggest that, in male mice, the androgen-AR system participates in normal cardiac growth and modulates cardiac adaptive hypertrophy and fibrosis during the process of cardiac remodeling under hypertrophic stress. (Keyword) Angiotensin II / Animals / blood pressure / Cardiomegaly / DNA-Binding Proteins / pulmonary fibrosis / Heart Rate / Male / Mice / Mice, Inbred C57BL / Mice, Inbred CBA / knockout mice / Mitogen-Activated Protein Kinase 1 / Mitogen-Activated Protein Kinase 3 / Mitogen-Activated Protein Kinase 7 / myocardium / RNA, Messenger / Receptors, Androgen / Smad2 Protein / Trans-Activators / Transforming Growth Factor beta / Transforming Growth Factor beta1 / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M411694200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15961403 ● Search Scopus @ Elsevier (PMID): 15961403 ● Search Scopus @ Elsevier (DOI): 10.1074/jbc.M411694200 (DOI: 10.1074/jbc.M411694200, PubMed: 15961403)

Academic Paper (Unrefereed Paper):

1.	Tetsuzo Wakatsuki, K Yamaguchi, T Niki, Kenya Kusunose, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : Long-term endothelial dysfunction after coronary artery stenting with drug-eluting stent associated with local inflammatory response., Circulation, Vol.118, S_749, 2008.
2.	K Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, K Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local hypercoagulability and endothelial dysfunction after sirolimus-eluting stent implantation: implication for late stent thrombosis., Circulation, Vol.118, S_651, 2008.
3.	Takashi Iwase, Hirotsugu Kurobe, Shusuke Yagi, 原朋子, 長楽雅仁, 藤村光則, Shuji Ozaki, Masashi Akaike, 安部正博, Yutaka Masuda, Hiroyuki Azuma, Toshio Matsumoto and Tetsuya Kitagawa : 末梢単核球細胞を用いた抹消動脈閉塞症に対する新たな血管新生治療の試み, Shikoku Acta Medica, Vol.62, No.3,4, 137-141, 2006. (Tokushima University Institutional Repository) ● Metadata: 49311 (Tokushima University Institutional Repository: 49311)

Academic Letter:

1.	Kenya Kusunose, Hirotsugu Yamada, Yoshihito Saijo, Susumu Nishio, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Preload Stress Echocardiography for the Assessment of Heart Failure With Preserved Ejection Fraction, JACC. Cardiovascular Imaging, Vol.15, No.2, 375-378, 2022. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2021.09.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34656477 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123584116 (DOI: 10.1016/j.jcmg.2021.09.005, PubMed: 34656477, Elsevier: Scopus)
2.	Kenya Kusunose, Hirotsugu Yamada, Rino Suzukawa, Yukina Hirata, Masami Yamao, Takayuki Ise, Shusuke Yagi, Masashi Akaike and Masataka Sata : Effects of Transthoracic Echocardiographic Simulator Training on Performance and Satisfaction in Medical Students., Journal of the American Society of Echocardiography, Vol.29, No.4, 375-377, 2016. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.echo.2015.12.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26743736 ● Summary page in Scopus @ Elsevier: 2-s2.0-84960912424 (DOI: 10.1016/j.echo.2015.12.002, PubMed: 26743736, Elsevier: Scopus)

Review, Commentary:

1.	Shinji Kawahito, Tomohiro Soga, Shusuke Yagi, Shingo Matsushita, Hiroe Tani and Sachiko Masuya : 周術期の血管機能保護戦略, Shikoku Acta Medica, Vol.73, No.1, 2, 47-58, Apr. 2017. (Summary) Potassium channels play an essential role in the membrane potential of arterial smooth muscle, and also in regulating contractile tone. Especially, in vascular smooth muscle, the opening of adenosine triphosphate(ATP)-sensitive potassium(KATP)channels leads to membrane hyperpolarization, resulting in muscle relaxation and vasodilation. This activation also plays a role in tissues during pathophysiologic events such as ischemia, hypoxia, and vasodilatory shock. In this review, we will describe the physiological and pathophysiological roles of vascular smooth muscle KATP channels in relation to the effects of anesthetics and perioperative managements. Although accumulated evidence suggests that many anesthetics and perioperative managements(especially, diabetes and hyperglycemia)modify the above function of K+ channels as a metabolic sensor. Use of effective volatile anesthetics and the strict glycemic control may contribute to protect perioperative vascular function. (Keyword) Vascular function / Anesthetics / KATP channel / Oxidative stress / Intensive insulin therapy (Tokushima University Institutional Repository) ● Metadata: 110415 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050845762395253888 (Tokushima University Institutional Repository: 110415, CiNii: 1050845762395253888)
2.	Shusuke Yagi and Masataka Sata : 非薬物降圧治療の可能性-RDN, デバイス，遠隔モニタリング, Journal of Clinical and Experimental Medicine, Vol.260, No.5, 484-485, Feb. 2017.
3.	Shusuke Yagi and Masataka Sata : 7 心臓病と肥満 -メタボリックシンドロームを中心に-, 循環器疾患最新の治療2016-2017(監修堀正二，編集長井良三，伊藤浩), 509-511, Mar. 2016.
4.	石井亜由美, 西川幸治, Takayuki Ise, 門田宗之, Shusuke Yagi, Takashi Iwase, Hajime Kinoshita, Miho Sakata, Yasunobu Hayabuchi, Tetsuya Kitagawa, Masashi Akaike, Shinsuke Katoh and Masataka Sata : 単心室症患児の開心術後にフェイススケールを用いて心臓リハビリテーションを試みた1症例, Heart, Vol.48, No.2, 181-186, Feb. 2016. (Keyword) 心臓リハビリテーション / infant / フェイススケール
5.	Takayuki Ise, 高木恵理, Takashi Iwase, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 心臓サルコイドーシス再燃に対してメトトレキサートの併用が有効であった1例, The Journal of the Japanese Society of Internal Medicine, Vol.104, No.6, 1175-1179, 2015. (Summary) 心臓サルコイドーシスの標準的治療はステロイドであるが，ステロイドを投与中であっても再燃を認めることも多く，またステロイドの多岐にわたる副作用も問題となることが多い．症例は70歳代，女性．心臓サルコイドーシスの診断でプレドニンを維持量5 mg/日で加療されていた．定期検査で施行した心電図で陰性T波，前壁心尖部に新規の左室壁運動異常を認めた．FDG-PET，Gaシンチグラフィーで壁運動異常部位に一致して集積を認め，心臓サルコイドーシスの再燃と判断した．本症例では，ステロイドの副作用として糖尿病，肥満，白内障などを認めており，ステロイド増量が躊躇され，メトトレキサートの併用を開始した．メトトレキサート開始後，特に副作用を認めず，心電図ならびに左室壁運動異常の改善が認められた．ステロイド投与で再燃を認める心臓サルコイドーシス症例にはメトトレキサート併用も考慮すべきであると考えられた． (Keyword) 心臓サルコイドーシス / 再燃 / steroid / メトトレキサート / 副作用 (Link to Publication Site) ● Publication site (DOI): 10.2169/naika.104.1175 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001206449318272 ● Search Scopus @ Elsevier (DOI): 10.2169/naika.104.1175 (DOI: 10.2169/naika.104.1175, CiNii: 1390001206449318272)
6.	今田久美子, Shusuke Yagi, Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, 太田理絵, 門田宗之, 高島啓, 松浦朋美, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Efficacy of percutaneous transluminal renal angioplasty for renovascular hypertension complicated with heart failure, Shikoku Acta Medica, Vol.70, No.3, 4, 87-92, Aug. 2014. (Summary) 【Background】 Percutaneous transluminal renal angioplasty (PTRA) is recommended for patients with heart failure due to renovascular hypertension ; however, the clinical characteristics of the patients and the effects of PTRA on heart failure and cardiorenal function have not been elucidated. 【Methods】 We retrospectively analyzed data for 4 PTRA-treated patients (male/female, 1/3 ; mean age, 70.0±10 years ; mean left ventricular ejection fraction, 51.5±15.2%) with heart failure due to renovascular hypertension and evaluated the effects of PTRA on heart failure and cardiorenal function 6 months after treatment. 【Results】 All patients had pro-arteriosclerotic diseases including diabetes mellitus, essential thrombocythemia, heparin cofactor II deficency, metabolic syndrome, and familial hypercholesterolemia, and 3 patients had ischemic heart disease. No abdominal bruit was heard and mean plasma renin activity was 4.5±3.6 ng/ml/hr, which was not elevated, contrary to expectation. All contralateral kidneys of PTRA were nonfunctioning, suggesting bilateral kidneys were disturbed in all patients. In all patients, PTRA was successfully performed and resolved heart failure. PTRA resulted in decreases in systolic blood pressure from 157±18 to 124±8.6 mmHg, mean serum creatinine from 3.2±2.6 to 2.7±2.2 mg/dl, and mean BNP from 919±998 to 243±291 pg/ml at 6 months after treatment. PTRA did not change left ventricular ejection fraction, a parameter of systolic fraction evaluated by an echocardiogram ; however, PTRA improved E/e', a parameter of left ventricular diastolic fraction, from 16.1±5.2 to 9.7±3.7. None of the patients were hospitalized due to heart failure during the 6-month period after PTRA. 【Conclusions】 Patients with heart failure with cardiovascular risk factors should be screened for renovascular hypertension regardless of abdominal bruit or plasma renin activity. PTRA is effective for resolving heart failure and for improving renal and cardiac diastolic functions in patients with renovascular hypertension complicated with heart failure. (Keyword) heart failure / cardiac disturbance syndrome / percutaneous transluminal renal angioplasty (Tokushima University Institutional Repository) ● Metadata: 109759 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050001337734629888 (Tokushima University Institutional Repository: 109759, CiNii: 1050001337734629888)
7.	Shusuke Yagi and Masataka Sata : 血圧日内変動を考慮したRAAS抑制薬による高血圧治療 (特集血圧サーカディアンリズム : 24時間血圧管理の重要性) -- (24時間パーフェクト血圧管理をめざした治療), Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.72, No.8, 1466-1471, Aug. 2014.
8.	Shusuke Yagi and Masataka Sata : 文献紹介「Stenting and medical therapy for atherosclerotic renal-artery stenosis」, 腎・高血圧の最新治療, Vol.3, No.3, 170-171, Jul. 2014.
9.	Shusuke Yagi, Masayoshi Ishida and Masataka Sata : 用語解説マイクロRNAと循環器疾患, Journal of JCS Cardiologists, Vol.21, No.1, 97, Mar. 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390564237987988864 (CiNii: 1390564237987988864)
10.	Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : RAS研究 -ラボの最前線- 徳島大学大学院ヘルスバイオサイエンス研究部循環器内科学・心臓血管病態医学, Angiotensin Research, Vol.10, No.1, 59-63, Jan. 2013.
11.	Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Effects of Statins on Cardiorenal Syndrome., International Journal of Vascular Medicine, Vol.2012, 162545, Jun. 2012. (Summary) Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS. (Link to Publication Site) ● Publication site (DOI): 10.1155/2012/162545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22792467 ● Search Scopus @ Elsevier (PMID): 22792467 ● Search Scopus @ Elsevier (DOI): 10.1155/2012/162545 (DOI: 10.1155/2012/162545, PubMed: 22792467)
12.	Shusuke Yagi and Masataka Sata : Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation., European Heart Journal Supplements, No.13, B15-B20, 2011. (Link to Publication Site) ● Publication site (DOI): 10.1093/eurheartj/sur012 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/eurheartj/sur012 (DOI: 10.1093/eurheartj/sur012)
13.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, Masashi Akaike and Toshio Matsumoto : Transforming Growth Factor-1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome., Cardiology Research and Practice, Vol.2011, 175381, Dec. 2010. (Summary) Transforming growth factor-1 (TGF-1) is a polypeptide member of the transforming growth factor superfamily of cytokines. It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell differentiation and apoptosis. In the cardiovascular system, TGF-1 plays pivotal roles in the pathogenesis of hypertension, restenosis after percutaneous coronary intervention, atherosclerosis, cardiac hypertrophy and heart failure. In addition, TGF-1 has been shown to be increased in adipose tissue of obese subjects with insulin resistance. Furthermore, TGF-1 is a potent initiator of proliferation of renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-1 expression leading to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-1 as a crucial factor for regulation and modulation of those pathological conditions. (Link to Publication Site) ● Publication site (DOI): 10.4061/2011/175381 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21234356 ● Search Scopus @ Elsevier (PMID): 21234356 ● Search Scopus @ Elsevier (DOI): 10.4061/2011/175381 (DOI: 10.4061/2011/175381, PubMed: 21234356)

Proceeding of International Conference:

1.	Natsumi Yamaguchi, TOMONORI Takahashi, Susumu Nishio, Robert Zheng, Yoshihito Saijyo, Muneyuki Kadota, Yutaka Kawabata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Elevated left atrial stiffness index is a poor prognostic factor in heart failure with preserved ejection fraction undergoing transcatheter aortic valve replacement, EUROECHO 2024, Dec. 2024.
2.	Tezuka Kazuki, Takeshi Soeki, Tomoko Takahashi, Tomomi Matsuura, Akihiro Tani, Ryo Bando, R Zheng, TOMONORI Takahashi, Yoshihito Saijo, Tomoya Hara, Muneyuki Kadota, Yutaka Kawabata, Rie Ueno, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Risk Factors For Intraoperative Instability In Sedated Patients Undergoing Pulmonary Vein Isolation Ablation, Sydney, Sep. 2024.
3.	Tomoko Takahashi, Takeshi Soeki, Tezuka Kazuki, TOMONORI Takahashi, Yoshihito Saijo, Tomoya Hara, Yutaka Kawabata, Muneyuki Kadota, Rie Ueno, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : NAFLD score predicts the onset of atrial fibrillation, APHRS 2024, Sydney, Sep. 2024.
4.	Yoshihito Saijo, Hirotsugu Yamada, Robert Zheng, TOMONORI Takahashi, Yutaka Kawabata, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Differential echocardiographic profiles in immunoglobulin light chain and transthyretin amyloid cardiomyopathy: insights from speckle tracking analysis, ESC 2024, London, Aug. 2024.
5.	R Bando, Tetsuzo Wakatsuki, Koji Yamaguchi, TOMONORI Takahashi, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Clinical outcome of DCB vs DES for de novo large coronary lesion in HBR patients, Euro PCR 2024, Paris, May 2024.
6.	Kohei Nagano, TOMONORI Takahashi, Tetsuzo Wakatsuki, Robert Zheng, Yoshihito Saijyo, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Long-Term Outcome of Stentless Coronary Intervention With Drug-Coated Balloon in Patients With High Bleeding Risk, AHA2023, Philadelphia, Nov. 2023.
7.	N Yamaguchi, Kenya Kusunose, Yukina Hirata, Susumu Nishio, TOMONORI Takahashi, Yoshihito Saijo, Muneyuki Kadota, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Improved Pressure-Flow Relationship With Sacubitril/Valsartan: A 6-min Walk Stress Echocardiographic Study, AHA2023, Philadelphia, Nov. 2023.
8.	Shusuke Yagi, Tserensonom Munkhtsetseg and Masataka Sata : Lipoprotein (a) is a Residual Risk Factor of Aortic Valve Calcification in Patients With High Risk of Atherosclerotic, AHA 2022, Chicago, Nov. 2022.
9.	Y Okushi, Kenya Kusunose, Hiromitsu Seno, TOMONORI Takahashi, Yoshihito Saijyo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : The Impact of Surveillance of Cancer Therapeutics-Related Cardiac Dysfunction by Periodic Echocardiography, ASE2022, Seattle, Jun. 2022.
10.	Koji Yamaguchi, Tetsuzo Wakatsuki, Y Okushi, Kumiko Suto, Kazuhisa Matsumoto, Tomonori Takahashi, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Early and chronic phased local coagulative responses following bioresorbable-polymer drug-eluting stent implantation, European Heart Journal, Vol.42, No.S1, ehab724.1245, Aug. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1093/eurheartj/ehab724.1245 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/eurheartj/ehab724.1245 (DOI: 10.1093/eurheartj/ehab724.1245)
11.	Miharu Arase, Kenya Kusunose, Sae Morita, N Yamaguchi, Yukina Hirata, Susumu Nishio, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Clinical Utility of Noninvasive Assessment of Flow-pressure Relationship in Scleroderma, American Heart Associeition, Dallas, Nov. 2020.
12.	Y Okushi, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Differences ofCancer Types in Hospital Mortality in Patients With Venous Thromboembolism, American Heart Association, Dallas, Nov. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1161/circ.142.suppl_3.13145 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1161/circ.142.suppl_3.13145 (DOI: 10.1161/circ.142.suppl_3.13145)
13.	Koji Yamaguchi, Tetsuzo Wakatsuki, Tomonori Takahashi, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Suppressed Local Coagulative Response After Newer-generation Ultrathin Strut SES Implantation Compared to Older-generation SES Implantation, American Heart Association, Dallas, Nov. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1161/circ.142.suppl_3.12894 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1161/circ.142.suppl_3.12894 (DOI: 10.1161/circ.142.suppl_3.12894)
14.	Takeshi Soeki, Kazuhisa Matsumoto, Daiju Fukuda, E Uematsu, Tomomi Matsuura, Takeshi Tobiume, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Toll-like receptor 9 is a novel therapeutic target to prevent atrial fibrillation, European Heart Journal, Vol.41, No.S2, ehaa946.0463, Aug. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1093/ehjci/ehaa946.0463 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/ehjci/ehaa946.0463 (DOI: 10.1093/ehjci/ehaa946.0463)
15.	Kenya Kusunose, Nishio Susumu, Hirata Yukina, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Pulmonary Artery Hypertension Specific Therapy Improves Exercise Tolerance and Outcomes in Exercise-Induced Pulmonary Hypertension, JACC. Cardiovascular Imaging, Vol.12, No.12, 2576-2579, Dec. 2019. (Keyword) Adult / Aged / Antihypertensive Agents / Arterial Pressure / Disease Progression / Echocardiography, Stress / Exercise / Exercise Tolerance / Female / Humans / Male / Middle Aged / Progression-Free Survival / Prospective Studies / Pulmonary Arterial Hypertension / Pulmonary Artery / Recovery of Function / Time Factors / Vasodilator Agents / Walk Test (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2019.07.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31422131 ● Search Scopus @ Elsevier (PMID): 31422131 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcmg.2019.07.002 (DOI: 10.1016/j.jcmg.2019.07.002, PubMed: 31422131)
16.	Yutaka Kawabata, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Daiju Fukuda, Takeshi Soeki and Masataka Sata : The relationship among local epicardial adipose tissue, coronary intraplaque microluminal structure, and coronary plaque formation -a fresh cadaveric study, AHA2019, Philadelphia, Nov. 2019.
17.	B Ganbaatar, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : S1p2 Receptor Antagonist Attenuates Endothelial Dysfunction And Inhibits Atherogenesis In Apolipoprotein-e-deficient Mice, AHA2019, Philadelphia, Nov. 2019.
18.	Sutou Kumiko, Daiju Fukuda, B Ganbaatar, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Pemafibrate, a novel selective peroxisome proliferator-activated receptor-a modulator, ameliorated diabetes-induced endothelial dysfunction, AHA2019, Philadelphia, Nov. 2019.
19.	A Kunduziayi, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Vildagliptin, a DPP-4 inhibitor, attenuates endothelial dysfunction and atherogenesis independent of its glucose lowering effect in apolipoprotein e-deficient mice, AHA2019, Philadelphia, Nov. 2019.
20.	Shusuke Yagi and Masataka Sata : Increased advanced glycation end products are a risk factor of epicardial adipose tissue thickness, AHA2019, Philadelphia, Nov. 2019.
21.	Naoji Mita, Shinji Kawahito, Tomohiro Soga, Shusuke Yagi, Kazumi Takaishi and Hiroshi Kitahata : Can strict blood glucose control by an artificial pancreas during hepatectomy improve patient outcomes?, The 8th Meeting of the International Federation for Artificial Organs, Osaka, Nov. 2019.
22.	Byambasuren Ganbaatar, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfuntion and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in disbetic apolipoprotein E-deficient, ESC Congress 2019, Paris, Sep. 2019.
23.	Koji Yamaguchi, Tetsuzo Wakatsuki, Rie Ueno, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : The improvement of chronic local coagulative response according to the progress of drug eluting stent, ESC Congress 2019, Paris, Sep. 2019.
24.	Maimaituxun Gulinu, Kenya Kusunose, Daiju Fukuda, Shusuke Yagi, Yuta Torii, Yukina Hirata, Susumu Nishio, nao Yamada, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Michio Shimabukuro : Impact of epicardial adipose tissue on global longitudinal strain: a study in patients with normal left ventricular ejection fraction, ESC Congress 2019, Paris, Sep. 2019.
25.	Maimaituxun Gulinu, Daiju Fukuda, Shusuke Yagi, Shoichiro Takao, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada, Masataka Sata and Michio Shimabukuro : Adipose tissue surrounding the kidney and its impact on coronary artery disease, ESC Congress 2019, Paris, Sep. 2019.
26.	Rahadian Arief, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfuntion in diabetic apolipoprotein e-deficient mice, ESC Congress 2019, Paris, Aug. 2019.
27.	Phuong Tran Pham, D Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, a Direct Inhibitor of Factor Xa, Attenuates Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mice Through the Inhibition of Protease-Activated Receptor 2 Signaling, AHA, Chicago, Nov. 2018.
28.	Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Inhibition of Thrombin-PARs Signaling by Dabigatran, a Direct Thrombin Inhibitor, Attenuates Endothelial Dysfunction in Diabetic Mice, AHA, Chicago, Nov. 2018.
29.	Y Saijo, Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yuta Torii, Y Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Right Ventricular Contractile Function Predicts Cardiac Events in Passive and Reactive Pulmonary Hypertension, AHA, Chicago, Nov. 2018.
30.	Ganbaatar Byambasuren, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Inhibition of S1P2 receptor ameliorates endothelial dysfunction and prevents atherogenesis in apolipoprotein-E-deficient Mice, ESC2018, Munich, Aug. 2018.
31.	Takeshi Soeki, E Uematsu, Tomomi Matsuura, Takeshi Tobiume, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : C-type natriuretic peptide improves left ventricular diastolic dysfunction and ischemia/reperfusion injury-associated ventricular arrhythmias., ESC2018, Munich, Aug. 2018.
32.	Hiroyuki Ito, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yutaka Kawabata, Takafumi Todoroki, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Growth of vasa vasorum is associated with local inflammation around coronary plaque in fresh cadavers, ESC2018, Munich, Aug. 2018.
33.	Ganbaatar Byambasuren, Daiju Fukuda, HM Salim, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Atheroprotective effects of ticagrelor, a P2Y12 antagonist, in apolipoprotein-E-deficient mice, ESC2018, Munich, Aug. 2018.
34.	Maimaituxun Gulinu, Michio Shimabukuro, Daiju Fukuda, Shusuke Yagi, Hirata Yukina, Takashi Iwase, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Gender disparities of distribution of epicardial adipose tissue and its impact on coronary artery disease, ESC2018, Munich, Aug. 2018.
35.	Takeshi Soeki, Tomomi Matsuura, E Uematsu, Takeshi Tobiume, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Epicardial Adipose Tissue Produces Proinflammatory Cytokines and Influences the Pathogenesis of Atrial Fibrillation, AHA Scientific Sessions2017, California, America, Nov. 2017.
36.	Maimaituxun. Gulinu, Michio Shimabukuro, Y Hirata, Takashi Iwase, S Takao, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, M Harada and Masataka Sata : Local Epicardial Adipose Tissue Thickness in Left Anterior Descending Artery Provides a New Prediction Model for Coronary Artery Disease, AHA Scientific Sessions2017, California, America, Nov. 2017.
37.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, Y Torii, Yukina Hirata, H Seno, Y Saijo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Echocardiography Predicts Outcomes in Patients With Preserved Ejection Fraction and Low Gradient Aortic Stenosis, AHA Scientific Sessions2017, California, America, Nov. 2017.
38.	Takeshi Soeki, Tomomi Matsuura, Daiju Fukuda, Etsuko Uematsu, Takeshi Tobiume, T Hara, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Activated Factor X Signaling Pathway via Protease-Activated Receptor-2 is a Novel Therapeutic Target to Prevent Atrial Fibrillation, AHA Scientific Sessions2017, California, America, Nov. 2017.
39.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, H Ito, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Preserved Endothelial Function and Suppressed Local Coagulative and Inflammatory Response After Biodegradable Polymer SES Implantation Compared to Durable Polymer SES, AHA Scientific Sessions2017, California, America, Nov. 2017.
40.	Tomomi Matsuura, Takeshi Tobiume, Takeshi Soeki, R Kato, M Hara, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Direct Slow Pathway Capture: A New Electrophysiological Method of Catheter Ablation for Atrioventricular Nodal Reentrant Tachycardia, AHA Scientific Sessions2017, California, America, Nov. 2017.
41.	Susumu Nishio, Kenya Kusunose, Hirotsugu Yamada, Yukina Hirata, H Seno, Y Saijo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Echocardiographic Epicardial Adipose Tissue Thickness is a Marker for the Detection of Vasospastic Angina, ASE2017, Baltimore, Jun. 2017.
42.	Shusuke Yagi, Takayuki Ise, Masashi Akaike and Masataka Sata : Adaptive Servo-ventilation Supported Exercise Increases Exercise Capacity in Patients With Severe Heart Failure, AHA Scientific Sessions 2016, New Orleans, Nov. 2016.
43.	Kenya Kusunose, Hirotsugu Yamada, Y Saijo, H Seno, Y Hirata, Y Torii, S Nishio, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Longitudinal Strain Distribution is a Powerful Predictor for Functional Recovery in Patients With Tachycardia-induced Cardiomyopathy, AHA Scientific Sessions 2016, New Orleans, Nov. 2016.
44.	HMM Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Dabigatran, a direct thrombin inhibitor, prevents the development of endothelial dysfunction in diabetic mice, 19th International Vascular Biology Meeting, Boston, Nov. 2016.
45.	HMM Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Glycemic control with canagliflozin, a SGLT2 inhibitor, inhibited inflammation in the vascular and adipose tissue, and ameliorated vascular complication in diabetic mice, 19th International Vascular Biology Meeting, Boston, Nov. 2016.
46.	Shusuke Yagi and Masataka Sata : Reduced levels of eicosapentaenoic acid and docosahexaenoic acid on admission predict in-stent restenosis in patients with acute coronary syndrome, 19th International Vascular Biology Meeting, Boston, Nov. 2016.
47.	Shusuke Yagi and Masataka Sata : The effects of edoxaban on thrombin generation and anti-coagrant systems in patients with acute venous thromboembolism, 19th International Vascular Biology Meeting, Boston, Nov. 2016.
48.	Daiju Fukuda, S Nishimoto, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Cell free DNA/Toll-like receptor 9 axis plays a pivotal role in chronic inflammation induced by metabolic disorders, leading to atherogenesis and insulin resistance, 19th International Vascular Biology Meeting, Boston, Nov. 2016.
49.	Nishimoto Sachiko, Daiju Fukuda, Higashikuni Yasutomi, Tanaka Kimie, Hirata Yoichiro, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Michio Shimabukuro and Masataka Sata : Genetic deletion of TLR9 promotes blood flow recovery in hind limb ischemia, 19th International Vascular Biology Meeting, Nov. 2016.
50.	Kenya Kusunose, Hirotsugu Yamada, H Seno, Y Saijo, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Longitudinal Strain Distribution is a Powerful Predictor for Functional Recovery in Patients with Tachycardia-induced Cardiomyopathy, KSC2016(The 60th Annual Scientific Meeting of The Korean Society of Cardiology), Seoul, Sep. 2016.
51.	Takeshi Soeki, Tomomi Matsuura, E Uematsu, S Bando, Takeshi Tobiume, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Increased local production of C-type natriuretic peptide in patients with vasospastic angina, ESC Congress 2016, Rome, Aug. 2016.
52.	Koji Yamaguchi, Tetsuzo Wakatsuki, R Ueno, H Ito, Takayuki Ise, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Paclitaxel eluting balloon angioplasty equals everolimus eluting stent implantation in local coagulative and inflammatory responses in stable angina patients, ESC Congress 2016, Rome, Aug. 2016.
53.	T Matsuura, Takeshi Soeki, E Uematsu, S Bando, Takeshi Tobiume, T Hara, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Oral Direct Factor Xa Inhibitor Prevents Atrial Fibrillation by Inhibiting Inflammation in Rapidly Paced Spontaneously Hypertensive Rats, ESC Congress 2016, Rome, Aug. 2016.
54.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi and Masahiro Abe : Pleiotropic Effects of Pitavastatin against Vascular Stress in eNOS-deficient Mice, The 10th Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases, Tokyo, Jul. 2016.
55.	H Seno, Kenya Kusunose, Hirotsugu Yamada, Y Saijo, S Nishio, Y Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Comparison of Right Ventricular Global Longitudinal Strain Between Vender-Dependent and Vender-Independent Two-Dimensional Speckle Tracking Software, ACC Scientific Sessions 2016, Chicago, Apr. 2016.
56.	S Bando, Takeshi Soeki, Tomomi Matsuura, Takeshi Tobiume, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Atrial Late Potentials and Atrial Substrate Remodeling in Patients With Atrial Fibrillation., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
57.	HM Salim, Daiju Fukuda, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, Ameliorates Endothelial Dysfunction and Atherogenesis in Apolipoprotein-e Deficient Mice Through GLP-1 Dependent and Independent Manners., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
58.	Takeshi Soeki, S Bando, Tomomi Matsuura, Takeshi Tobiume, E Uematsu, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Combination Of Clinical, Electrocardiographic and Echocardiographic Parameters Predict the Onset of Atrial Fibrillation., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
59.	T Hara, Daiju Fukuda, K Tanaka, Y Higashikuni, Y Hirata, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Hematopoietic Protease-activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in ApoE-Deficient Mice., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
60.	S Nishimoto, Daiju Fukuda, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Michio Shimabukuro and Masataka Sata : Toll-like Receptor 9 Plays a Pivotal Role in Angiotensin II-induced Atherosclerosis., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
61.	Kenya Kusunose, Hirotsugu Yamada, Mika Bando, S Nishio, Y Hirata, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Pressure-flow Relationship of Pulmonary Circulation Determines Six-minute Walk Distance in Connective Tissue Disease., AHA Scientific Sessions 2015, Orlando, Nov. 2015.
62.	R Hashimoto, Michio Shimabukuro, HM Salim, T Hara, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Antagonism of protease-activated receptor 2 (PAR-2) rescues vascular endothelial dysfunction in diabetic mice., ESC Congress 2015, London, Aug. 2015.
63.	S Nishimoto, Daiju Fukuda, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Michio Shimabukuro and Masataka Sata : The activation of toll-like receptor 9 deteriorates blood flow recovery after hind-limb ischemia., ESC Congress 2015, London, Aug. 2015.
64.	Koji Yamaguchi, Tetsuzo Wakatsuki, A Takashima, Mika Bando, S Bando, Tomomi Matsuura, Takayuki Ise, Junko Hotsuchi, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Differential response of local coagulation after implantation of new generation drug-eluting stents compared with sirolimus-eluting stent., AHA Scientific Sessions 2014, Chicago, Nov. 2014.
65.	S Nishimoto, Daiju Fukuda, Y Higashikuni, K Tanaka, Y Hirata, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Michio Shimabukuro and Masataka Sata : Genetic deletion of toll-like receptor 9 accelerates blood flow recovery after hindlimb ischemia., AHA Scientific Sessions 2014, Chicago, Nov. 2014.
66.	T Hara, D Fukuda, K Tanaka, Y Higashikuni, Y Hirata, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, a direct factor Xa inhibitor, attenuates neointima formation after mechanical vascular injury., AHA Scientific Sessions 2014, Chicago, Nov. 2014.
67.	H Yamazaki, Tetsuzo Wakatsuki, Koji Yamaguchi, K Imada, K Matsumoto, Y Takagawa, E Takagi, Y Saijo, T Hara, Y Saito, Mika Bando, A Takashima, S Bando, Tomomi Matsuura, Takayuki Ise, Junko Hotsuchi, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Differential responses of local coagulation after implantation of second-generation drug-eluting stent compared with first-generation drug-eluting stents., AHA Scientific Sessions 2014, Chicago, Nov. 2014.
68.	Michio Shimabukuro, Masayoshi Ishida, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki and Masataka Sata : Post-transcriptional regulation of adiponectin by microRNA-378 in adipose tissue: a novel mechanism for hypoadiponectinemia., ESC 2014, Barcelona, Aug. 2014.
69.	Junko Hotsuchi, Hirotsugu Yamada, Y Saijo, Mika Bando, S Hayashi, S Nishio, M Yamano, Y Torii, Y Hirata, R Amano, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Serial Changes of Exercise Stress Echocardiographic Parameters in Patients with Connective Tissue Disease without Overt Pulmonary Hypertension., ASE 2014, Portland, Jun. 2014.
70.	Y Saijo, Hirotsugu Yamada, Junko Hotsuchi, S Nishio, S Hayashi, Mika Bando, Y Hirata, R Amano, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Right ventricular systolic dysfunction in patients with exercise-induced pulmonary hypertension associated with connective tissue disease., ACC 2014, Washington, D.C., Mar. 2014.
71.	T Hara, Daiju Fukuda, K Tanaka, Y Higashikuni, Y Hirata, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, A Novel Oral Anticoagulant, Attenuates Plaque Progression in ApoE-Deficient Mice Through the Inhibition of Pro-Inflammatory Activation of Macrophages., American Heart Association AHA 2013, Dallas, Nov. 2013.
72.	Koji Yamaguchi, Takeshi Soeki, Tetsuzo Wakatsuki, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada and Masataka Sata : Impact Of Indoxy1 Sulfate, A Uremic Toxin, On Non-culprit Coronary Plaque Composition Assessed By Integrated Backscatter Intravascular Ultrasound In Patients With Coronary Artery Disease., American Heart Association AHA 2013, Dallas, Nov. 2013.
73.	Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Decreased Local Hypercoagulation after Implantation of Everolimus-Eluting and Zotarolimus-Eluting Stents Compared with Early-Generation Drug-Eluting Stents in patients with stable angina., American Heart Association AHA 2013, Dallas, Nov. 2013.
74.	Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Time-dependent Changes Of Local Vascular Response And Angiographic Peri-stent Contrast Staining Up To Five Years After Zotarolimus-eluting, Sirolimus-eluting, And Bare Metal Stent Implantation., American Heart Association AHA 2013, Dallas, Nov. 2013.
75.	S Nishimoto, Daiju Fukuda, Michio Shimabukuro, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Yutaka Nakaya and Masataka Sata : Macrophage Toll-like Receptor 9 Signaling Contributes to the Development of Insulin Resistance through the Promotion of Inflammation in Adipose Tissue., American Heart Association AHA 2013, Dallas, Nov. 2013.
76.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : Post-Transcriptional Regulation of Adiponectin by Micro-RNA 378 in Human Visceral and Subcutaneous Adipose Tissue., American Heart Association AHA 2013, Dallas, Nov. 2013.
77.	S Bando, Takeshi Soeki, T Matsuura, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro, Kenji Kangawa and Masataka Sata : Plasma Brain Natriuretic Peptide (BNP) level is elevated in patients with cancer., ESC Congress 2013, Amsterdam, Aug. 2013.
78.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : Differentiation of left ventricular systolic dysfunction related to cardiac sarcoidosis and other heart diseases using contrast-enhanced cardiovascular magnetic resonance., ESC Congress 2013, Amsterdam, Aug. 2013.
79.	K Nishikawa, Shusuke Yagi, Takayuki Ise, Yuka Ueda, Takashi Iwase, Masashi Akaike, Michio Shimabukuro, Shinsuke Katoh and Masataka Sata : Visceral fat mass is associated with daily physical activity, leg skeletal muscle mass and fiber intake in healthy men., ESC Congress 2013, Amsterdam, Aug. 2013.
80.	Koji Yamaguchi, Tetsuzo Wakatsuki, Toshiyuki Niki, Yoshio Taketani, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Differential responses of local coagulation after implantation of everolimus-eluting and zotarolimus-eluting stents compared with early-generation drug-eluting stents in patients with stable angina., ESC Congress 2013, Amsterdam, Aug. 2013.
81.	S Nishimoto, Daiju Fukuda, Michio Shimabukuro, S Matsumoto, Masayoshi Ishida, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Yutaka Nakaya and Masataka Sata : Genetic ablation of TLR9 improves insulin resistance through macrophage accumulation in adipose tissue., ESC Congress 2013, Amsterdam, Aug. 2013.
82.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : MicroRNA-100 regulates a cluster of adipocytokine expression: A human biopsy study in subcutaneous and visceral adipose tissue., ESC Congress 2013, Amsterdam, Aug. 2013.
83.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : MicroRNA miR-378 regulates adipocytokine fate by targeting transcriptional factors in human visceral and subctaneous adipose tissue., ESC Congress 2013, Amsterdam, Aug. 2013.
84.	S Hayashi, Hirotsugu Yamada, S Nishio, N Tomita, J Hotchi, Mika Bando, Takayuki Ise, Toshiyuki Niki, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Augmentation Index Measured by Tonometry Significantly Underestimates Atrial Stiffness in Ischemic Heart Disease in Japanese Population., 第77回日本循環器学会学術集会, Yokohama, Mar. 2013.
85.	Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, M Kadota, T Hara, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute Hemodynamic Effects of Adaptive Servo-Ventilation in Patients with Chronic Left Heart Failure., AHA Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
86.	Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Sumiko Yoshida, Yasumasa Ikeda, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma heparin cofactor II activity is an independent determinant for cardiac remodeling in subjects with cardiovascular risk factors, 20th International Society for Heart Research(ISHR), Kyoto, May 2010.
87.	Ken-ichi Aihara, Yuka Ueda, Takayuki Ise, Sumiko Yoshida, Yasumasa Ikeda, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Heparin cofactor II is a novel anticardiac remodeling factor against angiotensin II excess, 20th International Society for Heart Research(ISHR), Kyoto, May 2010.
88.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, K. Ishikawa, S. Yoshida, Yuka Ueda, Shusuke Yagi, Takashi Iwase, T. Matsumoto and Masataka Sata : Glucocorticoid causes vascular endothelial dysfunction through activation of mineralocorticoid receptor., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
89.	Ken-ichi Aihara, T. Ise, Yuka Ueda, S. Yoshida, Yasumasa Ikeda, R. Uemoto, Shusuke Yagi, Takashi Iwase, Y. Hirata, Masashi Akaike, Masataka Sata and T. Matsumoto : Plasma heparin cofactor II activity is an independent determinant for cardiac remodeling in subjects with cardiovascular risk factors., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
90.	Yuka Ueda, Ken-ichi Aihara, T. Ise, S. Yoshida, Yasumasa Ikeda, R. Uemoto, Shusuke Yagi, Takashi Iwase, Y. Hirata, Masashi Akaike, Masataka Sata and T. Matsumoto : Heparin cofactor II is a novel anticardiac remodeling factoragainst angiotensin II excess., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
91.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Suzuki Reiko, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, 14th International Congress of Endocrinology, Kyoto, Mar. 2010.
92.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo, Shusuke Yagi, T Niki, Kenya Kusunose, N Tomita, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masafumi Harada, Hiromu Nishitani and Masataka Sata : Utility of Cardiac Magnetic Resonance for Detection of Cardiac Involvement in Female Carriers of Duchenne Muscular Dystrophy., 第74回日本循環器学会総会・学術集会, Mar. 2010.
93.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, Takashi Iwase, Masashi Akaike, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Suzuki Reiko, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, 14th International Congress of Endocrinology, Kyoto, Japan, Mar. 2010.
94.	Yuka Ueda, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Exacerbation of Angiotensin ll-induced Cardiac Remodeling through Enhancement of NADPH oxidase-TGF- 1 Pathway in Heparin Cofactor ll-Deficient Mice, Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
95.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Nishio Susumu, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is an endothelial function-independent protective factor against carotid atherosclerosis., Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
96.	Ken-ichi Aihara, Mizuho Kinouchi, Yuichi Fujinaka, Sumiko Yoshida, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
97.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Predictors of Local Persistent Hypercoagulability After Sirolimus-eluting Stent Implantation: Implication for Correlates of Late Stent Thrombosis., American Heart Association 2009, Nov. 2009.
98.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, K Endo, H Takashima, C Mimura, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Prognostic Value of Changes in Transmitral Flow Velocity Pattern During Leg Positive Pressure in Mild Heart Failure: A Clinical Application of "Preload Stress Echocardiography", American Heart Association 2009, Nov. 2009.
99.	Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response After Coronary Artery Stenting. Bare Metal vs Sirolimus-Eluting vs Paclitaxel-Eluting Stent., American Heart Association 2009, Nov. 2009.
100.	Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response After Coronary Artery Stenting with Drug-Eluting Stent., American Heart Association 2009, Nov. 2009.
101.	Kunihiko Koshiba, Takeshi Soeki, T Niki, Kenya Kusunose, Y Hirata, Koji Yamaguchi, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Kenji Kangawa and Masataka Sata : C-type Natriuretic Peptide Ameliorates the Progression of Experimental Autoimmune Myocarditis., American Heart Association 2009, Nov. 2009.
102.	Y Fukuda, Takeshi Soeki, N Fukuda, S Morishita, K Sakabe, H Shinohara, Y Tamura, Masashi Akaike, Tetsuzo Wakatsuki, Hirotsugu Yamada, Takashi Iwase, Shusuke Yagi, Kunihiko Koshiba, Koji Yamaguchi, Kenya Kusunose, T Niki and Masataka Sata : Pentraxin 3, a Novel Inflammatory Marker, Predicts Left Ventricular Remodeling in Patients with Acute Myocardial Infarction., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
103.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, S Yoshida, Y Sumitomo, Ken-ichi Aihara, Toshio Matsumoto and Masataka Sata : Bosentan, an Endothelin Receptor Antagonist, Exerts Protective Actions against Systemic Sclerosis-related Peripheral Circulation Insufficiency., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
104.	Y Hirata, H Iwata, K Nakamura, Y Sakai, N Tomita, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Synthetic Prostacycline Agonist, ONO-1301, Ameliorates Left Ventricular Dysfunction and Cardiac Fibrosis in Cardiomyopathic Hamsters., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
105.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Prediction of Cardiac Response to Preload Augmentation by Dual Doppler Echocardiography and Left Arial Volume Auto Tracking System., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
106.	M Yamanaka, Hirotsugu Yamada, Kenya Kusunose, N Tomita, S Nishio, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinji Nagahiro and Masataka Sata : Utilization of Echocardiography in Stroke Care Unit of Tokushima University Hospital., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
107.	Takeshi Soeki, T Niki, Kunihiko Koshiba, Y Hirata, N Tomita, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, H Satoh and Masataka Sata : Plasma Concentration of Pentraxin 3 is a Useful Marker for Monitoring the Anti-plaque Effect of Telmisartan., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
108.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, S Yoshida, Y Sumitomo, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Pitavastatin Exerts LDL Cholesterol Reduction-independent Protective Action for Cardiac and Renal Function in Patients with Dyslipidemia., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
109.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, S Yoshida, Y Sumitomo, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Plasma Aldosterone Concentration is Associated with Cognitive Impairement in Patients with Hypertension., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
110.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, N Tomita, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local Persistent Hypercoagulability after Drug-Eluting Stent Implantation: Sirolimus-Eluting Stent vs. Paclitaxel-Eluting Stent., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
111.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo, Shusuke Yagi, T Niki, Kenya Kusunose, N Sakamoto, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masafumi Harada, Hiromu Nishitani and Masataka Sata : Early Detection of Myocardial Damage in Female Carriers of Duchenne Muscular Dystrophy - the Utility of Cardiac Magnetic Resonance., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
112.	Hirotsugu Yamada, Kenya Kusunose, N Tomita, S Nishio, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Angiotensin-II Receptor Blocker Prevents the Deterioration of Left Ventricular Geometry and Diastolic Function in Hypertrophic Cardiomyopathy., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
113.	Takeshi Soeki, Kunihiko Koshiba, T Niki, Y Hirata, N Tomita, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Effect of Ghrelin on Autonomic Activity in Healthy Volunteers., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
114.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Elevation of Left Ventricular End-diastolic Pressure Enhances Mismatch between Mitral Inflow and Annular Motion., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
115.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical utility of B-Flowimaging on ultrasound examination of carotid artery., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
116.	M Yamanaka, Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Postsystolic Shortening is Superior to Peak Systolic Strain on the Prediction of Ischemia in Normal Wall Motion Segments., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
117.	Tetsuzo Wakatsuki, Koji Yamaguchi, T Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response after Coronary Artery Stenting -BMS vs. SES vs. PES-, 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
118.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : The Mitral L-wave Predicts Adverse Response to Volume Overloading in Patients with Atrial Fibrillation., 58th American College of Cardiology, Mar. 2009.
119.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Tricuspid Annular Velocity Profile by Pulsed Tissue Doppler Imaging for the Assessment of Serial Change of Pulmonary Artery Pressure in Secondary Pulmonary Hypertension., 58th American College of Cardiology, Mar. 2009.
120.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Increased serum triglyceride but not LDL cholesterol is associated with left ventricular diastolic dysfunction., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
121.	Takayuki Ise, Ken-ichi Aihara, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Ishikawa Kazue, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma Heparin Cofactor II Activity Is Inversely Associated with Left Atrial Volume and Left Ventricular Diastolic Dysfunction., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
122.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is an antivascular remodeling factor in elderly individuals., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
123.	Takashi Iwase, Hirotsugu Kurobe, Masashi Akaike, Shunji Nakano, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Ken-ichi Aihara, Shuji Ozaki, Masahiro Abe, Natsuo Yasui, Toshio Matsumoto, Tetsuya Kitagawa and Masataka Sata : Erythropoietin administration with autologous blood donation - a novel strategy to enhance mobilization of circulating progenitor cells, American Heart Association Sessions 2008, New Orleans, Nov. 2008.
124.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, Ishikawa Kazue, Sumitomo Yuka, Sumiko Yoshida, Takashi Iwase, Toshio Matsumoto and Masataka Sata : Pitavastatin, an HMG-CoA Reductase Inhibitor, Prevents Glucocorticoid-induced Hypertension through Ameliorating Imbalance of Oxidative Stress and Nitric Oxide Production, American Heart Association Sessions 2008, New Orleans, Nov. 2008.
125.	Tetsuzo Wakatsuki, K Yamaguchi, T Niki, Kenya Kusunose, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : Long-term endothelial dysfunction after coronary artery stenting with drug-eluting stent associated with local inflammatory response., American Heart Association 2008, New Orleans, Nov. 2008.
126.	K Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, K Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local hypercoagulability and endothelial dysfunction after sirolimus-eluting stent implantation: implication for late stent thrombosis., American Heart Association 2008, New Orleans, Nov. 2008.
127.	Masashi Akaike, Ken-ichi Aihara, Shusuke Yagi, Yasumasa Ikeda, Ishikawa Kazue, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Takashi Iwase and Toshio Matsumoto : Pitavastatin, an HMG-CoA Reductase Inhibitor, Prevents Glucocorticoid-induced Hypertension through Increased Nitric Oxide Production as a Pleiotropic Effect on Vascular Endothelial Cells, Hypertension 2008 18th Scientific Meeting of the European Society of Hypertension 22nd Scientific Meeting of the International Society of Hypertension, Berlin, Jun. 2008.
128.	Takashi Iwase, Masashi Akaike, Shunji Nakano, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Ken-ichi Aihara, Natsuo Yasui and Toshio Matsumoto : Single erythropoietin administration with autologous blood donation - a novel strategy to enhance mobilization of endothelial progenitor cells, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
129.	Sumitomo Yuka, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Acceleration of angiotensin II-induced cardiac remodeling through enhancement of oxidative stress in heparin cofactor II knockout mice, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
130.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Dehydroepiandrosterone sulfate regulates carotid blood flow in elderly individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
131.	Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Serum Lipid Disorder is Associated with Left Ventricular Diastolic Dysfunction in Elderly Individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
132.	Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : The active form of vitamin D, 1,25(OH)2D3, prevents vascular remodeling and glucose intolerance in elderly individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
133.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Sumitomo Yuka, Masataka Sata, Kato Shigeaki and Toshio Matsumoto : Heparin Cofactor II Deficiency Causes Accelerated Thrombosis and Atherosclerosis in Mice, American Heart Association Scientific Sessions 2006, Chicago, USA, Nov. 2006.
134.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Fujimura Mitsunori, Hashizume Shunji, Takashi Iwase, Shusuke Yagi, Kondo Akira, Hiroyuki Azuma and Toshio Matsumoto : Valsartan Enhances Nitric Oxide Bioavailability and Reduces Arterial Stiffness in Patients with Essential Hypertension, The 21st Scientific Meeting of the International Society of Hypertension, 2006, Fukuoka, Japan, Oct. 2006.
135.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Fujimura Mitsunori, Shusuke Yagi, Hashizume Shunji, Yasumasa Ikeda, Takashi Iwase, Takamori Nobuyuki, Tetsuya Kitagawa and Toshio Matsumoto : Plasma Heparin Cofactor II Activity is a Predictor for Incidence of Peripheral Arterial Disease in Patients with Cardiovascular Risk Factors, XIV International Symposium on Atherosclerosis, 2006 Rome, Italy, Jun. 2006.
136.	Ken-ichi Aihara, Mihara Masatomo, Hiroyuki Azuma, Masashi Akaike, Takaya Matsushita, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Hashizume Shunji, Fujimura Mitsunori and Toshio Matsumoto : Argatroban, a synthetic thrombin antagonist, can reduce insulin resistance though thrombin inactivation in the db/db mouse model of type 2 diabetes mellitus, XIV International Symposium on Atherosclerosis, 2006 Rome, Italy, Jun. 2006.
137.	R Bando, Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Predictors of late lumen enlargement after drug coated balloon angioplasty for denovo coronary lesions, ACC 2024, Atlanta, Apr. 202.

Proceeding of Domestic Conference:

1.	八木一成, Shusuke Yagi, 相原泰, 松山和男, Masaki Yamamoto, 石田卓也, Hiroto Yoneda, Keisuke Nakanishi, Yasuhiko Nishioka, Masataka Sata and Tetsuya Kitagawa : 一般演題1「末梢動脈1(手技，合併症)」急激に指趾壊疽が進行した1例, 日本血管外科学会中国四国地方会第54回総会, Aug. 2024.
2.	FUJIMOTO Saori, 古本みゆ, 石井亜由美, 西川幸治, 小河ゆか, 筑後桃子, 橋本脩平, 小笠有加, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, 鈴木佳子, Masataka Sata and 阪上浩 : 経口補助食品を用いた栄養・水分管理が有効であった冠状動脈バイパス術後の透析患者の一例, 第30回日本心臓リハビリテーション学会学術集会, Jul. 2024.
3.	古本みゆ, FUJIMOTO Saori, 石井亜由美, 西川幸治, 東條恵, 濱野愛莉沙, 粟田由佳, 西麻希, 山田静恵, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, Yoshiko Suzuki, Masataka Sata and 阪上浩 : 体組成評価を用いた栄養管理が効果的であった高度肥満合併の若年心不全患者の心臓リハビリの一例, 第30回日本心臓リハビリテーション学会学術集会, Jul. 2024.
4.	Yoshiko Suzuki, FUJIMOTO Saori, 古本みゆ, 石井亜由美, 西川幸治, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, Masataka Sata and 阪上浩 : 徳島大学病院の心臓リハビリテーションでの栄養管理の取り組み, 第30回日本心臓リハビリテーション学会学術集会, Jul. 2024.
5.	石井亜由美, Takayuki Ise, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : 心リハ専従看護師の役割と他部門連携, 第30回日本心臓リハビリテーション学会学術集会, Jul. 2024.
6.	Takayuki Ise, 石井亜由美, 西川幸治, Muneyuki Kadota, Rie Ueno, Shusuke Yagi, Hirokazu Ohminami, Yutaka Taketani and Masataka Sata : 進歩するSHDに対する治療と心臓リハビリテーション, 第30回日本心臓リハビリテーション学会学術集会, Jul. 2024.
7.	Tserensonom Munkhtsetseg, Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Muneyuki Kadota, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 経カテーテル的大動脈弁置換術後血清Lp【a】の上昇は予後不良のリスクファクター, 第45回日本循環制御医学会総会・学術集会, Jun. 2024.
8.	Yoshihito Saijyo, Hirotsugu Yamada, Zengu Robahto, TOMONORI Takahashi, BANDO Ryo, TAKAHASHI Tomoko, Tomoya Hara, Muneyuki Kadota, Yutaka Kawabata, Rie Ueno, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, 笹聡一郎, 滝沢宏光 and Masataka Sata : Mechanical circulatory supportを要した重症がん治療関連心機能障害の1例, 第124回日本循環器学会中国・四国合同地方会, Jun. 2024.
9.	八木一成, Shusuke Yagi, Yoshihito Saijyo, TAKAHASHI Tomoko, Zengu Robahto, BANDO Ryo, TOMONORI Takahashi, Tomoya Hara, Muneyuki Kadota, Yutaka Kawabata, Rie Ueno, Tomomi Matsuura, 伊勢孝之, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, 秦広樹 and 菅野幹雄 : 心室中隔欠損症・感染性心内膜炎を合併した大動脈縮窄証による二次性高血圧症の一例, 第124回日本循環器学会中国・四国合同地方会, Jun. 2024.
10.	Shusuke Yagi, BANDO Ryo, Koji Yamaguchi, Takeshi Soeki, Masashi Akaike, Tetsuzo Wakatsuki and Masataka Sata : 腎血管性高血圧を合併した左室駆出率の保たれた心不全の1例, 第130回日本内科学会四国地方会, Jun. 2024.
11.	Shusuke Yagi, Takeshi Soeki, Masashi Akaike and Masataka Sata : 高血圧患者における塩分摂取量の特徴の検討, 第130回日本内科学会四国地方会, Jun. 2024.
12.	BOLLOS CHRISTINE ANNE LEAH LOCSIN, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Tomomi Matsuura, Tamaki Otani, BANDOH Takanori, UEKI Yuya, MATSUDA Noritake, 高志智, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis After Atrial Fibrillation Ablation, 第268回徳島医学会学術集会, Mar. 2024.
13.	Ryo Bando, Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, TOMONORI Takahashi, Hayato Orino, Issei Yagi, TOMONORI Takahashi, Zheng Robert, Yoshihito Saijyo, Tomoya Hara, Muneyuki Kadota, Tomomi Matsuura, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Predictors of Late Lumen Enlargement after Drug Coated Balloon Angioplasty for de Novo Coronary Lesions, 第88回日本循環器学会学術集会 JCS2024, Mar. 2024.
14.	Yutaka Kawabata, Koji Yamaguchi, Tetsuzo Wakatsuki, TOMONORI Takahashi, BANDO Ryo, Yoshihito Saijyo, Muneyuki Kadota, Tomomi Matsuura, Takayuki Ise, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Microvasculature and Gene Expression in Pericoronary Adipose Tissue According to Coronary Plaque Progression Stage in Fresh Cadavers, 第88回日本循環器学会学術集会, Mar. 2024.
15.	Yoshihito Saijyo, Hirotsugu Yamada, 長野絋平, 折野逸人, 八木一成, TAKAHASHI Tomoko, Zengu Robahto, BANDO Ryo, TOMONORI Takahashi, Tomoya Hara, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Incremental Value of Relative Apical Sparing Index for Discrimination of Cardiac Amyloidosis Subtypes, 第88回日本循環器学会学術集会, Mar. 2024.
16.	M Tserensonom, Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Muneyuki Kadota, Tomoya Hara, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : High Serum lipoprotein (a) level is a risk factor of poor prognosis after transcatheter aortic valve implantation, 第88回日本循環器学会学術集会 JCS2024, Mar. 2024.
17.	西川幸治, Takayuki Ise, 石井亜由美, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : 心不全を伴う若年の高度肥満患者に対する心臓リハビリテーションの経験, 日本心臓リハビリテーションン学会第7回四国支部地方会, Mar. 2024.
18.	Hirokazu Ohminami, KITAMURA Ayano, Masashi Masuda, Takayuki Ise, Shusuke Yagi, Masataka Sata and Yutaka Taketani : 心不全マウスに対する高脂肪食と運動の併用効果，優秀演題アワードセッショ, 日本心臓リハヒリテーション学会第7回四国支部地方会, Mar. 2024.
19.	八木一成, Yoshihito Saijyo, 長野絋平, 折野逸人, Naofumi Yoshida, TAKAHASHI Tomoko, Zengu Robahto, BANDO Ryo, TOMONORI Takahashi, Tomoya Hara, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : ALおよびATTR心アミロイドーシス間のエコー図検査的特徴の相違に関する検討, 第123回日本循環器学会四国支部地方会, Dec. 2023.
20.	YAMAGUCHI Natsumi, Kenya Kusunose, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi and Masataka Sata : ARNI投与による慢性心不全患者の安静時および運動時心機能に対する影響:負荷エコーを用いた検討, 第27回日本心不全学会学術集会, Oct. 2023.
21.	石井亜由美, 西川幸治, Muneyuki Kadota, Kenya Kusunose, Shusuke Yagi, Hirokazu Ohminami, 内藤紘一, Yutaka Taketani and Masataka Sata : 情報発信WEB 「リカバルクラブ」を用いた多職種患者教育の取り組み, 第71回日本心臓病学会学術集会，2023年9月8日(金)∼10日(日)，東京, Sep. 2023.
22.	Takayuki Ise, 石井亜由美, 西川幸治, 上野理恵, Muneyuki Kadota, Shusuke Yagi, Hirokazu Ohminami, 内藤紘一, Yutaka Taketani and Masataka Sata : 遠隔伴走型心リハ「リカバル」による新たな在宅心リハの取り組み, 第29回日本心臓リハヒリテーション学会学術集会, Jul. 2023.
23.	Hirokazu Ohminami, Ayano KITAMURA, MINA Matsubara, Masashi Masuda, Takayuki Ise, Shusuke Yagi, Masataka Sata and Yutaka Taketani : 動物モデルから探る心リハ栄養としての糖・脂質組成の意義, 第29回日本心臓リハビリテーション学会学術集会, Jul. 2023.
24.	石井亜由美, Takayuki Ise, 西川幸治, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi, Tetsuya Matsuura and Masataka Sata : 心リハ専従看護師としての働き方, 第29回日本心臓リハビリテーション学会学術集会, Jul. 2023.
25.	Zengu Robahto, Muneyuki Kadota, Keita Ohtani, Hayato Orino, Yusuke Negishi, Tomoko Takahashi, Ryo Bando, Hiromitsu Seno, TOMONORI Takahashi, Yoshihito Saijyo, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : A Case of Biopsy-Proven Giant Cell Myocarditis, 第37回日本心エコー図学会学術集会, Apr. 2023.
26.	Takayuki Ise, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi, Hirokazu Ohminami, Yutaka Taketani and Masataka Sata : 遠隔伴走型心臓リハヒリテーション「リカバル」を用いた新たな取り組み, 日本心臓リハヒリテーション学会第6回四国支部地方会, Mar. 2023.
27.	Ryota Miyamoto, Takayuki Ise, Muneyuki Kadota, Shusuke Yagi, Takaaki Samura, 石井亜由美, 西川幸治 and Masataka Sata : 急性僧帽弁閉鎖不全症に対してImpella 5.5留置下にリハビリを進め，MICS-MVPに繋げた一例, 日本心臓リハヒリテーション学会第6回四国支部地方会, Mar. 2023.
28.	西川幸治, Takayuki Ise, 石井亜由美, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : 心不全を伴う若年の高度肥満患者に対する心臓リハヒリテーションの経験, 日本心臓リハヒリテーション学会第6回四国支部地方会, Mar. 2023.
29.	Ryo Bando, Tetsuzo Wakatsuki, Koji Yamaguchi, Yutaka Kawabata, Ryota Miyamoto, Zengu Robahto, TOMONORI Takahashi, Yoshihito Saijyo, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Two-year Outcomes of Drug-coated Balloon-only Strategy for De Novo Lesions in Large Coronary Vessels, 第87回日本循環器学会学術集会, Mar. 2023.
30.	Yoshihito Saijyo, Yuichiro Okushi, Kenya Kusunose, Hirotsugu Yamada, Zengu Robahto, TOMONORI Takahashi, Hiromitsu Seno, Susumu Nishio, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Utility of Periodic Echocardiographic Surveillance for Early Detection of Cardiac Dysfunction from Chemotherapy in Breast Cancer Patients, 第87回日本循環器学会学術集会, Mar. 2023.
31.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, BANDO Ryo, Yoshihito Saijyo, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : The Impact of Coronary Plaque Progression Stage on Coronary Neovascularization Structures in Fresh Cadavers, 第87回日本循環器学会学術集会, Mar. 2023.
32.	Takayuki Ise, Shusuke Yagi, Rie Ueno, Muneyuki Kadota, Keita Ohtani, Yusuke Negishi, Ryota Miyamoto, BANDO Ryo, Zengu Robahto, Hiromitsu Seno, TOMONORI Takahashi, Yutaka Kawabata, Yoshihito Saijyo, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Novel Home-based Cardiac Telerehabilitation System Using a Wearable Device and a Web Application, 第87回日本循環器学会学術集会, Mar. 2023.
33.	Shusuke Yagi and Masataka Sata : Epicardial Adipose Tissue as a Novel Target of Pemafibrate in Preventing Cardiovascular Disease through Reduction of Triglyceride and Oxidative Stress, 第87回日本循環器学会学術集会, Mar. 2023.
34.	S Yamaguchi, M Maeda, K Ohba, M Glinu, O Arasaki, Shusuke Yagi, Kenya Kusunose, Takeshi Soeki, Hirotsugu Yamada, Daiju Fukuda, H Masuzaki, Masataka Sata and Michio Shimabukuro : Sex Differences in the Association between Epicardial Adipose Tissue Volume and Left Atrial Volume Index, 第87回日本循環器学会学術集会, Mar. 2023.
35.	Hirokazu Ohminami, 北村彩乃, 松原未奈, Masashi Masuda, Takayuki Ise, Shusuke Yagi, Masataka Sata and Yutaka Taketani : 動物モデルから探る病期別心リハ栄養の可能性, 第12回日本リハビリテーション栄養学会学術集会, Jan. 2023.
36.	北村彩乃, Hirokazu Ohminami, 松原未奈, Masashi Masuda, Takayuki Ise, Shusuke Yagi, Masataka Sata and Yutaka Taketani : 高脂肪食が心不全マウスの骨格筋エネルギー代謝に及ぼす影響, 第26回日本病態栄養学会年次学術集会, Jan. 2023.
37.	吉田知哉, Takayuki Ise, 宮本亮太, BANDO Ryo, Zengu Robahto, Hiromitsu Seno, Tomonori Takahashi, Yutaka Kawabata, Tomomi Matsuura, Yoshihito Saijyo, Muneyuki Kadota, Kenya Kusunose, Takeshi Soeki, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki, 飯間努, 山本浩史 and Masataka Sata : 劇症型心筋炎に対してECPELLA導入で救命しえた症例, 第121回日本循環器学会四国地方会, Dec. 2022.
38.	Tomonori Takahashi, Kenya Kusunose, Zheng Robert, Seno Hiromitsu, Yoshihito Saijyo, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 心房細動患者におけるイソプロテレノール負荷経食堂心エコー図法の有用性, 第121回日本循環器学会四国地方, Dec. 2022.
39.	吉田知哉, Tetsuzo Wakatsuki, 山木浩二, Yoshihito Saijyo, Yutaka Kawabata, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 冠動脈入口部および鎖骨下動脈に特徴的な血管内超音波所見を認めた高安動脈炎の2例, 第70回日本心臓病学会学術集会, Sep. 2022.
40.	Takayuki Ise, 内藤紘一, 佐藤聡見, 小野慎太郎, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : ウェアラブルデバイスとコミュニケーションアプリを用いた遠隔伴走型心リハシステムの開発, 第70回日本心臓病学会学術集会, Sep. 2022.
41.	Yuichiroh Ohkushi, Kenya Kusunose, Hiromitsu Seno, Tomonori Takahashi, Yoshihito Saijyo, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 心エコー検査によるサーベイランスのがん治療関連心筋障害への影響, 第5回日本腫瘍循環器学会学術集会, Sep. 2022.
42.	松崎慶仁, Yoshihito Saijyo, Takayuki Ise, 太田啓太, 折野逸人, 吉田知哉, 根岸佑典, 宮本亮太, 坂東遼, Rovert Zheng, Hiromitsu Seno, Tomonori Takahashi, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 急性A型大動脈解離をきたしたMarfan症候群の一例, 第265回徳島県医学学術集会, Jul. 2022.
43.	Yusuke Negishi, Muneyuki Kadota, Koji Yamaguchi, Hirotsugu Yamada, 折野逸人, 太田啓太, 吉田知哉, 宮本亮太, BANDO Ryo, Zheng Rovert, Hiromitsu Seno, Tomonori Takahashi, Yoshihito Saijyo, Rie Ueno, Tomoya Hara, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, 田蒔昌憲 and Masataka Sata : 腎動脈拡張術により心不全の著名な改善を認めたCardiac Disturbance syndrome の1例, 第265回徳島県医学学術集会, Jul. 2022.
44.	Shusuke Yagi, Takayuki Ise, Muneyuki Kadota, Yutaka Kawabata, Tomoya Hara, Rie Ueno, Yoshihito Saijyo, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : パンデミック下の臨床実習におけるオンライン医学教育の実際と問題点, 第265回徳島県医学学術集会, Jun. 2022.
45.	北村彩乃, Hirokazu Ohminami, Masashi Masuda, Hisami Okumura, Takayuki Ise, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Masataka Sata and Yutaka Taketani : 運動介入中の脂質摂取の違いが心不全マウスの病態に及ぼす影響, 第28回日本心臓リハビリテーション学会学術集会, Jun. 2022.
46.	石井亜由美, Muneyuki Kadota, 西川幸治, 大南博和, Takayuki Ise, Shusuke Yagi and Masataka Sata : 外来心リハ患者に対するアンケート調査から, Jun. 2022.
47.	西川幸治, Takayuki Ise, 石井亜由美, 大南博和, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : コロナ禍における外来心リハ患者の体重変化と健康意識調査, 第28回日本心臓リハビリテーション学術集会, Jun. 2022.
48.	Takayuki Ise, 内藤紘一, 佐藤聡見, 小野慎太郎, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : ウェアラブルデバイスとコミュニケーションアプリを用いた遠隔伴走型心リハシステムの開発, 第28回日本心臓リハビリテーション学術集会, Jun. 2022.
49.	Takayuki Ise, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi, Hirotsugu Yamada, 竹谷豊 and Masataka Sata : Withコロナに対応した心リハオンライン臨床実習システムの構築, 第28回日本心臓リハビリテーション学術集会, Jun. 2022.
50.	Rikako Takahashi, Muneyuki Kadota, Takayuki Ise, Yoshihito Saijyo, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 免疫抑制療法の導入により心機能が劇的に改善した巨細胞性心筋炎の一例, 第120回日本循環器学会中国・四国合同地方会, May 2022.
51.	Muneyuki Kadota, Kenya Kusunose, Shusuke Yagi, Yutaka Kawabata, Yoshihito Saijyo, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 慢性心不全におけるサクビトリル / バルサルタンのナトリウム利尿ペプチドに対する急性反応の検討, 第120回日本循環器学会中国・四国合同地方会, May 2022.
52.	Munkhtsetseg Tserensonom, Shusuke Yagi, Takayuki Ise, Daiju Fukuda, Muneyuki Kadota, Yutaka Kawabata, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 動脈硬化性疾患の高リスク患者において大動脈弁の石灰化と血清リポ蛋白との関連, 第9回日本心血管脳卒中学会学術集会, Apr. 2022.
53.	Shusuke Yagi, Oyunbileg Bavuu, Daiju Fukuda and Masataka Sata : The novel non-steroidal mineralocorticoid receptor blocker esaxerenoneameliorates insulin resistance, 第9回日本心血管脳卒中学会学術集会, Apr. 2022.
54.	Y Okushi, Kenya Kusunose, Zheng Robert, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Findings from the JROAD-DPC Registry across 6 Studies Conducted in a Year, 第86回日本循環器学術集会, Mar. 2022.
55.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yoshihito Saijyo, Muneyuki Kadota, Tomomi Matsuura, 伊勢孝之, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : First Assessment of Coronary Plaque Vulnerability and Lipid Core Burden Assessed by Near-Infrared Spectroscopy-Intravascular Ultrasound in a Fresh Cadaver, 第86回日本循環器学会学術集会, Mar. 2022.
56.	Tserensonom Munkhtsetseg, Shusuke Yagi and Masataka Sata : The Association of Lp(a) with Aortic Calcium Score in Patients with High Risk of Atherosclerotic Disease, 第86回日本循環器学会学術集会, Mar. 2022.
57.	Tomonori Takahasi, Kenya Kusunose, Yukina Hirata, Susumu Nisio, Yuichiro Okushi, Hiromitsu Seno, Y Saijo, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Cardiovascular Risk Factors Associated with Left Ventricular Strain Distribution in Patients without Known Cardiovascular Disease, 第86回日本循環器学会学術集会, Mar. 2022.
58.	Ayano Kitamura, Hirokazu Ohminami, Masashi Masuda, Hisami Okumura, Takayuki Ise, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Masataka Sata and Yutaka Taketani : 運動および栄養介入が心不全マウスの病態に及ぼす影響, 日本心臓リハビリテーション学会第 5 回四国支部地方会, Jan. 2022.
59.	Muneyuki Kadota, 石井亜由美, Takayuki Ise, 西川幸治, Shusuke Yagi, 大南博和, 竹谷豊 and Masataka Sata : 当院における末期心不全に患者に対する緩和ケアの取り組み, 日本心臓リハビリテーション学会第5回四国支部地方会, Jan. 2022.
60.	石井亜由美, Muneyuki Kadota, 西川幸治, 大南博和, Takayuki Ise, Shusuke Yagi and Masataka Sata : 外来心リハ患者に対するACPアンケート調査から, 日本心臓リハビリテーション学会第5回四国支部地方会, Jan. 2022.
61.	西川幸治, Takayuki Ise, 石井亜由美, 大南博和, Muneyuki Kadota, Shusuke Yagi and Masataka Sata : 心リハ研修施設としての活動報告, 日本心臓リハビリテーション学会第5回四国支部地方会, Jan. 2022.
62.	Takayuki Ise, 石井亜由美, 西川幸治, Muneyuki Kadota, Shusuke Yagi, 大南博和, 竹谷豊 and Masataka Sata : Withコロナに対応したオンライン臨床実習システムの構築, 日本心臓リハビリテーション学会第5回四国支部地方会, Jan. 2022.
63.	Munkhtsetseg Tserensonom, Shusuke Yagi and Masataka Sata : 動脈硬化性疾患の高リスク患者において大動脈弁の石灰化と血清リポ蛋白との関連, 第33回日本老年医学会四国地方会, Jan. 2022.
64.	Yoshihito Saijyo, Takaaki Samura, Tomoko Takahashi, Yuichiroh Ohkushi, Hiromitsu Seno, 高橋智紀, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Hiroki Hata and Masataka Sata : 滲出性収縮性心膜炎の1例, 第119回日本循環器学会四国地方会, Dec. 2021.
65.	Kumiko Suto, Daiju Fukuda, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : マクロファージ特異的DNaseII欠損が動脈硬化に与える影響, 第119回日本循環器学会四国地方会, Dec. 2021.
66.	Yuichiroh Ohkushi, Kenya Kusunose, Yoshihito Saijyo, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 心エコー検査によるがん治療関連心筋障害サーベイランスの有効性, 第119回日本循環器学会四国地方会, Dec. 2021.
67.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Muneyuki Kadota, Takayuki Ise, Kenya Kusunose, Tomomi Matsuura, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 冠動脈塞栓症を発症した2症例の臨床的検討, 第69回日本心臓病学会学術集会, Sep. 2021.
68.	Tomoya Yoshida, Hiromitsu Seno, Kazuhisa Matsumoto, Tomomi Matsuura, Yoshihito Saijyo, Muneyuki Kadota, Yutaka Kawabata, Kenya Kusunose, Takayuki Ise, Takeshi Soeki, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki, 多田恵曜 and Masataka Sata : ペースメーカー植え込み後に発覚した側頭葉てんかんによる発作性心静止の一例, 第263回徳島医学会学術集会, Aug. 2021.
69.	M Tserensonom, Shusuke Yagi, Takayuki Ise, Muneyuki Kadota, Yutaka Kawabata, Yoshihito Saijyo, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 動脈硬化性疾患の高リスク患者において大動脈弁の石灰化と血清リポ蛋白との関連, 第263回徳島医学会学術集会, Aug. 2021.
70.	Kazuki Tezuka, Tomonori Takahashi, Yoshihito Saijyo, Yutaka Kawabata, Muneyuki Kadota, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Takaaki Samura, Hiroki Hata and Masataka Sata : ポスタ-セッション左冠動脈主幹部の急性冠症候群の2症例, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
71.	Takayuki Ise, Muneyuki Kadota, Yutaka Kawabata, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Takaaki Samura, Eiki Fujimoto, Hiroki Hata and Masataka Sata : 合同シンポジウムカテ-テル大動脈弁置換術(TAVI)によって激変した大動脈弁狭窄症治療, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
72.	Takayuki Ise, 石井亜由美, 西川幸治, Muneyuki Kadota, 鈴木佳子, Hirokazu Ohminami, Shusuke Yagi and Masataka Sata : 大動脈狭窄症に対するTAVI後認知機能の変化, 第11回日本脳血管・認知症学会総会, Aug. 2021.
73.	Takeshi Soeki, Daiju Fukuda, Tomomi Matsuura, Takeshi Tobiume, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Toll-Like Receptor 9 Is a Novel Therapeutic Target to Prevent Atrial Fibrillation, JHRS2021 第67回日本不整脈心電学会学術大会, Jul. 2021.
74.	Hirokazu Ohminami, Ayano Kitamura, Miku Yamaguchi, Masaki Takikawa, Kohta Ohnishi, Masashi Masuda, Hisami Okumura, Takayuki Ise, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Masataka Sata and Yutaka Taketani : 心不全マウスを用いた心リハ評価系の確立, 第27回日本心臓リハビテーション学会, Jun. 2021.
75.	西川幸治, Takayuki Ise, 石井亜由美, 鈴木佳子, 大南博和, Muneyuki Kadota, Shusuke Yagi, 加藤真介 and Masataka Sata : AVI患者におけるADLスコア(FIM)の変化, 第27回日本心臓リハビリテーション学会学術集会, Jun. 2021.
76.	石井亜由美, Takayuki Ise, 西川幸治, 鈴木佳子, 大南博和, Muneyuki Kadota, Shusuke Yagi, 加藤真介 and Masataka Sata : 外来心臓リハビリテーション通院に関する患者の意識調査, 第 27 回日本心臓リハビリテーション学会学術集会, Jun. 2021.
77.	西川幸治, Takayuki Ise, 石井亜由美, 鈴木佳子, 大南博和, Muneyuki Kadota, Shusuke Yagi, 加藤真介 and Masataka Sata : TAVI患者におけるADLスコア(FIM)の変化, 第 27 回日本心臓リハビリテーション学会学術集会, Jun. 2021.
78.	Akihiro Tani, Shusuke Yagi, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : 肺動脈性肺高血圧症に対する静注プロスタグランジン投与で高心拍出を呈した症例, 第116回第118回日本循環器学会中国・四国合同地方会, Jun. 2021.
79.	Yuichiroh Ohkushi, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : ループ利尿薬使用下における心保護薬併用療法の有用性, 第116回第118回日本循環器学会中国・四国合同地方会, Jun. 2021.
80.	Hiromitsu Seno, Kazuhisa Matsumoto, Tomomi Matsuura, Takeshi Tobiume, Takeshi Soeki, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : ペースメーカー植込み後にj発覚した側頭葉てんかんによる発作性心静止の1例, 第124回日本内科学会四国地方会, May 2021.
81.	PP Tran, Daiju Fukuda, Kumiko Suto, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : DNA Damage Caused by Diabetes Induced Vascular Dysfunction : The Role of The Stimulator of Interferon Genes, 第85回日本循環器学会学術集会, Mar. 2021.
82.	PP Tran, Daiju Fukuda, Kumiko Suto, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Stimulator of Interferon Genes Plays a Pivotal Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-deficient Mice, 第85回日本循環器学会学術集会, Mar. 2021.
83.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yuichiroh Ohkushi, Kumiko Suto, 松本和久, Tomonori Takahashi, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Early and Chronic Phased Local Coagulative Responses Following Bioresorbable-polymer Drug-eluting Stent Implantation, 第85回日本循環器学会学術集会, Mar. 2021.
84.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, 添木武 and Masataka Sata : Relationship between Coronary Intraplaque Microluminal Structure and Epicardial Adipose Tissue and Plaque Formation -A Fresh Cadaveric Study-, 第85回日本循環器学会学術集会, Mar. 2021.
85.	Yukina Hirata, Kenya Kusunose, 辻拓将, 藤森康平, YAMAGUCHI Natsumi, Sae Morita, Susumu Nishio, Yuichiroh Ohkushi, Hiromitsu Seno, 高橋智紀, Takayuki Ise, 飛梅威, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, 添木武, Tetsuzo Wakatsuki, 古徳純一 and Masataka Sata : Deep Learning for Detection of Elevated Pulmonary Artery Wedge Pressure Using Standard Chest X-Ray, 第85回日本循環器学会学術集会, Mar. 2021.
86.	Shusuke Yagi and Masataka Sata : Angiogenetic Gene Therapy with Hepatocyte Growth Factor Plasmid in Patients with Chronic Limb-threatening Ischemia, 第85回日本循環器学会学術集会, Mar. 2021.
87.	阿部美保, Kenya Kusunose, Y Okushi, Zheng Robert, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Effects of Vitamin D Supplementation on Heart Failure Mortality from Japanese Registry of All Cardiac and Vascular Datasets, 第85回日本循環器学会学術集会, Mar. 2021.
88.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Hiroyuki Ito, Takayuki Ise, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 光干渉断層法で観察される冠動脈壁微小管腔構造と局所冠動脈周囲脂肪内炎症および冠動脈プラークの関連 -未固定遺体における検討-, Beyond Angiography Japan XXV, Mar. 2021.
89.	石井亜由美, Takayuki Ise, 西川幸治, 鈴木佳子, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi, 加藤真介 and Masataka Sata : 心臓リハビリテーションの日独比較 ∼ドイツ心リハ研修から∼, 第4回日本心臓リハビリテーション学会四国支部地方会, Mar. 2021.
90.	遠藤朱門, Shusuke Yagi, Takayuki Ise, Muneyuki Kadota, 石井亜由美, 西川幸治, 鈴木桂子, 大南博和, 加藤真介 and Masataka Sata : 若年健常人において，終末糖化産物は筋肉量・筋力の規定因子である, 第4回日本心臓リハビリテーション学会四国支部地方会, Mar. 2021.
91.	Takayuki Ise, Muneyuki Kadota, Shusuke Yagi, 石井亜由美, 西川幸治, 鈴木佳子, 大南博和, 加藤真介 and Masataka Sata : TAVI 実施症例の至適心臓リハビリテーションの考察, 第4回日本心臓リハビリテーション学会四国支部地方会, Mar. 2021.
92.	西川幸治, Takayuki Ise, 石井亜由美, 鈴木佳子, 大南博和, Muneyuki Kadota, Shusuke Yagi, Shinsuke Katoh and Masataka Sata : TAVI 施行前後の認知機能の変化について, 第4回日本心臓リハビリテーション学会四国支部地方会, Mar. 2021.
93.	Takuya Yamada, Akihiro Tani, Muneyuki Kadota, Takayuki Ise, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 大動脈四尖弁に対してTAVIを施行した一症例, 第262回徳島医師学会学術集会, Mar. 2021.
94.	ムギー (名), Shusuke Yagi, Muneyuki Kadota, Yutaka Kawabata, 松本和久, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Tomomi Matsuura, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 当院におけるイバブラジンの使用経験, 第262回徳島医師学会学術集会, Mar. 2021.
95.	平田有紀奈, Kenya Kusunose, 辻拓将, 藤森康平, 山口夏美, 森田沙瑛, 西尾進, 大櫛祐一郎, 瀬野弘光, 高橋智紀, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, 古徳純一 and Masataka Sata : ディープラーニングによる胸部X-pを用いた肺動脈圧上昇の検出, 第85回日本循環器学会学術集会, Mar. 2021.
96.	Muneyuki Kadota, Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute Hormonal Effect of the Angiotensin Receptor-Neprilysin Inhibitor in Patients with Chronic Heart Failure, 第85回日本循環器学会学術集会, Mar. 2021.
97.	Hiroshi Kawano, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, Masataka Sata, Hiroshi Nokihara and Yasuhiko Nishioka : 高安動脈炎による難治性皮膚潰瘍に対してべペルミノゲンペルプラスミド(ヒト肝細胞増殖因子プラスミドベクター)投与が奏効した1例, 第48回日本臨床免疫学会総会, Oct. 2020.
98.	Shusuke Yagi and Masataka Sata : Modifying the Quality of Food Increases the Oral Caloric and Protein Intake in Patients with Heart Failure, 第84回日本循環器学会学術集会, Aug. 2020.
99.	泉侑希, Shunsuke Ishida, 長谷川結美, 武智研志, Mitsuhiro Goda, Yoshito Zamami, 桐野靖, 中村敏己, 寺岡和彦, Shusuke Yagi, Masataka Sata and Keisuke Ishizawa : 高齢者の薬物療法管理ツールを活用した薬剤業務の効率化, 第84回日本循環器学会学術集会, Jul. 2020.
100.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yuichiroh Ohkushi, Kumiko Sutou, Kazuhisa Matsumoto, Tomonori Takahashi, Muneyuki Kadota, 上野理絵, Yutaka Kawabata, Tomomi Matsura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : The Effect of Lower Strut Thickness and Faster Polymer Resorption on Chronic Local Coagulative Response after Drug Eluting Stent Implantation, 第84回日本循環器学会学術集会, Jul. 2020.
101.	Gulinu Maimaituxun, Kenya Kusunose, Daiju Fukuda, Shusuke Yagi, Hirata Yukina, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata and Michio Shimabukuro : Impact of Epicardial Adipose Tissue on Global Longitudinal Strain in Patients with Normal Left Ventricular Ejection Fraction, 第84回日本循環器学会学術集会, Jul. 2020.
102.	Ganbaatar Byambasuren, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : S1P2 Receptor Antagonist Attenuates Endothelial Dysfunction and Prevents Atherogenesis in Apolipoprotein-E-deficient Mice, 第84回日本循環器学会学術集会, Jul. 2020.
103.	Suto Kumiko, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Pemafibrate, a Novel Selective Peroxisome Proliferator-activated Receptor-α Modulator, Attenuates Vascular Inflammation and Endothelial Dysfunction in Diabetic Mice, 第84回日本循環器学会学術集会, Jul. 2020.
104.	西川幸治, Takayuki Ise, 石井亜由美, 鈴木佳子, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi, Shinsuke Katoh and Masataka Sata : TAVI後の認知機能低下に関連する因子の検討, 第26回日本心臓リハビリテーション学会学術集会, Jul. 2020.
105.	Muneyuki Kadota, Shusuke Yagi, Takayuki Ise, 石井亜由美, 西川幸治, 鈴木佳子, Hirokazu Ohminami, Shinsuke Katoh and Masataka Sata : イハブラジン導入前後の運動耐容能の推移を観察した虚血性心筋症の一例, 第26回日本心臓リハビリテーション学会学術集会, Jul. 2020.
106.	石井亜由美, Takayuki Ise, 西川幸治, Yukako Honma, 鈴木佳子, Hirokazu Ohminami, Muneyuki Kadota, Takeshi Tobiume, Shusuke Yagi, Yasunobu Hayabuchi, Shinsuke Katoh and Masataka Sata : 心配停止をきたしQT延長症候群と診断されS-ICD植込みとなった5歳児に対する心リハの経験, 第26回日本心臓リハビリテーション学会学術集会, Jul. 2020.
107.	Kenya Kusunose, Akihiro Haga, Muneyuki Kadota, 石井亜由美, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada and Masataka Sata : 心エコーへのAI応用について, 第26回日本心臓リハビリテーション学会学術集会, Jul. 2020.
108.	石井亜由美, Takayuki Ise, 西川幸治, Yukako Honma, 鈴木佳子, Hirokazu Ohminami, Muneyuki Kadota, Shusuke Yagi, Yasunobu Hayabuchi, Shinsuke Katoh and Masataka Sata : 小児に関する心臓リハビリテーションの取り組みと症例から学んだこと, 第26回日本心臓リハビリテーション学会学術集会, Jul. 2020.
109.	Shusuke Yagi and Masataka Sata : 見た目の老化と筋力低下は冠動脈疾患の危険因子である, 脳心血管抗加齢研究会2019(第16回学術大会), Dec. 2019.
110.	Muneyuki Kadota, Kenya Kusunose, Takayuki Ise, Tomonori Takahashi, 藤本裕太, Yuichiroh Ohkushi, Kumiko Sutou, Kazuhisa Matsumoto, 上野理絵, Yutaka Kawabata, nao Yamada, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : ドブダミン負荷下での血行動態評価を行った潜在性閉塞性肥大型心筋症2症例の検討, 第115回日本循環器学会四国地方会, Dec. 2019.
111.	Koji Yamaguchi, Tetsuzo Wakatsuki, Kazuhisa Matsumoto, Tomonori Takahashi, 上野理絵, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : クライオバルーンアブレーション後の肺静脈狭窄に対するDrug coated balloonの使用経験, 第115回日本循環器学会四国地方会, Dec. 2019.
112.	Koji Yamaguchi, Tetsuzo Wakatsuki, Kazuhisa Matsumoto, Tomonori Takahashi, 上野理絵, Yutaka Kawabata, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 新規病変に対するDrug coated balloonの効果―局所血管反応と臨床成績について―, 第115回日本循環器学会四国地方会, Dec. 2019.
113.	Ganbaatar Byambasuren, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : S1P2 antagonist attenuates endothelial dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient Mice, 日本性機能学会第30回学術集会, Sep. 2019.
114.	Pham Tran Phuong, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Rivaroxaban,a direct inhibitor of FXa,attenuated diabetes-induced endothelial dysfunction in wild-type mice, 日本性機能学会第30回学術集会, Sep. 2019.
115.	Arief Rahadian, Daiju Fukuda, Hotima Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : SGLT2 inhibitor,Canagliflozin,Ameliorate Endothelial Dysfunction and Atherosclerosis in Diabetic ApoE-/- Mice, 日本性機能学会第30回学術集会, Sep. 2019.
116.	Aini Kunduziayi, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Vildagliptin,a DPP-4 Inhibitor,prevents endothelial dysfunction in nondiabetic apolipoprotein E-deficient mice, 日本性機能学会第30回学術集会, Sep. 2019.
117.	Shusuke Yagi, Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Masashi Akaike and Masataka Sata : 心血管病における性機能障害と男性ホルモンの心血管保護作用, 日本性機能学会第30回学術集会,シンポジウム, Sep. 2019.
118.	梶川正人, 丸橋達也, 日高貴之, 中野由紀子, 栗栖智, 大原康樹, 廣高史, 平山篤志, 椎名一紀, 冨山博史, Shusuke Yagi, 天野里江, Hirotsugu Yamada and Masataka Sata : 2型糖尿病患者におけるサキサグリプチンの血管内皮機能に及ぼす効果, 第67回日本心臓病学会学術集会, Sep. 2019.
119.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, nao Yamada, Kenya Kusunose, Takayuki Ise, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Optical coherence omographyにより器質化血栓の存在が疑われた肺癌術後急性冠症候群の1例, 第67回日本心臓病学会学術集会, Sep. 2019.
120.	木田貴弘, Takeshi Tobiume, 松本和久, 坂東左知子, Tomomi Matsuura, Takeshi Soeki, 志村拓哉, 髙橋智子, 谷彰浩, 藤本裕太, 大櫛祐一郎, 數藤久美子, 髙橋智紀, 上野理絵, 門田宗之, 川端豊, Mika Bando, 山田なお, Hiroyuki Ito, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : 房室ブロックの進行に伴い明らかになり，恒久的ペースメーカー植込み術後のファーフィールドR波センシングへの関与が疑われた束枝心室間副伝導路の1例, 第259回徳島医学会学術集会, Aug. 2019.
121.	井口裕貴, Takeshi Tobiume, 松本和久, 坂東左知子, Tomomi Matsuura, Takeshi Soeki, 志村拓哉, 髙橋智子, 谷彰浩, 藤本裕太, 大櫛祐一郎, 數藤久美子, 髙橋智紀, 上野理絵, 門田宗之, 川端豊, Mika Bando, 山田なお, Hiroyuki Ito, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : 房室ブロックの予防に順行性速伝導路と順行性遅伝導路のマッピングが有用であった順行性速伝導路の下方偏位を伴う遅速型房室結節リエントリー性頻拍の1例, 第259回徳島医学会学術集会, Aug. 2019.
122.	Naoto Uyama, 松下知樹, 新井悠太, Hideki Otsuka, Youichi Otomi, Masafumi Harada, Shusuke Yagi and Masataka Sata : 当院における慢性血栓塞栓性肺高血圧症 5症例の臨床像について, 第259回徳島医学会学術集会, Aug. 2019.
123.	石井亜由美, 西川幸治, Takayuki Ise, Takayuki Ise, Yoshiko Suzuki, 高川由利子, Shusuke Yagi, Shinsuke Katoh and Masataka Sata : 大動脈弁狭窄症に対するTAVI施行患者の認知機能の変化について, 第25回日本心臓リハビリテーション学会学術集会, Jul. 2019.
124.	Masataka Sata, 石井亜由美, 西川幸治, Shusuke Yagi, Takayuki Ise and Yuka Ueda : ``異所性脂肪''から考える動脈硬化の成因と心臓リハビリテーションの効果, 第25回日本心臓リハビリテーション学会学術集会指定講演,日本循環器学会・日本心臓リハビリテーション学会ジョイントセッション, Jul. 2019.
125.	西川幸治, 石井亜由美, Takayuki Ise, Yoshiko Suzuki, 高川由利子, Shusuke Yagi, Shinsuke Katoh and Masataka Sata : 継続的な活動量の記録は半年後の運動習慣の獲得につながるか, 第25回日本心臓リハビリテーション学会学術集会, Jul. 2019.
126.	Gulinu Maimaituxun, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, Takashi Iwase, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Michio Shimabukuro : Gender specific impact of epicardial adipose tissue thickness on coronary artery disease, 第19回日本抗加齢医学会総会, Jun. 2019.
127.	數藤久美子, Kenya Kusunose, Tomomi Matsuura, 山田なお, 松本和久, 上野理絵, 川端豊, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 進行性心不全を呈す抗ミトコンドリア抗体陽性筋炎の症例, 第114回日本循環器学会中国・四国合同地方会, Jun. 2019.
128.	谷彰浩, Kenya Kusunose, 松本和久, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 拡張期僧帽弁逆流の治療適応判断に心房心室同時ペーシングが有効であった1例, 第114回日本循環器学会中国・四国合同地方会, Jun. 2019.
129.	志村拓哉, Takayuki Ise, 川端豊, 藤本裕太, 松本和久, 上野理絵, 山田なお, Hiroyuki Ito, Tomomi Matsuura, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Hirotsugu Kurobe, Eiki Fujimoto and Masataka Sata : 先天性二尖弁に対するTAVIの2例, 第114回日本循環器学会中国・四国合同地方会, Jun. 2019.
130.	中村昌史, 川端豊, Takayuki Ise, 藤本裕太, 原田貴文, 松本和久, 西條良仁, 上野理絵, 山田なお, Hiroyuki Ito, 轟貴史, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 経食道心エコーガイド下の経皮的腫瘍生検により早期に診断し得た心臓原発血管肉腫の一例, 第114回日本循環器学会中国・四国合同地方会, Jun. 2019.
131.	Gulinu Maimaituxun, Daiju Fukuda, Shusuke Yagi, Tsukasa Iwase, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Michio Shimabukuro : Type 2 diabetes but not apicardial adipose tissue thickness is a predictor for coronary artery diseases in women, 第62回日本糖尿病学会年次学術集会, May 2019.
132.	Gulinu Maimaituxun, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, T Iwase, Takeshi Soeki, Masataka Sata and Michio Shimabukuro : Impact of epicardial adipose tissue thickness on left ventricular diastolic dysfunction in human, 第92回日本内分泌学会学術総会, May 2019.
133.	Gulinu Maimaituxun, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, T Iwase, S Takao, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada, Masataka Sata and Michio Shimabukuro : Kidney fat and its impact on coronary artery disease, 第4回日本血管不全学会学術集会・総会, Apr. 2019.
134.	Gulinu Maimaituxun, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, T Iwase, S Takao, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada, Masataka Sata and Michio Shimabukuro : Peri-renal fat volume is negatively associated with the adiponectin expression in human, 第4回日本血管不全学会学術集会・総会, Apr. 2019.
135.	石井亜由美, 西川幸治, Takayuki Ise, Yoshiko Suzuki, Shusuke Yagi, 高川由利子, Shinsuke Katoh and Masataka Sata : 外来心臓リハビリテーションにより外出への不安感が軽減し運動耐容能の向上を認めた症例, 日本心臓リハビリテーション学会第3回四国支部地方会, Apr. 2019.
136.	石井亜由美, 西川幸治, Takayuki Ise, Yoshiko Suzuki, 高川由利子, Shusuke Yagi, Shinsuke Katoh and Masataka Sata : Wearable ICD装着患者に対する心リハの経験, 日本心臓リハビリテーション学会第3回四国支部地方会, Apr. 2019.
137.	Pham Tran Phuong, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro and Masataka Sata : Rivaroxaban, A Direct Inhibitor of FXa, Attenuated Diabetes-induced Endothelial Dysfunction by Inhibiting FXa-protease Activated Receptor 2 Signaling, 第83回日本循環器学会学術集会, Mar. 2019.
138.	Hiroyuki Ito, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, 川端豊, 轟貴史, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Microluminal structures of coronary plaque and vasa vasorums affect coronary inflammation: A fresh cadaveric studys, 第83回日本循環器学会学術集会, Mar. 2019.
139.	川端豊, Tetsuzo Wakatsuki, Koji Yamaguchi, Hiroyuki Ito, Daiju Fukuda, 轟貴史, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Coronary intraplaque microluminal structure are associated with the quality and quantity of epicardial adipose tissue -A fresh cadaveric stury-, 第83回日本循環器学会学術集会, Mar. 2019.
140.	平田有紀奈, Kenya Kusunose, Hirotsugu Yamada, 森田沙瑛, 鳥居裕太, 西尾進, ゼングロバート, 西條良仁, Shusuke Yagi, Takeshi Soeki and Masataka Sata : マラソン完走後の左房リザーバーストレイン反応を予測する指標の検討, 第83回日本循環器学会学術集会, Mar. 2019.
141.	Arief Rahadian, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Canagliflozin, a Sglt-2 Inhibitor, Prevents Endothelial Dysfunction and Atherosclerosis in Diabetic Apolipoprotein E-deficient Mice, 第83回日本循環器学会学術集会, Mar. 2019.
142.	Byambasuren Ganbaatar, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Empagliflozin Attenuates Endothelial Dysfunction and Atherogenesis by Inhibiting Inflammation in the Vasculature and Adipose Tissue in Diabetic Apolipoprotein E-deficient Mice, 第83回日本循環器学会学術集会, Mar. 2019.
143.	Aini Kunduziayi, Daiju Fukuda, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Vildagliptin, a DPP-4 Inhibitor, Prevents Atherogenesis Targeting Multiple Cell-types in Non-diabetic Apolipoprotein E-deficient Mice, 第83回日本循環器学会学術集会, Mar. 2019.
144.	平田有紀奈, Kenya Kusunose, Hirotsugu Yamada, 森田沙瑛, 鳥居裕太, 西尾進, 山口夏美, Zengu Robahto, 西條良仁, Shusuke Yagi, Takeshi Soeki and Masataka Sata : カーフスリーブは下腿浮腫を軽減するか:表在エコー検査による検討, 第83回日本循環器学会学術集会, Mar. 2019.
145.	藤本裕太, Kenya Kusunose, 西條良仁, Zheng Robert, 原田貴文, 松本和久, 上野理絵, 川端豊, 山田なお, Hiroyuki Ito, 轟貴史, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Hirotsugu Kurobe and Masataka Sata : Staphylococcus による感染性内膜炎の一例, 第113回日本循環器学会四国合同地方会, Dec. 2018.
146.	Zheng Robert, Takayuki Ise, 川端豊, Shusuke Yagi, 西條良仁, 上野理絵, Mika Bando, Hiroyuki Ito, 轟貴史, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Hirotsugu Kurobe, Eiki Fujimoto, Tetsuya Kitagawa and Masataka Sata : Single coronary 合併重症ASに対してTAVIを施行し救命し得た1例, 第113回日本循環器学会四国合同地方会, Dec. 2018.
147.	工藤明宏, 待井典剛, 小野利夫, 大城義人, 高橋隆, 種田嘉信, 比嘉盛丈, Shusuke Yagi, 仲地健, 小林淳, 及川雅啓, Hirotsugu Yamada, 竹石恭知, Masataka Sata and Michio Shimabukuro : 時効型インスリン療法中の2型糖尿病患者におけるタバグリフロジンの血糖日内変動に及ぼす効果, 第39回日本肥満学会(神戸), Oct. 2018.
148.	Yutaka Kawabata, Tetsuzo Wakatsuki, Koji Yamaguchi, Hiroyuki Itou, Kenya Kusunose, Tomomi Matsuura, Takafumi Todoroki, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 未固定遺体において光干渉断層法で観察される冠動脈壁微小管腔構造と局所周囲脂肪炎症との関連, 第66回日本心臓病学会学術集会, Sep. 2018.
149.	Hiroyuki Ito, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yutaka Kawabata, Takayuki Ise, Kenya Kusunose, Tomomi Matsuura, Takafumi Todoroki, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 未固定遺体における冠動脈壁小管腔構造と局所心臓周囲脂肪内炎症との関連, 第66回日本心臓病学会学術集会, Sep. 2018.
150.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yoshihito Saijoh, 上野理絵, Yutaka Kawabata, Mika Bando, Hiroyuki Ito, Takafumi Todoroki, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : 第三世代薬剤溶出性ステント留置後における局所凝固反応塗装ステント長の関連性, 第66回日本心臓病学会学術集会, Sep. 2018.
151.	Daiju Fukuda, Koji Yamaguchi, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki, Takeshi Soeki and Masataka Sata : 活性型血液凝固第X因子が冠動脈硬化に与える影響, 第66回日本心臓病学会学術集会, Sep. 2018.
152.	Hiroyuki Ito, Takeshi Soeki, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : AVNRTアブレーション治療後に発生したJunctional Tachycardiaの1例, 第112回日本循環器学会中国・四国合同地方会, Jun. 2018.
153.	Takafumi Todoroki, Tetsuzo Wakatsuki, Koji Yamaguchi, Seno Hiromitsu, Kumiko Sutou, Yoshihito Saijoh, Yutaka Kawabata, 上野理絵, Hiroyuki Ito, Tomomi Matsuura, Kenya Kusunose, Takayuki Ise, Takeshi Tobiume, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : EES留置3年後，術前に抗血小板剤中止しペパリン置換したにもかかわらず2枝同時ステント閉塞を起こした1例, 第112回日本循環器学会中国・四国合同地方会, Jun. 2018.
154.	Zheng Robert, Kumiko Sutou, Kenya Kusunose, Tomomi Matsuura, Hiromitsu Seno, Yoshihito Saijoh, 上野理絵, Yutaka Kawabata, Mika Bando, ito hironori, Takafumi Todoroki, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 薬物治療が著効したSLE関連心筋炎の一例, 第112回日本循環器学会中国・四国合同地方会, Jun. 2018.
155.	Yoshihito Saijoh, Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Hiromitsu Seno, Kumiko Sutou, Yutaka Kawabata, 上野理絵, Hiroyuki Itou, Takafumi Todoroki, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : アトラサイクリン系抗癌剤による心筋障害の局在性および化学療法関連心筋障害との関連の検討, 第112回日本循環器学会中国・四国合同地方会, Jun. 2018.
156.	Kenya Kusunose, Yoshihito Saijoh, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Right Ventricular Function Predicts Beneficial Effects of Cardiac Rehabilitation in Patients with Chronic Heart Failure, 第82回日本循環器学会, Mar. 2018.
157.	Yoshihito Saijoh, Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yukina Hirata, Yuta Torii, Kumiko Sutou, 上野理絵, Yutaka Kawabata, Hiroyuki Itou, Takafumi Todoroki, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Anthracyclines induce early changes in localized left ventricular dysfunction., 第82回日本循環器学会, Mar. 2018.
158.	Takeshi Soeki, Tomomi Matsuura, Daiju Fukuda, Takeshi Tobiume, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : C-type natriuretic peptide improves left ventricular diastolic dysfunction in HFpEF model rats., 第82回日本循環器学会, Mar. 2018.
159.	BYAMBASUREN GANBAATAR, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Ticagrelor, a P2Y12 Antagonist,Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein-E-deficient Mice., 第82回日本循環器学会, Mar. 2018.
160.	Yutaka Kawabata, Takeshi Soeki, Takayuki Ise, Tomomi Matsuura, Yoshihito Saijoh, Takeshi Tobiume, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Effects of L-/N-type Calcium Channel Blocker on Proteinuria and Angiotensin -renin Feedback in Hypertensive Patients, 第82回日本循環器学会, Mar. 2018.
161.	Takayuki Ise, Shusuke Yagi, Yutaka Kawabata, Seno Hiromitsu, Kumiko Sutou, Yoshihito Saijoh, Rie Ueno, Hiroyuki Ito, Takafumi Todoroki, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute Hemodynamic Effect of Handgrip Stress in Patients with Chronic Heart Failure., 第82回日本循環器学会, Mar. 2018.
162.	Shusuke Yagi and Masataka Sata : Inhibition of Endothelin-1 Actions Improved Systemic Sclerosis-related Vasculopathy through Anti-oxidant Effects Leading to Increased Nitric Oxide Bioavailability., 第82回日本循環器学会, Mar. 2018.
163.	Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Inhibition of Thrombin Signaling by Dabigatran, a Direct Thrombin Inhibitor,Attenuates Endothelial Dysfunction in Diabetic Mice., 第82回日本循環器学会, Mar. 2018.
164.	Yukina Hirata, Kenya Kusunose, Hirotsugu Yamada, Yuta Torii, Susumu Nishio, Hiromitsu Seno, Tomomi Matsuura, Koji Yamaguchi, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Impact of Marathon Running on Left Atrial function in healthy trained volunteers, 第82回日本循環器学会, Mar. 2018.
165.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, Hiroyuki Itou, Takafumi Todoroki, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Differential Response of Local Coagulation after Coronary Angioplasty with Paclitaxel., 第82回日本循環器学会, Mar. 2018.
166.	Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yutaka Kawabata, 轟貴史, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Growth of vasa vasorum is associated with local inflammation around coronary plaque in fresh cadavers., 第82回日本循環器学会, Mar. 2018.
167.	Hiroyuki Ito, Tetsuzo Wakatsuki, Koji Yamaguchi, Daiju Fukuda, Yutaka Kawabata, 轟貴史, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Growth of Vasa Vasorum is Associated with Local Inflammation around Coronary Plaque in Fresh Cadavers(和訳中), 日本循環器学会学術集会抄録集, PJ007-3, Mar. 2018.
168.	Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, Hiroyuki Ito, 轟貴史, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki and Masataka Sata : Differential Response of Local Coagulation after Coronary Angioplasty with Paclitaxel(和訳中), 日本循環器学会学術集会抄録集, PJ022-1, Mar. 2018.
169.	Yutaka Kawabata, Takeshi Soeki, Takayuki Ise, Tomomi Matsuura, Kenya Kusunose, Takeshi Tobiume, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Tetsuzo Wakatsuki and Masataka Sata : Effects of L-/N-type Calcium Channel Blocker on Proteinuria and Angiotensin II-renin Feedback in Hypertensive Patients(和訳中), 日本循環器学会学術集会抄録集, PJ067-4, Mar. 2018.
170.	Gulinu Maimaituxun, Michio Shimabukuro, Daiju Fukuda, Shusuke Yagi, Yukina Hirata, Takashi Iwase, Shoichiro Takao, Tomomi Matsuura, Takayuki Ise, Tetsuzo Wakatsuki, Masafumi Harada and Masataka Sata : The impact of epicardial adipose tissue thickness on left ventricular diastolic dysfunction in patients with preserved ejection fraction, 日本老年医学会四国地方会, Feb. 2018.
171.	KUNDUZIAYI AINI, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki and Masataka Sata : Combination of vildagliptin,a DPP-4 Inhibitor, and metformin have additive beneficial effects on endothelial function and atherogenesis in non-diabetic apolipoprotein-E deficient mice, 日本老年医学会四国地方会, Feb. 2018.
172.	Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Hiroyuki Ito, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 経カテーテル大動脈弁植込み術を施した超高齢大動脈弁狭窄症の1例, 日本老年医学会四国地方会, Feb. 2018.
173.	Shusuke Yagi, 西山誠一, 和田敏裕, 板垣達三, 植淵昌毅, 竹治尚志 and Masataka Sata : �

Designated Professor : Yagi, Shusuke

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Academic Letter:

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference: